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The adaptive immune system is essential for production of anti-tumor immune 
responses, with the majority of current immunotherapeutics designed to modulate the 
interaction between adaptive immunity and tumor cells within the tumor-immune 
microenvironment.  This dissertation addresses three translational goals regarding our 
understanding and modulation of anti-tumor adaptive immunity: 1) Improvement of 
understanding for existing immunotherapies such as checkpoint inhibitor therapy 
(Chapter 2.1); 2) Improvement of efficacy for novel immunotherapeutics currently in 
development including tumor neoantigen vaccines (Chapter 4); and 3) Development of 
next-generation immunotherapies through identification of novel anti-tumor vaccine 
targets (Chapter 3), as well as development of diagnostic tools including biomarkers of 
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CHAPTER 1: General introduction to tumor immunology 
1.1 Introduction to the immune system 
The immune system is the body’s host defense composed of barrier structures 
(e.g. skin, mucosal barrier), cells (leukocytes), and soluble factors (e.g. cytokines, 
chemokines, complement proteins, immunoglobulins) which work in a concerted effort 
to recognize and respond to foreign entities.  Classically, immunity is divided into the 
innate and adaptive arms of the immune system.  The former is an evolutionarily older 
defense system whose major functions include recruitment of immune cells through 
release of cytokines and chemokines, activation of the compliment cascade, removal of 
foreign targets or debris through phagocytosis, and activation of the adaptive immune 
system through antigen presentation.  While an innate immune response can react 
rapidly against a broad set of targets, there is low target specificity with little evidence 
currently of immunological memory.  In contrast, the adaptive immune system is 
composed of T and B lymphocytes (including B-cell generated antibodies) that develop 
in response to specific immunological antigens.  Development of a primary adaptive 
immune response takes 7-10 days in humans and mice, with formation of 
immunological memory allowing for a faster and more robust secondary response 
against the same antigen (i.e. immunological memory).  Adaptive immunity targets 
include antigens derived from pathogens (e.g. viruses and bacteria) and tumor-derived 




immunity to promote anti-cancer immunological responses, which has laid the 
foundation for development of cancer immunotherapies within the past century. 
1.2 The tumor immune microenvironment 
The interaction between cancer and the immune system is dictated by the ability 
of the immune system to recognize non-self-antigens that arise during tumorigenesis.  
Recognition of tumor antigens and inflammatory signals can promote infiltration of 
immune cells, including sentinel antigen presenting cells (APC; e.g. dendritic cells [DC], 
macrophages/monocytes), neutrophils, natural killer [NK] cells, and T/B lymphocytes).  
In addition to infiltration, anti-tumor immune responses also necessitate an inflamed 
state, allowing for lymphocytes to carry out effector function.  This combination of 
infiltration and inflammation has led to classification of tumors into several states: 1) 
Infiltrated-excluded “cold” tumors (characterized by exclusion of lymphocytes from the 
tumor core), 2) Infiltrated-inflamed “hot” tumors (characterized by infiltration of the tumor 
core by lymphocytes, with high expression of programmed cell death protein 1 [PD-1] 
and its corresponding ligands [PD-L1/PD-L2]), and 3) infiltrated tumors with inclusion of 
tertiary lymphoid structures (characterized by formation of lymphoid structures within the 
tumor secondary to enhanced inflammation, often associated with positive prognosis)1. 
T cells are widely recognized as the most important immune cell population for 
performing anti-tumor immunity, including direct anti-tumor cytotoxicity in the case of 
CD8+ T cells and generation of pro-inflammatory cytokines and chemokines in the case 
of CD4+ T cells.  The T-cell receptor (TCR) is typically comprised of variable alpha and 
beta chains (with gamma and delta chains expressed on a minority of alternative T 




unique variable region (comprised of a recombinant V [variable], D [diversity], and J 
[joining] region), while alpha chains undergo VJ recombination without an intervening D 
region.  Pairing of recombined alpha and beta chains allows for specificity of binding to 
a particular antigen bound to a major histocompatibility complex (MHC) complex.  
Subsequently to formation of the TCR, thymic deletion occurs to TCRs incapable of 
binding to any antigen/MHC (positive selection) as well as those which bind too strongly 
to self-antigens (negative selection).  T cell recognition of tumor antigens occurs 
through TCR engagement with tumor-specific antigenic peptides presented on MHC, 
either on the surface of antigen presenting cells during T cell activation or directly on the 
tumor cell during T cell effector function.  CD8+ T cells bind to class I MHC, while CD4+ 
bind to class II MHC, with CD8 and CD4 acting as TCR co-receptors that enhance 
binding affinity of the TCR to the MHC.   
Activation of T cells requires three distinct signals.  Signal 1 is the binding of the 
TCR to an antigen/MHC complex, which begins intracellular signaling cascades to 
promote T cell activation through key transcriptional pathways (MAPK, NK-kB, NFAT).  
However, proper activation of these pathways additionally requires Signal 2, which is 
signaling through a T cell co-stimulatory molecule.  The best characterized of these co-
stimulatory molecules is CD28, which interacts with CD80 and CD86 on the surface of 
antigen presenting cells, resulting in completion of the intracellular signals necessary for 
proliferation, differentiation, and survival of the T cell.  Activation of the TCR without 
concurrent co-stimulation may result in T cell anergy, deletion, or immune tolerance.  




type I interferon [IFN], IL-12 for activation of CD8+ T cells), which are necessary for 
continued survival, proliferation, and memory-formation of Signal 1/2 activated T cells. 
Subsequently to activation, T cells upregulate checkpoint molecules which can 
act as a “break” to downregulate effector function.  The expression of the checkpoint 
molecules on tumor infiltrating T lymphocytes is a major indicator for inflammatory 
status.  Perhaps the best characterized and biologically important of these markers is 
PD-1, a surface receptor expressed on multiple immune populations whose function is 
most clearly elucidated in T cells, where upregulation occurs secondary to T-cell 
receptor (TCR) signaling.  Subsequent binding of PD-1 to its ligands PD-L1 and PD-L2 
results in downregulation of T cell effector function.  This occurs through the PD-1 
intracellular immunoreceptor tyrosine-based inhibitory motif (ITIM), which recruits 
binding of SHP-2 to suppress TCR signaling through the ZAP-70 domain.  Within the 
tumor microenvironment, where PD-L1/L2 are frequently expressed by both tumor and 
immune cells, PD-1 expression on T lymphocytes is associated with an exhausted 
immune phenotype, whereby memory and effector T cells which have recognized tumor 
antigens have decreased functions characterized by decreased proliferation, decreased 
inflammatory cytokine and IL-2 production, increased apoptosis, and upregulation of 
other exhaustion markers such as LAG-3, CD244, and CD1602.  As such, therapeutic 
antibodies that act to prevent PD-1/PD-L1 interactions have become an essential 
aspect of cancer immunotherapy. 
1.3 Development of immunotherapies for cancer treatment 
In addition to PD-1, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is 




“break” for T cell function, competing against the binding of T cell protein CD28 (a co-
stimulatory receptor for T cell activation) to its ligands CD80/86 (expressed on activated 
APCs).  As such, CTLA-4 is not frequently used as a marker for T cell exhaustion but 
can be similarly targeted as PD-1 to prevent immune checkpoint regulation.  PD-1 and 
CTLA-4 were first characterized in the early 1990’s, primarily by Drs. James Allison and 
Tasuku Honjo, respectively.  Since initial studies demonstrating the effects of these two 
checkpoint molecules, therapeutics aimed to block their pathways (known as checkpoint 
inhibitor therapies) have been developed for cancer immunotherapies.  Currently, anti-
PD-1 (aPD-1) and/or anti-PD-L1 therapies are standard of care for a wide variety of 
cancer types, including melanoma, urothelial cancer, non-small cell lung cancer, renal 
cell carcinoma, Hodgkin lymphoma, gastric cancer, colorectal cancer, hepatocellular 
carcinoma, Merkel cell carcinoma, and all cancers with high microsatellite instability 
(MSI)3.  aPD-1 therapy has revolutionized our ability to treat these cancers, providing 
cure with long lasting immunological memory against tumor in a subset of patients that 
would have otherwise had incurable disease with conventional therapies.  Despite these 
advances, responders to aPD-1 therapy comprise a minority of all treated patients in 
most tumor types.  As such, a key goal in the field of immuno-oncology has been to 
elucidate factors which associate with checkpoint inhibitor response. 
Among the set of features currently known to associate with response to 
immunotherapies includes tumor molecular subtyping, which (unlike conventional 
histological subtyping) is defined by genomic characteristics of the tumor.  The first 
description of tumor molecular subtyping was in human breast cancers, grouped into 




Subsequently, other cancers have been shown to contain similar molecular subtypes, 
including bladder cancer, which contains basal and luminal subtypes as the two major 
classifications5–7.  However unlike breast cancer, a limited repertoire of in vivo tumor 
models exist in bladder cancer, with no molecular subtype specific models described 
until recently.  Lack of animal models has encumbered capacity to study the differential 
effects of immunotherapies in subtype specific bladder cancers, making the 
development of biologically faithful murine models of bladder cancer a vital goal.  In 
Chapter 2, we will discuss our efforts in the design of molecular subtype-specific models 
of basal and luminal bladder cancer, with elucidation of tumor response/nonresponse in 
a basal-like bladder cancer model that demonstrates a mixed response phenotype to 
aPD-1 therapy (Chapter 2.1).  We additionally describe the use of these subtype-
specific models in the design of novel immuno-based PET/CT imaging modalities to 
study in vivo T cell infiltration (Chapter 2.2). 
1.4 Molecular characterization of the tumor 
In an attempt to identify the mechanism behind patient 
responsiveness/nonresponsiveness to aPD-1 therapy, many investigators have applied 
next generation sequencing immunogenomic techniques (e.g. DNA/RNA-sequencing) to 
elucidate the molecular profiles associated with various patient outcomes.  Below is a 
summary of several landmark papers which have applied immunogenomic techniques 
to examine biomarkers for aPD-1 response: 
 Hugo et al. 20168: Identification of an innately resistant tumor signature to PD-1 




mesenchymal transition, cell adhesion, extracellular matrix remodeling, 
angiogenesis, and wound healing. 
 Riaz et al. 20179: Study of whole exome, whole transcriptome, and TCR repertoire 
sequencing in aPD-1 +/- anti-CTLA-4 treated melanoma patients.  In responders to 
therapy, neoantigen load was reduced relative to pre-treatment baseline, with 
evidence of clonal T cell expansion post-treatment.  Responders also demonstrated 
higher gene levels corresponding to CD8+ T cells and NK cells, with significant 
decreases in macrophage signatures. 
 Auslander et al. 201810: Study of melanoma and neuroblastoma patient sample 
derived RNA-seq data to build an immuno-predictive score (IMPRES) based upon 
pairwise ratios of immune checkpoint related genes.  This study outperformed 
several previous papers, including the Hugo et al. IPRES signature. 
 Smith et al. 201811 and Panda et al. 201812: We have identified that the expression 
of several specific human endogenous retroviruses in pre-treatment nephrectomy 
samples from clear cell renal cell carcinoma patients is associated with subsequent 
responsiveness to aPD-1 therapy.  These studies are covered in Chapter 3 and 
Appendix IV, respectively.  
From these above studies, it is clear that the use of immunogenomic techniques 
to probe the tumor immune microenvironment can provide molecular signatures 
predictive for patient responsiveness to aPD-1 therapy.  Summary of methods for RNA-
sequencing characterization of the tumor microenvironment is covered in Appendix I.  
Common themes among these above studies show that responsiveness to aPD1 




(memory T cells, B cells, M1 polarized macrophages, activated DCs), 2) exclusion of 
immunosuppressive populations (regulatory T cells [Tregs], myeloid derived suppresser 
cells [MDSC], M2 polarized macrophages), 3) evidence of TCR clonal expansion, and 
4) presence and presentation of targetable tumor antigens.  This set of features 
underscores the importance of generating T cell responses against tumor-specific 
antigens (TSA) in order for patients to generate robust tumor immunity.  With evidence 
that responsiveness to aPD-1 therapy is largely dependent upon T cell activation 
against TSAs, it has become widely hypothesized that vaccine therapies against TSAs 
could be an effective strategy to generate or boost existing anti-tumor immunity.  
1.5 Classical and non-classical tumor-specific antigens 
The role of tumor specific antigens (TSA) as targets of anti-cancer immunity has 
been well recognized throughout the past century, with studies of TSA-based vaccines 
becoming more prevalent this past decade13–15.  Neoantigens are variant peptides 
derived from proteins encoded by genetic variations present in the tumor but not normal 
DNA, presented by MHC molecules, and recognized by T cells. The most commonly 
studied class of neoantigens are those derived from single nucleotide variations (SNV), 
which cause non-synonymous changes in a protein that subsequently may trigger 
antigen-specific T-cell responses against the tumor. These conventional neoantigens 
have the distinct advantage over other classes of tumor antigens (e.g. tumor associated 
self-antigens and cancer/testis antigens) in having no expression in normal tissues.  As 
a result, T cells with specificity for these neoantigens can escape thymic negative 




Despite advantages of SNV-neoantigens, their applicability as vaccine targets 
may be limited to cancers with high mutational burden.  While metastatic melanoma 
(which contains the highest SNV burden of any cancer) has been the primary focus of 
current neoantigen clinical studies, other cancers with lower mutation rates may contain 
a limited repertoire of potential targets.  As such, SNV-neoantigen vaccine development 
may be hindered in these cancers. 
In response, many investigators including our group have begun to evaluate non-
classical TSAs – here defined as high-specificity tumor antigens arising from non-SNV 
genomic sources.  Genomic analysis of tumor-antigen burden has demonstrated 
expression of various classes of TSAs are not always co-correlated, suggesting non-
classical TSAs may be targetable in certain cancers despite low SNV-neoantigen 
burden.  This is exemplified by clear cell renal cell carcinoma (ccRCC), a checkpoint 
inhibitor sensitive cancer which contains a low SNV burden but high expression of 
frameshift-neoantigens16 and tumor-specific endogenous retroviral antigens11.  
Additionally, leukemia and sarcoma (which contain among the lowest SNV burden of 
any cancers) express shared gene fusion mutations and splice variant transcripts, both 
of which can produce neoantigens.  Among non-classical TSAs include those generated 
from 1) mutational frameshifts, 2) splice variants, 3) gene fusions, 4) viral antigens, 5) 
endogenous retroviral antigens, and other less well characterized classes such as HLA-
somatic mutation derived antigens, minor histocompatibility mismatch antigens, and 















Table 1.1: Advantages and disadvantages of targeting tumor specific antigen classes, 





Advantages Disadvantages Relevant Cancers 
SNV 
neoantigens 
• Well studied 
• Simple prediction 
• Relatively high 
burden 
• Similar to self-antigen 
• Rarely shared between 
patients 
• Melanoma 
• Lung (adeno and 
squamous) 




• Many targets per 
mutation 
• More dissimilar from 
self-antigen 
• Relatively low burden 
• Microsatellite instability-
high tumors 
• Clear cell, papillary, and 





• High number of 
predicted targets 
• More dissimilar from 
self-antigen 
• Fewer tools available 
• Not well validated in 
vivo 
• Current tools do not 
account for nonsense 
mediated decay 
• Acute myelogenous 
Leukemia 
• Chronic myelomonocytic 
leukemia 







• More dissimilar from 
self-antigen 
• Shared targets 
between tumors 
• More potential 
targets per mutation 
• Relatively low burden 
• Acute myelogenous 
leukemia 
• Acute lymphoblastic 
leukemia 





• Large number of 
targets per virus 
• Higher 
immunogenicity 
• Shared between 
patients 
• Can be 100% tumor 
specific 
• Limited repertoire of 
cancers with specific 
expression 
• Cervical cancers 
• Head and neck 
squamous cell carcinoma 
• Hepatocellular carcinoma 




• Large number of 
targets per ERV 
• Higher 
immunogenicity 
• Shared between 
patients 
• Less well studied 
• Potential for off-target 
effects 
• Difficult to validate 
protein translation 
• Clear cell renal cell 
carcinoma 
• Low grade glioma 




1.6 Human endogenous retroviral derived cancer antigens 
Among the classes of non-classical TSAs listed above, a major focus of the work 
presented here addresses the role of human endogenous retroviruses (hERVs) in 
modulation of the tumor immune microenvironment (Chapter 3).  hERVs are remnants 
of exogenous retroviruses which incorporated into the genome throughout evolution17.  
hERVs impact pathogenesis and progression of cancers, including melanomas, 
lymphoma, leukemia, ovarian, prostate, urothelial, and renal carcinomas18–27.  
Expression of tumor-specific/enriched hERVS partly arise through epigenetic 
dysregulation of the cancer genome, resulting in expression of hERV-containing 
genomic regions otherwise not observed under physiological conditions28,29.  These 
tumor-specific/enriched hERVs can impact both the innate and adaptive immune 
system through distinct mechanisms.  In the innate immune system, hERVs signal 
through innate sensors, most commonly the RIG-I-like pathway recognition of viral 
double stranded RNAs28,29.  This results in downstream NF-κb-mediated inflammation, 
with release of type I IFN which causes immune activation and increased tumor class I 
MHC expression.  Additionally, hERV-derived protein antigens can induce B- and T-cell 
activation30–32.  As such, it is speculated that tumor-specific hERV antigens could be 
applied for anti-tumor adoptive cellular therapies and therapeutic vaccines. 
hERV-derived therapies are particularly relevant for several cancer types.  In 
addition to INDEL-derived neoantigens, hERVs have been proposed as key driver of 
anti-tumor immunity in ccRCC11,12.  In ccRCC, hERV expression is strongly prognostic 
and predictive for checkpoint inhibitor therapy response.  As such, hERV-derived 




evidence suggests a potential role for hERVs in the modulation of low grade glioma 
(LGG) where SNV burden is among the lowest of any cancer11 and testicular cancer 
(particularly those with KIT mutations) where global DNA hypomethylation is associated 
with high hERV expression33.  
Several computational methods for hERV quantification currently exist, with the 
majority providing quantification of hERV-like or retrotransposon-like elements (partial or 
full-length) rather than full-length, intact hERVs at specific genomic coordinates.  The 
most well-known tool is RepeatMasker, designed to identify interspersed repeats and 
low complexity sequences of any class, including simple and tandem repeats, 
segmental duplications, and interspersed repeats (including hERV-like elements, long 
and short interspersed nuclear elements [LINE/SINE], long terminal repeats [LTR], and 
other classes)34.  RepeatMasker used in its default state is not optimal for detection of 
hERVs.  However, nearly all hERV-specific databases (e.g. HERVd35, HESAS36, 
EnHERV37) have been subsequently generated using RepeatMasker.  A more recently 
quantifier designed by our group aimed specifically for analysis of hERVs from RNA-seq 
data is hervQuant11, which quantifies full-length, intact hERV proviral sequences.  The 
hervQuant reference is derived from Vargiu et al. which compiled genomic coordinates 
for 3,173 full-length hERV proviruses38.  As these above methods are quantifiers of 
hERV/hERV-like element expression, they must be paired with downstream epitope 
prediction software (e.g. NetMHCpan39) for hERV-antigen prediction. 
Until recently, the majority of hERV-related studies have examined particular 
hERVs (e.g. hERV-K HML-2, CT-RCC HERV-E) in the pathology of a particular disease 




genomic look into the interaction between hERVs and the tumor-immune 
microenvironment, demonstrating three of 66 hERVs (ERVH-5, ERVH48-1, ERVE-4) 
identified in a previous study from Mayer et al.40 to have tumor specific expression and 
to correlate with expression of a cytotoxicity signature (GZMA and PRF1) in several 
cancers41.  Based on this study, as well as several other translational studies showing 
the presence of a hERV-specific T-cell response in ccRCC31,42, we (Smith et al.11) and 
Panda et al.12 performed comprehensive analyses into the role of hERVs in ccRCC.  
hervQuant analysis of TCGA pan-cancer dataset provided broad correlative 
descriptions for the role of hERVs upon patient outcome and immune features, 
demonstrating hERV expression to most strongly associate with patient clinical 
outcomes in ccRCC and LGG11.  Both studies demonstrated the association between 
hERV expression in pre-treatment ccRCC nephrectomy samples with subsequent 
response to anti-PD-1 checkpoint blockade therapy, providing evidence for hERVs as a 
biomarker for immunotherapy response and potentially as a direct immunological tumor-
specific target. 
With substantial evidence in favor of a hERV-directed tumor-specific immune 
response, several studies have described the translational application of tumor-specific 
hERV targets.  A 2016 study from Cherkasova et al. identified a CD8+ T cell (CTL) clone 
from a patient with regressing ccRCC and found the clone to have tumor-specific 
cytotoxicity against tumor cells in vitro31.  The CTL recognized an antigen from a 
specific hERV CT-RCC HERV-E – which coincidentally was the same as one of the 
tumor-specific hERVs (ERVE-4) described by Rooney et al. and was also identified 




particular CTL clone is being studied in clinical trials for adoptive T-cell therapy in 
metastatic ccRCC (NCT03354390).  Our analysis additionally identified a second hERV 
(hERV 4700) with preferential expression in ccRCC compared to normal tissues, 
evidence of translation, and presence of tumor infiltrating CTLs specific for gag and pol 
derived antigens of the virus11.  Notably, this provided the first description of a broad 
genomic screening method for tumor-specific hERV antigens. 
1.7 Computational prediction of tumor-specific antigens 
Recent advancements in DNA and RNA sequencing have allowed for 
development of genomic and computational methods of TSA prediction (Table 1.2).  
Methods for generating TSA therapies generally rely on a conserved set of steps: 1) 
Variant calling, 2) HLA-typing, 3) peptide enumeration, 4) HLA binding prediction, and 5) 
therapy generation (Figure 1.2). Variant calling is the identification of genomic regions 
with high tumor specificity.  In the case of SNV, INDEL, and gene fusions neoantigens, 
variants are derived from mutations within the tumor exome.  Alternatively, viral and 
endogenous retroviral (ERV) antigens are derived from RNA expression data, selected 
for viruses/ERVs with higher expression in the tumor compared to matched normal 
tissues.  Splice variant neoantigens can be identified through a variety of techniques, 
discussed later in detail.  Subsequently, tumor HLA type is derived using an HLA caller 
(e.g. POLYSOLVER43, OptiType44, PHLAT45, HLAScan46, HLAProfiler47), which relies 
on DNA and/or RNA sequencing data, depending upon the software.  Peptide 
enumeration is then performed, whereby variant genomic regions are translated into 
peptide sequences, with translation-incompatible sequences removed (e.g. nonsense 




prediction software (e.g. NetMHCpan39), with binding typically accepted in the literature 
as ≤ 500 nM15,48,49.  Lastly, predicted TSAs are used to generate a therapeutic product, 
either as a vaccine (i.e. DNA/RNA, peptide, or dendritic cell vaccine) or a cellular 
therapy product (i.e. adoptive T cell therapy).  Below, we will discuss the relevant 
biology for each non-classical TSA class, with detailed descriptions of available tools. 
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1.8 Clinical translation of non-classical tumor-specific antigens 
Recent studies (including several from our group) have provided estimates for 
antigenic burden of each TSA class among TCGA pan-cancer data, which we have 
compiled here (Figure 1.3, 1.4)11,50–53.   
In addition to the clinical applicability of hERVs in ccRCC and LGG, testicular 
cancer (TGCT) contained substantially greater burden of hERV-derived TSAs than any 
other cancer type.  This is in agreement with previous findings that TGCT was among 
the cancer types with the greatest hERV expression due to widespread 
hypomethylation11,33.   
Viral antigen burden was highest in cervical (CESC; HPV) and hepatocellular 
(LIHC; HBV) cancers, but also observed in subsets of head/neck squamous cell (HNSC; 
HPV) and stomach adenocarcinoma (STAD; EBV) tumors.  Associated with these 
findings, therapeutic cancer vaccines are currently in development for HPV-driven 
cervical cancer (VGX-310054), as well as EBV-driven nasopharyngeal cancers and 
NK/T-cell lymphomas (MVA-EL55 and CMD-00356).  Currently, no HBV therapeutic 
vaccines have demonstrated convincing therapeutic efficacy.   
INDEL- and SNV-neoantigen counts derived from a recent TCGA pan-cancer 
analysis demonstrated significant co-correlation among all cancer types (coefficient: 
0.81, p < 0.0001)50.  In agreement with Turajilic et al., notable outliers were clear cell 
and papillary RCC, where the INDEL-to-SNV ratio was significantly higher than other 
cancer types (KIRC: 0.85 and KIRP: 0.90; all others: 0.43 – 0.72).  In addition, colon 
adenocarcinoma (COAD) demonstrated a distinct population of INDEL-high tumors, 




characterized by impaired DNA mismatch repair pathways, contain significantly greater 
INDEL burden compared to non-MSI-H tumors57,58.  These data suggest that in RCC, 
MSI-H tumors, and cancer types known to have high SNV-burden, INDEL-derived 
neoantigens should also be considered for vaccine selection.   
Mean burden of fusion-derived neoantigens per sample was highest in sarcomas 
(SARC: 1.1, UCS: 0.78), with carcinoma fusion burden highest in breast and prostate 
cancer (BRCA: 0.70, PRAD: 0.58).  SARC, BRCA, and PRAD all fall within the lower 
half of SNV-neoantigen number among all cancer types, making fusion-derived 
neoantigens another potential avenue for vaccine development.  While gene fusion data 
was not available for acute myeloid leukemia (LAML), gene fusion neoantigens have 
been a focus of study in leukemia (particularly AML, acute lymphocytic leukemia [ALL], 
and chronic myelogenous leukemia [CML]59).   
Splice variant neoantigens demonstrated similar burden to INDEL-neoantigens, 
with significant co-correlation with INDEL- and SNV-neoantigen burden.  A notably 
outlier is thyroid cancer (THCA), where average number of splice variant neoantigens 
per sample is higher than SNV-neoantigens.  Mutations in spliceosome proteins (e.g. 
SF3B1, SRSF2, U2AF1/2) are common in myelodysplastic syndrome, acute 
myelogenous leukemia (AML), chronic myelomonocytic leukemia (CMML), and chronic 
lymphocytic leukemia (CLL)60–64, resulting in the hypothesis that spliceosome mutations 
may cause expression of splice variant mRNA, leading to translation of neoantigens65–
67.  As splice variant neoantigens have greater potential for dissimilarity from reference 





Conventional SNV-neoantigens remain the most well studied class of TSA, with 
distinct advantages of ease of prediction, prevalence in a wide cohort of patients, and 
promising pre-clinical therapeutic evidence.  While SNV-neoantigens will continue to be 
a driving force for therapeutic vaccine development in the coming years, many groups 
have broadened the search for other non-classical TSAs derived from self and non-self-
antigens.  While certain non-classical TSAs have been studied for decades (e.g. fusion 
proteins), the advent of powerful computational methods for patient-specific prediction 
of TSAs has expanded the breadth of targets available for clinical application.  Unlike 
SNV-neoantigens, which are largely patient specific in expression, many non-classical 
TSAs are shared among the population (e.g. viral, hERV, gene fusions), making them 
ideal for off-the-shelf therapies.  Additionally, many of these peptide sequences are 
entirely dissimilar from germline (e.g. frameshifts, viral, hERV), allowing for potentially 
greater immunogenicity than SNV-neoantigens.  Thus, non-classical TSAs should play 





Figure 1.3: Average tumor specific antigen counts by cancer type. Plots represent 
number of unique identified epitopes by TCGA cancer type.  SNV and INDEL epitopes 
are derived from Thorsson et al. (Immunity, 2018).  Fusion epitopes are derived from 
Gao et al. (Cell Reports, 2018).  Splice variant epitopes are derived from Jayasinghe et 
al. (Cell Reports, 2018). Viral epitopes are derived from Selitsky et al. (mSystems, 
2018).  hERV epitopes are derived from Smith et al. (JCI, 2018).  All TSA classes 
represent the average number of predicted class I HLA binders (8-11mers, <500 nM) 
predicted from NetMHCPan.  STAD INDEL and SNV calls were absent from Thorsson 







Figure 1.4: Number of unique tumor specific antigens by cancer type.  Plots represent 
number of unique identified epitopes by TCGA cancer type.  SNV and INDEL epitopes 
are derived from Thorsson et al. (Immunity, 2018).  Fusion epitopes are derived from 
Gao et al. (Cell Reports, 2018).  Splice variant epitopes are derived from Jayasinghe et 
al. (Cell Reports, 2018). Viral epitopes are derived from Selitsky et al. (mSystems, 
2018).  hERV epitopes are derived from Smith et al. (JCI, 2018).  All TSA classes 
represent number of predicted class I HLA binders (8-11mers, <500 nM) predicted from 
NetMHCPan. STAD INDEL and SNV calls were absent from Thorsson et al.  ESCA, 
LAML, and OV were omitted from all reports. 
 
1.9 Therapeutic platforms for tumor antigen vaccination 
The efficacy of a therapeutic vaccine is greatly affected by the delivery vehicle.  
The most common vaccine strategy is combination of free-peptide with an immune 
adjuvant, delivered as a subcutaneous/intradermal injection.  However, free-peptide 
vaccines with adjuvant have limited efficacy, due to inadequate immune stimulation and 




concerns, nanoparticle-based vaccine platforms have been proposed as an alternative 
vehicle strategy for tumor antigen vaccines. 
Nanotherapeutics encompasses a class of delivery vehicles, including 
nanoparticles, liposomes, dendrimers, and nano-discs.  While nanotherapeutic delivery 
vehicles have been widely studied for vaccine platforms throughout the last several 
decades, neoantigen-based nano-vaccine platforms have arisen within the last several 
years68,69.  The first description of a nanotherapeutic neoantigen vaccination platform 
was from Kreiter et al., where mRNAs encoding for neoantigen epitope sequences were 
encompassed within a liposomal delivery system to generate tumor-specific T cell 
responses in several murine tumor models70.  Built off of a previous report from Castle 
et al.71, the research group led by Ugur Sahin and Ozlem Tureci demonstrated the 
efficacy of these neoantigen epitope encoding mRNAs to be derived from simultaneous 
activation of intra-cytoplasmic TLR7 (providing a DC activation and maturation signal) 
and mRNA translation within sentinel dendritic cells (DCs), which subsequently present 
these neoantigen epitopes alongside co-stimulatory receptor signaling ligands to 
activation neoantigen-specific T cells (primarily CD4 T cells) that induced anti-tumor 
response14,72.  
Since this initial description, several other groups have provided peptide-based 
nanotherapeutic approaches for tumor therapeutic vaccination.  Relying upon previously 
published neoantigen sequences, Kuai et al. designed a high density lipoprotein based 
nanodisc platform loaded with neoantigen peptides, importantly capable of cross-
presentation to induce a CD8 T cell response to a higher degree than demonstrated by 




generate poly(lactic-co-glycolic acid (PLGA)-based antigen-capturing nanoparticles to 
improve the abscopal effect after B16F10 tumor irradiation75.  Among the antigens 
captured by the particles included several that were derived from proteins which 
contained neoantigenic epitopes, suggesting neoantigenic priming may be a potential 
mechanism behind the efficacy of this platform.  Following these approaches, our work 
presented in Chapter 4.2 focuses on the design of a PLGA-based neoantigen peptide 
delivery platform.   
1.10 Concluding remarks and contributions of this work 
The studies presented in this document provide a multidisciplinary approach to 
address key understudied aspects of immuno-oncology, including aims to better 
understand the mechanism of currently immunotherapies, and to discover and develop 
the next generation of immunotherapeutics to further advance our ability to cure 
cancers.  The work presented here was made possible through many collaborative 
efforts.  Additionally, Dr. Benjamin Vincent provided co-mentorship for all projects 
described in this dissertation.  Chapter 2.1 was performed in collaboration with the lab 
of William Kim.  Chapter 2.2 was performed in collaboration with the lab of Matthew 
Parrott.  Chapter 3 was performed in collaboration with the lab of W. Kymrin Rathmell 
and Sara Selitsky of the Lineberger Bioinformatics Group.  Chapter 4.2 was performed 







Appendices to this dissertation include a summary of RNA-seq methods 
(Appendix I), molecular characterization of human ccRCC (Appendix II) and gastric 
(Appendix III) cancers, complimentary analyses of hERVs in ccRCC (Appendix IV), 
design of nanoparticle strategies for immunotherapy delivery (Appendix V), and study of 
CD30-directed chimeric antigen receptor (CAR) cellular therapies (Appendix VI).  My 






CHAPTER 2: Design and study of subtype-specific murine tumor models 
2.1 Development of subtype specific mouse models of bladder cancer. 
 2.1.1 Introduction 
In the United States, bladder cancer is the fifth most common malignancy with 
approximately 79,000 new cases and nearly 17,000 deaths expected in 201776. Bladder 
cancer is comprised of both low-grade and high-grade tumors. Although low-grade 
tumors are almost uniformly noninvasive (Ta), high-grade tumors can become muscle-
invasive and metastatic. 
Multiple studies have now identified distinct RNA expression subtypes within both 
low- and high-grade bladder cancer5–7,77–82. Building upon the work of Hoglund and 
colleagues77, we along with others have recently described distinct subtypes of high-
grade muscle-invasive urothelial carcinoma, which we have termed luminal-like and 
basal-like, that have gene expression patterns that appear to be consistent with 
differentiation states of normal urothelium and reflect gene expression patterns and 
biology between breast and bladder cancer5–7,83. 
Cisplatin-based chemotherapy has been the only FDA-approved therapy to treat 
advanced bladder cancer for over two decades until the recent approval of immune 
checkpoint antibodies targeting the PD-1/PD-L1 axis. PD-1 axis blockade induces a 
response in approximately 20% to 30% of patients with advanced urothelial carcinoma, 




immunosuppression84–89. Response to PD-1 axis inhibition in urothelial bladder cancer 
has been associated with a number of intrinsic tumor features such as tumor mutational 
burden and tumor molecular subtype, as well as tumor microenvironment features such 
as the presence of PD-L1–expressing tumor-infiltrating immune cells, CD8+ cytotoxic T 
cells in the tumor, and expression of effector T-cell genes by gene expression 
profiling85. 
Multiple immunocompetent mouse models of bladder cancer currently exist 
including the carcinogen-induced models: MB49 (DMBA-derived cell line) and BBN [N-
butyl-N-(4-hydroxybutyl)nitrosamine]90,91 as well as numerous autochthonous, 
genetically engineered murine (GEM) models92, some of which progress to muscle-
invasive bladder cancer and metastasis93–96. 
We report here the generation of a novel GEM model of high-grade, muscle-
invasive bladder cancer that faithfully recapitulates the luminal molecular subtype of 
bladder cancer: Upk3a-CreERT2; Trp53L/L; PtenL/L; Rosa26LSL-Luc (UPPL) mice. 
This model is characterized by papillary histology and decreased levels of immune 
infiltration relative to basal tumors derived from BBN-treated animals, a pattern that is 
similar to human disease7,77,83. We have generated cell line adoptive transfer models for 
luminal-like UPPL tumors as well as for basal tumors derived from BBN-treated animals. 
Cell line–derived tumors from the UPPL model maintain luminal-like characteristics, 
such as high expression of Pparg and Gata3 gene signatures. Moreover, gene 
expression profiles from BBN and UPPL models more closely map to human bladder 
cancer and to normal murine urothelial cells than the commonly used MB49 model, 




biology in immunocompetent mice, these models can be used to interrogate subtype-
specific responses to immune checkpoint inhibition and other immunotherapy strategies 
in vivo. 
 2.1.2 Materials and Methods 
Mouse models and establishment of mouse bladder cancer cell lines 
All animal studies were reviewed and approved by The University of North 
Carolina at Chapel Hill Institutional Animal Care and Use Committee. For the BBN 
carcinogen-induced mouse bladder cancer model, C57BL/6 mice (Charles River 
Laboratories) were continuously exposed to 0.05% N-butyl-N-(4-hydroxybutyl) 
nitrosamine (BBN) in drinking water. Trp53 and Pten conditional knockout mice were 
obtained from The Jackson Laboratory (STOCK: 008462) and Terry Van Dyke (National 
Cancer Institute, Bethesda, MD; ref. 25)97, respectively, and crossed with Upk3a-
CreERT2 allele (The Jackson Laboratory STOCK: 015855) and the Rosa26LSL-
Luciferase allele (The Jackson Laboratory, STOCK: 005125; UPPL model) or crossed 
with Krt5-CreERT2 allele (a gift from Brigid Hogan, Duke University, Durham, NC) and 
Rosa26LSL-tdTomato (The Jackson Laboratory, STOCK: 007914; KPPT model). In 
order to induce Cre recombination in the bladder of UPPL or KPPT mice, 5 mg of 
tamoxifen was given orally by gavage in both the UPPL and KPPT model. In the KPPT 
model, transurethral injection of 4-hydroxy-tamoxifen was also performed. Tumor 
development was regularly monitored by bladder ultrasonography. 
Mice were sacrificed for the humane endpoints as follows. For the autochthonous 




or tumor size diameter of >7 mm as evaluated by bladder ultrasound. In our studies, all 
mice were sacrificed because of tumor size. The endpoint for allograft models was 
tumor volume >500 mm3, skin ulcer formation, or weight loss greater than 20% body 
weight. 
Generation of UPPL1541 and BBN963 cell lines 
Once the bladder tumors became >7 mm in diameter, they were harvested for 
pathologic evaluation, in vitro analysis, and for establishing cell lines. Tumors were 
dissociated and digested with collagenase and dispase (Roche). The dissociated tumor 
cells were resuspended in growth media and plated to a plastic plate as described 
previously98. Cell lines were passaged more than 10 times before use. Mycoplasma 
testing was performed monthly while cells were in culture. 
MB49 cell lines were obtained from Molly Ingersol (Institut Pasteur, Paris, 
France). Mycoplasma testing was performed monthly while cells were in culture. 
RNA/DNA extraction, library prep, and RNA sequencing or whole-exome sequencing 
RNA was extracted from the primary tumors and the established cell lines using 
an RNeasy Kit (QIAGEN), and DNA was extracted from primary tumors, established cell 
lines, and tail clippings using a DNeasy Kit (Qiagen). Whole-exome and transcriptome 
library preparation was performed using Agilent SureSelect XT All Exon and Illumina 
TruSeq Stranded mRNA Library Preparation Kits, respectively. Libraries were 





RNA sequencing analysis 
Sequence reads were aligned to the murine genome (mm9), and gene 
expression was generated as reads per kilobase of exon model per million mapped 
reads per gene by using MapSplice and upper quartile normalized via RSEM (University 
of Kentucky Bioinformatics Labs, Lexington, KY; ref. 27)99. 
RNA sequencing (RNA-seq) data were normalized for variations in read counts, 
log2 transformed, and median centered before analysis. When combining datasets, we 
adjusted for batch effects using the surrogate variable analysis R package (version 
3.12.0; R Foundation). Subtype calls were made using the BASE47 classification 
algorithm based on the median-centered expression of Mus musculus homologs of 
genes found in the classifier7. Clustering was done using average linkage clustering 
with a centered correlation similarity metric. Immune gene signature scores were 
derived as described previously83. 
Gene data were grouped into immune gene signatures, which were murine 
orthologs of signatures previously identified through unsupervised clustering and gene 
expression profiling of sorted immune cells83,100,101. Gene data were matched to 
predefined immune gene signature clusters via Entrez IDs. Each gene signature was 
calculated as the average value of all genes included in the signature. Differential 
expression for each gene signature was analyzed between tumor models and treatment 
groups via ANOVA (one-way ANOVA), adjusted for multiple testing using an FDR of 
0.05. To determine the prognostic value of each immune gene signature, linear 




variable compared with tumor size. Heat map of the log10 transformed P value of gene 
signature correlations was displayed with color gradient calculated via: 
−(𝑙𝑜𝑔10(𝑝 − 𝑣𝑎𝑙𝑢𝑒) − 𝑙𝑜𝑔10(0.05))  ∙ 𝑠𝑖𝑔𝑛 𝑜𝑓 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 
Gata3 and Pparg gene signatures 
The PPARy gene signature was derived by determining the genes that are 
significantly upregulated (samr package FDR < 0.05) in UMUC9 cells treated with 
rosiglitazone, a PPARy agonist in the GSE47993 dataset83. The GATA3 gene signature 
was pulled from the BIOCARTA curated gene signature set in MSigDB. Gene 
expression data have been deposited GSE112973. 
PvClust 
The significance of clustering nodes was determined using the pvclust R 
package (version 2.0-0, R Foundation; ref. 30)102. Significance of all nodes was 
calculated with a correlation distance metric and average linkage clustering. 
qPCR normalization for TCR/BCR repertoire profiling 
Tumor RNA concentrations were determined using a Qubit RNA BR Assay Kit, 
1:200 in dilution buffer. Using a Qiagen Quantitect Reverse Transcription Kit, cDNA was 
synthesized from 50 ng to 1 μg starting total RNA. RNA derived from column-purified 
T/B cells was included as a positive control, and DI H2O was included as a negative 
control. The reaction was carried out according to the manufacturer's instructions, using 




Quantitative PCR was performed in triplicate with 0.5 μmol/L of each forward and 
reverse primers, 0.1 μmol/L TaqMan probe [T-cell receptor (TCR): FAM reporter with 
TAMRA quencher; B-cell receptor (BCR): VIC reporter with TAMRA quencher], cDNA 
(2.5 μL), and Bio-Rad SsoAdvanced Universal Probe Supermix (2×) and DI H2O for a 
final volume of 10 μL per well. Cycling conditions for TCR and BCR were both set for 45 
cycles of recommended TaqMan conditions for the QuantStudio 6 Flex system. 
Purified T/B-cell cDNA was used for positive control and calibration curve, and 
the template-free cDNA synthesis reaction was used for negative control. The 
calibration curve was determined using Ct values from purified T/B-cell cDNA, 10-fold 
serially diluted in nuclease-free water ranging from 1:0 (cDNA: H2O, v/v) to 1:1 × 1012. 
For both T- and B-cell calibration curves, Ct values were detectable as dilute as 1:1 × 
105, with a coefficient of determination of >0.99 for the linear fit of log10(dilution) versus 
Ct. Each sample's Ct value was read out as the ratio of T- or B-cell cDNA to total cDNA. 
5′ RACE amplification of TCR/BCR sequences 
Based on qPCR results, all tumor samples were normalized by T- or B-cell RNA 
starting template. Using a Clontech SMARTer RACE 5′/3′ Kit, cDNA was generated 
using the manufacturer's protocol. cDNA was diluted with tricene/EDTA buffer, and 5′ 
RACE was carried out using the manufacturer's protocol with 0.5 μmol/L custom 
barcoded gene-specific reverse primer, using a Veriti thermocycler (Applied Biosystems 
Veriti 96-well) with the following cycling conditions: 
30 cycles: 




 68°C, 30 seconds 
 72°C, 3 minutes 
5′ RACE products were pooled, and clean-up/concentration were performed 
using a Zymogen Genomic DNA Clean & Concentrator. Pools of samples were eluted in 
32 μL of nuclease-free water heated to 70°C. DNA concentration was measured using a 
Qubit DNA HS Assay Kit. Purity (A260/280nm and A260/230nm ratios) was determined 
using a ND-1000 spectrophotometer. Pooled DNA (1–5 μL) was visualized in a 1.5% 
agarose gel to confirm the presence of proper band sizes (TCR and BCR: 400–500 bp). 
TCR/BCR repertoire profiling 
For TCR/BCR repertoire studies, pooled TCR or BCR amplicons were size 
selected using a Sage Science Pippin Prep 1.5% agarose cassette (HTC1510). Bands 
were size selected at 450 to 650 bp. After size selection, samples were analyzed using 
either Agilent 2100 Bioanalyzer or Tapestation to ensure purity. Illumina MiSeq library 
preparation was performed using a KAPA Biosystems DNA Preparation Kit. Libraries 
were run at 6 pmol/L on an Illumina MiSeq using a 600-cycle kit (2 × 300 paired-end), 
with 15% PhiX spike-in. 
Mouse allograft model and treatment by anti–PD-1 antibody 
BBN963 and UPPL1541 cell lines were injected subcutaneously in C57BL/6J 
mice at 1 × 107 and 1 × 106 cells, respectively. Once tumors reached 200 mm3 in tumor 
volume, treatment either by anti–PD-1 antibody (clone RMP1-14, Millipore) or isotype 




administered once a week at a dose of 10 mg/kg. The tumor size was measured by 
caliper weekly or twice weekly. 
Flow cytometry 
For tissue dissociation, tissues were homogenized in cold media using the 
GentleMACs Dissociator, and the samples were passed through a 70 μm cell strainer 
using a 5-mL syringe plunger. The samples were centrifuged for 7 minutes at 290 RCF, 
4°C, decanting the supernatant. The remaining pellet was resuspended into 1 mL of 
ACK lysis buffer (150 mmol/L NH4Cl, 10 mmol/L, KHCO3, 0.1 nmol/L Na2EDTA in 
DPBS, pH 7.3) for 2 minutes at room temperature before quenching with 10 mL of cold 
media. The samples were centrifuged for 7 minutes at 290 RCF, 4°C, resuspended in 
10 mL of cold media, and passed through a 40 μm cell strainer. Cell counting was 
performed by running a diluted aliquot of sample on a MACSQuant flow cytometer, 
counting lymphocytes as gated by forward scatter area versus side scatter area. 
Samples were washed and resuspended in cold DPBS, normalized by count, and 
transferred onto a 96-well V-bottom plate at 2.5 × 106 lymphocytes per well. Cells were 
resuspended in FVS700 viability stain (BD, 1:1,000 dilution in 100 μL DPBS) for 40 
minutes on ice. Wells not receiving viability staining were resuspended in DPBS. Cells 
were washed twice in staining buffer (0.02% NaN3, 2% BSA in DPBS), resuspended in 
50 μL Fc block (1:50 dilution in staining buffer), and incubated on ice for 15 minutes. 
Antibody master mix was added to samples at 50 μL per sample with final antibody 
concentrations as indicated in Supplementary Table S1 (all mAbs from BD 




Cells were incubated on ice in the dark for 45 minutes and washed twice with 
staining buffer. Cells were fixed in 2% paraformaldehyde overnight. The following 
morning, a minimum of 100,000 events were collected for each sample on a BD 
LSRFortessa flow cytometer. FlowJo flow software Version 10 (Treestar) was used for 
analyses. Fluorescence Minus One controls were used to guide gating strategies. 
Analysis and statistics 
All flow cytometry, TCR/BCR sharing, and Shannon entropy statistics were 
calculated with Mann–Whitney U test. 
For TCR/BCR amplicon sequencing analyses, raw .fastq files were demultiplexed 
by barcode sequences of the gene-specific primers. Sorted R1 and R2 files were 
respectively merged. Sequencing quality was confirmed through the FastQC quality 
control tool. TCR and BCR amplicon data were analyzed via IMGT/HighV-QUEST. Data 
were converted into standard in-lab format, and downstream analysis was performed 
with custom scripts as well as the tcR R package. 
Neoantigen prediction 
C57BL/6 mice were given a single subcutaneous flank injection of BBN963, 
UPPL1541, or MB49 cells. Tumor growth was monitored until tumors reached 100 
mm3, at which point mice were humanely sacrificed with CO2 asphyxiation followed by 
cervical dislocation. Tumors were dissected for downstream DNA/RNA extraction as 
described above. Matched normal DNA was extracted from tail-clippings or liver from 
the mouse in which the cell lines were respectively derived. Library prep and 




neoantigens was performed as described previously83. Predicted neoantigens were 
filtered on expression in all replicates with >5× read support. 
Vaccine/ELISPOT assay for neoantigen immunogenicity 
Predicted neoantigen peptides were synthesized by New England Peptide, using 
custom peptide array technology. C57BL/6 mice were vaccinated with predicted 
neoantigen peptides, given as a subcutaneous injection of a pool of 8 equimolar 
peptides (5 nmol total peptide) and 50 μg poly(I:C) in PBS. A second identical injection 
was repeated 6 to 7 days after primary injection. Mice were humanely sacrificed with 
CO2 asphyxiation followed by cervical dislocation 5 to 6 days after second injection. 
Spleens were harvested and prepared into a red blood cell lysed, single-cell 
suspension. Splenocytes were plated in triplicate at 5 × 105 cells per 100 μL media onto 
an IFN-γ capture antibody-coated ELISPOT plate (BD Biosciences) for 48 hours, along 
with 1 nmol of a single peptide against which the respective mouse was vaccinated. 
IFN-γ expression was compared with splenocytes incubated with vehicle control. 
Neoantigen-enriched T-cell coculture 
C57BL/6 mice were vaccinated with either a pool of the top 8 predicted BBN963 
neoantigens or irrelevant peptide (SIINFEKL) control, with a second identical booster 
given 7 days after primary vaccine. One week after secondary vaccination, spleens 
were harvested and prepared into a red blood cell lysed, single-cell suspension. T cells 
were isolated using Miltenyi murine Pan T Cell Isolation Kit II. Using previously 
described methods103, T cells were expanded in the presence of bone marrow–derived 




vaccinated against. Seven days following ex vivo expansion, 1 × 105 T cells were 
cocultured 10:1 with BBN963 cells onto an IFN-γ capture ELISPOT plate for 72 hours. 
Controls included T cell only, BBN963 only, and media only negative controls, as well 
as antigen-enriched T cells cocultured with respective peptide-pulsed UPPL1541 cells 
as positive control. Signal intensity was read out using an ELISPOT plate reader. T-
cell/BBN963 coculture spot counts were subtracted from their respective T-cell only 
control, and then taken as a percentage of the counts from their respective peptide-
pulsed target positive controls. 
Supplemental material 
All supplemental figures and tables cited in Chapter 2.1 are listed according to 
the original published manuscript, which can be found at 
http://cancerres.aacrjournals.org/content/78/14/3954.figures-only. 
 2.1.3 Results 
Inactivation of Pten and Trp53 in Uroplakin3a-expressing cells results in muscle-
invasive, high-grade urothelial carcinoma 
Our previously published studies describing luminal-like and basal-like molecular 
subtypes of bladder cancer demonstrated that these subtypes reflect the gene 
expression patterns of the differentiation states of the normal urothelium7. Basal-like 
bladder tumors harbor gene expression patterns most similar to basal and intermediate 
cell layers of the bladder, whereas luminal tumors harbor gene expression patterns 
most similar to umbrella cells5,7. To determine whether different cells of origin account 




grade, muscle-invasive bladder cancer, we conditionally inactivated Pten and Trp53 in 
Keratin5 (K5) or Uroplakin3a (Upk3a)-expressing basal/intermediate and 
umbrella/intermediate cell layers, respectively, using previously reported K5-
CreERT2104 and Upk3a-CreERT2 (The Jackson Laboratory) transgenic mice. Dual 
inactivation of Pten and Trp53 by surgical injection of adenoviral cre into the bladder 
has been previously shown to induce bladder cancer in mice96. Using standard animal 
husbandry, we generated cohorts of Upk3a-CreERT2; Trp53L/L; Pte/L/L; Rosa26LSL-
Luc mice (hereafter termed “UPPL”) as well as K5-CreERT2; Trp53L/L; PtenL/L; 
Rosa26LSL-tdTomato mice (hereafter called “KPPT”) that were backcrossed 10 times 
to a C57BL/6 background. Both UPPL and KPPT mice were gavaged with tamoxifen 
every other day for 3 doses starting at 6 to 8 weeks of age to induce CreERT2 activity. 
Serial in vivo luminescence (for UPPL mice) and ultrasound of the bladder were used to 
monitor for tumor development and growth. UPPL mice demonstrated gradually 
increasing luminescence signal over time in the region of the bladder (Figure 2.1A,B). 
In addition, by ultrasound, papillary-appearing tumors began to be apparent at a median 





Figure 2.1: Inactivation of Pten and Trp53 in Upk3a-expressing cells results in high-grade 
muscle-invasive bladder tumors. (A) Bioluminescent images of UPPL mice at indicated 
time points. (B) Quantification of luminescence over the region of the bladder. (C) 
Ultrasound images of bladder tumor formation. (D) Tumor-free survival as detected by 
ultrasound. (E) Gross images of the kidneys and bladder from a tumor-bearing UPPL 
mouse. (F) Tumor stage assessed histologically based on human TNM staging. 
 
In contrast, KPPT mice administered tamoxifen by gavage died rapidly of 
epithelial hyperplasia of the snout, paws, and papillary skin lesions (Supplementary Fig. 
S1A–S1C). This likely represents the inactivation of Pten and Trp53 (and pursuant 
epithelial overgrowth) in K5-expressing basal cells in multiple organs including the 
epidermis, trachea, and gastrointestinal tract. In an attempt to activate K5-CreERT2 
solely in the K5-expressing basal cells of the bladder, we administered 4-
hydroxytamoxifen (4-OHT) intravesically at various concentrations (2,000 and 200 




attenuated phenotype to KPPT mice that had been gavaged with tamoxifen 
(Supplementary Fig. S1B and S1C) and had a shortened survival. In contrast, KPPT 
mice injected with intravesical 4-OHT at 200 nmol/L had an extended survival but did 
not develop bladder tumors despite Cre-mediated recombination as evidenced by 
increased tdTomato signal over the region of the bladder by IVIS imaging 
(Supplementary Fig. S1D). Moreover, histologic examination of the bladders of mice 
injected with intravesical 4-OHT at 2,000 or 200 nmol/L showed no significant histologic 
changes of the urothelium (Supplementary Fig. S1E). 
Approximately 95% of UPPL mice developed tumors within 77 weeks (Figure 
2.1D). Grossly, bladder tumors in UPPL mice appeared to be papillary in nature (Figure 
2.1E), which is a feature documented to be enriched in the luminal-like molecular 
subtype5,6. Histologically, the UPPL tumors were characterized as high grade by an 
expert genitourinary pathologist (S.E. Wobker) and were found to be of varying tumor 
stage (Figure 2.1F) as well as rarely metastatic (Figure 2.2A). UPPL tumors also had 
microscopic papillary features (Figure 2.2B-D) and some had prominent squamous 
differentiation (Figure 2.2D,E). In addition, UPPL tumors were noted to have different 
depths of invasion into the bladder wall including both lamina propria invasion (Figure 
2.1F, 2.2F) and muscularis propria invasion (Figure 2.2G). In keeping with the known 
field defect of urothelial tumors in human disease, tumors were also noted to form in the 
renal pelvis and ureters of about a third of mice (Figure 2.1E, 2.2A,H,I). Finally, rare 





Figure 2.2: Representative histology of UPPL tumors. (A) Bar graph indicating the 
percentage of UPPL mice that developed bladder tumors, upper tract tumors, and distant 
metastases at the time of sacrifice. (B) Low-power view of papillary-appearing UPPL 
tumor. (C) High-power view of papillary UPPL tumor. (D) Low-power view of papillary 
tumor with squamous histology. (E) High-power view of squamous histology. (F) UPPL 
tumor showing lamina propria invasion. (G) UPPL tumor with muscularis propria invasion. 
(H) Upper tract tumor demonstrating invasion into the renal parenchyma. (I) High-power 
view of urothelial tumor invading renal parenchyma. (J) Cervical lymph node metastases. 




BBN and UPPL models are basal- and luminal-like models, respectively, of human 
bladder cancer 
Bladder tumors induced by the carcinogen N-Butyl-N-(4-hydroxybutyl) (BBN) 
have been previously documented to harbor a number of histologic features (e.g., 
squamous differentiation, Supplementary Fig. S2A–S2D) and gene expression patterns 
known to be found in basal-like bladder tumors79. We therefore established 11 
independent BBN-induced bladder tumors by continuously administering 0.05% BBN in 
drinking water as described previously91. Given the papillary nature of UPPL tumors, we 
hypothesized that they correspond to a luminal-like molecular subtype. We therefore 
performed global transcriptome profiling of 9 UPPL and 11 BBN mouse tumors using 
RNA-seq. We first performed molecular subtype classification using our previously 
published BASE47 (bladder cancer analysis of subtypes by gene expression; ref. 3)7 
subtype classifier and found that 8 of the 9 UPPL tumors had high correlation to the 
luminal centroid of gene expression (Figure 2.3A). To further validate our observation, 
we coclustered the UPPL and BBN murine tumors with human tumors from the The 
Cancer Genome Atlas (TCGA; n = 408) using genes with corresponding homologs 
across the species and found that the majority of UPPL and BBN tumors coclustered 





Figure 2.3: BBN and UPPL tumors recapitulate the human basal and luminal molecular 
subtypes of bladder cancer. (A) Waterfall plot of the correlation to the basal centroid for 
BBN and UPPL primary tumors, with an accompanying confusion matrix indicating the 
subtype calls. (B) Unsupervised clustering heatmap of BBN and UPPL primary tumor 
samples with the TCGA BLCA dataset across genes in the BASE47 classifier. (C) 
Representative flowchart of the workflow to transition a primary tumor extracted from a 




heatmap of MB49, BBN963, UPPL1541, and normal urothelium (KT) cell lines across 
the top 10% most differentially expressed genes across the samples. (E) Unsupervised 
clustering heatmap of MB49, BBN963, and UPPL1541 cell line–derived tumors across 
the top 10% most differentially expressed genes across the samples. (F) Box plots of 
Pparg and Gata3 gene signature scores from RNA-seq data of BBN963 and UPPL1541 
cell line–derived tumors. (G) IPA analysis plots showing activated pathways in MB49 
cell line–derived tumors relative to BBN963 and UPPL1541 cell line–derived tumors. (H) 
Flow cytometry plot for EpCAM expression in 3T3, MB49, UPPL1541, and BBN963 cell 
lines. (I) Western blot of whole-cell lysates from 3T3, MB49, MBT2, and BBN963 cell 
lines blotted for the indicated antibodies. 
Currently, very few cell lines exist for modeling bladder cancer in 
immunocompetent mice; therefore, we set out to generate additional cell lines that could 
be utilized in future studies. In particular, MB49 cells have long been the workhorse of 
syngeneic bladder cancer cell lines90 for studies requiring an immunocompetent host. 
Given the long latency of tumor formation in the UPPL model, we established tumor cell 
lines from both UPPL and BBN tumors using the conditional reprogramming of cells 
(CRC) method described previously98. Specifically, transplantable cell lines were 
established from BBN (BBN963) and UPPL (UPPL1541) tumors (Figure 2.3C) and 
have been confirmed to grow in C57BL/6 mice. In parallel, using the CRC method, we 
generated three primary cell lines derived from normal mouse urothelium of tamoxifen-
treated K5-CreERT2; Rosa26LSL-tdTomato mice, hereafter called KT mice (KT1044, 
KT1975, and KT1970) as a normal reference for comparison. Interestingly, the vast 
majority of epithelial cells that grew in vitro from CRC culture of KT mouse bladders 
expressed tdTomato, suggesting they at some point had expressed K5 (Supplementary 
Fig. S3). 
To assess the similarities between our newly generated models and MB49 cells, 
we performed whole-transcriptome profiling on the BBN963 and UPPL1541 cell lines, 




and KT1970). Unsupervised hierarchical clustering of the cell lines on differentially 
regulated genes across samples (Supplementary Table S2) demonstrated that MB49 
cells had transcriptome profiles that differed significantly from the other cell lines 
(Figure 2.3D) when tested by multiscale bootstrap resampling (P = 0.0, Supplementary 
Fig. S4A), whereas BBN963 and UPPL1541 cells had transcriptome profiles that more 
closely resembled normal urothelial (KT) cells. To ensure that we had not tainted our 
MB49 cells, we obtained MB49 cells from an independent source (Phil Abbosh, Fox 
Chase Cancer Center, Philadelphia, PA) and performed transcriptome profiling. We 
found that the transcript level (across all genes) is highly correlated when comparing 
“UNC MB49” with “FCCC MB49” (R = 0.94 respectively, Supplementary Fig. S4B), 
suggesting our MB49 cells were genuine. Intriguingly, hierarchical clustering of MB49 
cells with 3T3 cells, our three primary mouse urothelial cell lines, BBN963 cells, and 
UPPL1541 cells demonstrated that the MB49 cells coclustered with 3T3 cells 
(Supplementary Fig. S4C) significantly by PVClust (Supplementary Fig. S4D). To 
examine the RNA expression profiles of these cell lines in the context of the tumor 
microenvironment, we generated RNA expression data on cell line–derived tumors from 
MB49, BBN963, and UPPL1541 cells. Clustering of these cell line–derived tumors using 
differentially regulated genes (Supplementary Table S3) again demonstrated that MB49 
tumors have significantly divergent transcriptome profiles when tested by multiscale 
bootstrap resampling (P = 0.0, Supplementary Fig. S5A) and demonstrate that this 
finding is not merely an artifact of cell culture (Figure 2.3E). Finally, reassuringly, Pparg 




tumors (Figure 2.3F), demonstrating that cell line–derived UPPL1541 tumors maintain 
molecular features of a luminal-like molecular subtype. 
We next performed Ingenuity Pathway Analysis comparing MB49, UPPL1541, 
and BBN963 cell line–derived tumors. General pathways related to cancer were 
enriched in BBN963 tumors relative to UPPL1541 tumors (Supplementary Fig. S5B). In 
contrast, pathways related to fibrosis and epithelial-to-mesenchymal transition (EMT) 
appeared to be highly upregulated in MB49 cell line–derived tumors compared with 
either the BBN963 or UPPL1541 tumors (Figure 2.3G). Based on these observations, 
we examined the expression of a set of epithelial markers in the mouse bladder cell 
lines. Assessment of EpCAM by flow cytometry demonstrated that a significant 
proportion of BBN963 and UPPL1541 cells expressed cell surface EpCAM while MB49 
cells had little to no EpCAM expression, similar to the mouse fibroblast line 3T3 (Figure 
2.3H). In keeping with this finding, we also noted that MB49 cells did not express K5 or 
K14 in immunoblots of whole-cell lysates (Figure 2.3I), implying that MB49 cells have 
lost characteristic urothelial cytokeratin expression patterns potentially from undergoing 
EMT. Furthermore, we noted that MB49 cell line–derived tumors had relatively high and 
low expression of vimentin and Cdh1 (E-cadherin), respectively, consistent with MB49 
cells being more mesenchymal than BBN963 and UPPL1541 cell line–derived tumors 
(Figure 2.3I; Supplementary Fig. S6). In aggregate, these findings suggest that MB49 
cells and tumors more closely resemble fibroblasts than urothelial cells and highlight the 
potential benefit of our models. 




Human basal-like and luminal-like bladder cancers demonstrate different patterns 
of immune infiltration and are also correlated with differential response to checkpoint 
inhibitor therapy83,85, suggesting subtype-specific differences in the tumor-immune 
microenvironment. Immune gene signature expression derived from previously 
published studies were compared among 11 BBN and 9 UPPL models83,100,101,105. 
Consistent with immune gene signature patterns observed in human tumors, BBN 
(basal-like) tumors demonstrated greater overall expression of immune gene signatures 
(Figure 2.4A; Supplementary Fig. S7A) than did UPPL (luminal-like) tumors, including 






Figure 2.4: Immune characterization of UPPL1541 and BBN963 subtype-specific bladder 
models. (A) Immune gene signature expression across 9 UPPL and 11 BBN primary 
tumors. (B) Flow cytometric characterization of tumor-infiltrating T cells (CD3+) in cell 
line–derived (allograft) BBN963 and UPPL1541 tumors. Each datapoint represents an 
independent mouse. (C) Frequency of CD8+ to CD4+ T cells in cell line–derived BBN963 
and UPPL1541 tumors. (D) Flow cytometric characterization of tumor-infiltrating B cells 
(B220+) in cell line–derived BBN963 and UPPL1541 tumors. (E) T-cell phenotypic 




increased phenotypes highlighted with respective colors (Mann–Whitney U test, *, P < 
0.05; **, P < 0.001). (F and G), Heatmap (F) and respective quantification (G) of T-cell 
receptor clonotype sharing within cell line–derived BBN963 and UPPL1541 tumors, 
derived from whole-tumor RNA-based T-cell receptor amplicon sequencing. H) Predicted 
neoantigen burden (class I and II, >500 nmol/L predicted binding affinity) in MB49, 
BBN963, and UPPL1541 cell line–derived tumors. 
To further explain the observed immunologic differences between BBN and 
UPPL tumors, we performed flow cytometric analysis in cell line–derived BBN963 and 
UPPL1541 tumors. Comparing the frequency of tumor infiltrating lymphocytes (TIL) by 
flow cytometry from BBN963 and UPPL1541 tumors, we observed significantly greater 
frequencies of CD3+ T cells (Figure 2.4B), as well as increased ratio of CD8+ cytotoxic 
T cells to CD4+ helper T cells (Figure 2.4C) in BBN963. Somewhat surprisingly, the 
proportion of B cells was higher in UPPL tumors; however, the overall proportion of B 
cells in the lymphocytic infiltrate was low (Figure 2.4D). To further characterize the 
phenotype of the tumor-infiltrating T cells, expressions of CD44 and CD62L were used 
to identify naïve (CD44−, CD62L+), central memory (CM; CD44+, CD62L+), and 
effector memory (EM; CD44+, CD62L−) populations. Among CD4+ T cells, UPPL1541 
tumors were enriched for naïve T cells, whereas the frequency of the total memory pool 
(CD44+) was significantly greater in BBN963 tumors (Figure 2.4E). Moreover, EM and 
CM frequencies both trended higher in BBN963. Among CD8+ T cells, the CM 
frequency was significantly greater in BBN963. In addition, CD4+ FoxP3+ regulatory T 
cells trended toward higher frequency in BBN963. Thus, memory subpopulations of 
both CD8+ and CD4+ T cells had increased frequencies in the BBN tumors, suggesting 
the presence of an antigen driven T-cell response in BBN963. 
Analyzing BBN963 and UPPL1541 cell line–derived tumors by TCR repertoire 




animals (Figure 2.4F,G), suggesting that there may be greater convergent repertoire 
selection in BBN tumor-infiltrating T cells in the context of an antigen-driven response. 
To examine whether the increased immune infiltration and TCR repertoire sharing seen 
in BBN tumors were associated with the number of targetable tumor antigens, we 
performed neoantigen prediction on BBN963 and UPPL1541 cells and not unexpectedly 
observed significantly higher neoantigen burden in BBN963 compared with UPPL1541 
(Figure 2.4H; Supplementary Tables S4 and S5). This, in combination with the 
increased TCR repertoire sharing, further supports the hypothesis that the immune 
infiltration seen in BBN tumors is driven by an antigen-specific immune response. 
To investigate the functional significance of immune infiltrating T-cell 
subpopulations, we performed univariable linear regression with frequency of T-cell 
phenotypic subpopulations as a continuous predictor variable and tumor mass as the 
response variable in untreated mice. In BBN963, the frequency of total and naïve CD8+ 
T cells was positively associated with tumor mass, and the frequency of CD4+ memory, 
CD4+ CM, total CD8+ memory, and CD8+ EM T cells were all inversely correlated with 
tumor mass (Supplementary Fig. S7B). In UPPL1541, no features were positively 
associated with tumor mass, whereas CD8+ total memory and specifically CD8+ CM T 
cells were both weakly inversely correlated with tumor mass. These associations are 
suggestive of tumor-infiltrating memory T cells being functional and capable of antitumor 
activity in both BBN and UPPL, with greater functional significance in BBN963. 




The relative overexpression of immune gene signatures and evidence of an 
antigen driven T-cell response in BBN963 cell line–derived tumors are suggestive of 
possible greater responsiveness to immune checkpoint inhibitor therapy in BBN963. 
Accordingly, we observed dramatic decreases in mean tumor volume in BBN963 
following anti–PD-1 therapy, while UPPL1541 tumors demonstrated only modest control 
of tumor growth (Figure 2.5A,B). Despite the mean tumor size being substantially 
controlled in BBN963 following anti–PD-1 therapy, the growth pattern of individual 
tumors demonstrated a mixed-response pattern (Figure 2.5C). There was 
heterogeneity of anti–PD-1 response in UPPL1541 tumors as well (Figure 2.5D). The 
difference in responsiveness between BBN963 and UPPL1541 tumors did not appear to 
be secondary to differential expression of PD-L1 as both BBN963 and UPPL1541 cell 





Figure 2.5: Anti–PD-1 treatment of BBN963 and UPPL1541 cell line–derived tumors. (A) 
Mean tumor volume of C57BL/6 mice bearing BBN963 tumors treated with either control 
IgG or anti–PD-1 antibody. Anti–PD-1 treatment was begun when tumors reached 200 
mm3. (B) Mean tumor volume of C57BL/6 mice bearing UPPL1541 tumors treated with 




reached 200 mm3. (C) Tumor volume of individual mice from A. (D) Tumor volume of 
individual mice from B. (E) BBN963 and UPPL1541 cells were treated with IFN-γ, and 
flow cytometry was used to detect cell surface PD-L1 expression. 
In order to elucidate the immune correlates of these two phenotypes in response 
to anti–PD-1 therapy, we repeated anti–PD-1 antibody treatments (Figure 2.6A) and 
analyzed the TIL populations among anti–PD-1 responder and nonresponder BBN963 
tumors once response class could be determined on day +14 following tumor 
inoculation. Surprisingly, no significant changes were observed in the overall T- and B-
cell infiltration frequencies by flow cytometry in responders versus nonresponders 
(Figure 2.6B). In addition, phenotyping of tumor-infiltrating T cells demonstrated only 
significantly greater frequencies of total CD4+ among nonresponders, with subtle, 
nonsignificant variations among other T-cell phenotypic subpopulations (Figure 2.6C). 
Despite these minimal differences, comparison of subpopulation ratios demonstrated an 
overall significant increase in the frequency of total memory-to-regulatory T cells as well 
as significantly higher ratios of CD8+ to CD4+ T cells in responders (Figure 2.6D). To 
further examine the role of TILs among responder and nonresponder tumors, we 
calculated immune gene signatures derived from total tumor RNA-seq and 
independently correlated these signatures to tumor mass. Although nonresponders only 
demonstrated modest inverse correlation between a single CD8+ T-cell immune 
signature and tumor mass, responder tumor mass was inversely correlated with multiple 
immune cell signatures, most significantly with cytotoxic T-cell and CD8+ T-cell 
signatures (Figure 2.6E). These data in aggregate demonstrate the potential 
importance of the balance of effector to suppressor T-cell subpopulations, rather than 






Figure 2.6: Description and immune characterization of BBN963 mixed-response 
phenotype. (A) Tumor growth curves of anti–PD-1 treated, cell line–derived BBN963 
tumors, showing responders (black) and nonresponders (red) to therapy. (B) Flow 
characterization of tumor-infiltrating T cells (CD3+) and B cells (B220+) in untreated 
(black), responder (red), and nonresponder (blue) BBN963 tumors. (C) T-cell phenotypic 




increased phenotypes highlighted with respective colors (Mann–Whitney U test, *, P < 
0.05). (D) Frequency of memory to regulatory T cells (CD3+CD44+: CD3+CD4+FoxP3+) 
and CD8+ to CD4+ T cells in responder versus nonresponder BBN963 tumors. (E) 
Univariable correlation of tumor size to immune gene signature expression in responder 
(left) and nonresponder (right) BBN963 tumors. Shannon entropy index (F) and receptor 
clonotype sharing (G) of tumor-infiltrating B-cell receptor heavy chain expression in 
responder and nonresponder BBN963 tumors. 
To address the role of clonality of the tumor-infiltrating lymphocytes in controlling 
tumor growth in anti–PD-1 responsive BBN963 tumors, we performed TCR and BCR 
repertoire profiling of responder and nonresponder whole tumor RNA. We observed a 
modest, nonsignificant increase in TCR clonotype sharing (Supplementary Fig. S8A and 
S8B) and no differences in Shannon entropy (Supplementary Fig. S8C) between 
responder and nonresponder tumors. In contrast, BCR profiling demonstrated 
significantly lower Shannon entropy indices (Figure 2.6F) and significantly greater 
clonotype sharing among responders (Figure 2.6G), suggesting a potentially important 
role for B-cell clonal shift in mediating response in the BBN963 model. 
BBN963 and UPPL1541 models express targetable, immunogenic neoantigens 
With the recent interest in neoantigens as biomarkers of immunotherapy 
response and therapeutic targets for personalized immunotherapy, we sought to identify 
and validate neoantigen targets in our subtype-specific bladder models. Using 
previously described methods83, neoantigens were predicted in BBN963, MB49, and 
UPPL1541 cell line–derived tumors (Figure 2.7A), selecting for predicted class I and II 
binders by NetMHCpan and NetMHCIIpan (affinity < 500 nmol/L). Using 5x RNA-seq 
coverage and expression in all replicates as cutoffs, we observed BBN963 to have the 
greatest number of class I (48) and class II (18) predicted neoantigens, followed by 




potential of these predicted neoantigens, we synthesized 96 of 110 predicted 
neoantigens and performed vaccination/ELISPOT analyses to identify the ability of each 
peptide to induce an IFN-γ response in T cells stimulated by neoantigen peptide-pulsed 
dendritic cells. Mice were vaccinated with a pool of eight random, equimolar peptides, 
and splenocytes derived from vaccinated mice were subsequently pulsed with one of 
the eight peptides on an IFN-γ capture ELISPOT plate (Figure 2.7B,C). Based on the 
number of spots induced by each peptide, we observed MB49 to contain the most 
highly immunogenic class I and II peptides, holding eight of the top 10 neoantigens by 
IFN-γ response. This is followed by BBN963, and lastly by UPPL1541, which contained 
only one peptide within the top 15. Class I and II neoantigens were equally represented 
among the top binders, with four and six of 10 top neoantigens predicted as class II and 
class I, respectively. Finally, to test the potential for these peptides to generate 
neoantigen-enriched T-cell populations, we performed two rounds of vaccination in wild-
type C57BL/6 mice using the top eight BBN963 neoantigens, followed by ex vivo 
stimulation using one of the respective peptides. Coculture of these neoantigen-
enriched T cells with BBN963 tumor cells demonstrated an IFN-γ response over that of 
irrelevant peptide control in five of eight peptides, emphasizing the potential of these 





Figure 2.7: Neoantigen prediction and validation in BBN963, UPPL1541, and MB49. (A) 
Schema for neoantigen prediction workflow, using tumor DNA, tumor RNA, and matched 
normal DNA to call mutations via UNSeqr, epitope prediction to identify predicted class I 
and II binders, and vaccine/ELISPOT validation. (B) Summary of vaccine/ELISPOT 
results in MB49, BBN963, and UPPL1541, with background subtracted counts ranked by 
number of spots and representative figures of highly immunogenic wells (G1, C4, G9), 
weakly immunogenic wells (F4, H7, C5), and controls. (C) Summary of top eight predicted 
neoantigens in MB49 (red), BBN963 (blue), and top four predicted neoantigens in 
UPPL1541 (green), including sequence, predicted MHC class, and rank among all 
screened peptides within all three models. (D) IFN-γ ELISPOT results of BBN963 
neoantigen-enriched T cells cocultured with BBN963 tumors, as a percentage peptide-
pulsed target positive control. Blue dashed line marks IFN-γ intensity of irrelevant peptide 




 2.1.4 Discussion 
We describe here the first molecular subtype-specific murine model of luminal-
like bladder cancer. The BBN model was derived from carcinogen-treated mice that 
develop spontaneous bladder tumors and exhibit a basal phenotype as previously 
described by others79. We extend these findings by demonstrating that the BBN model 
also has an immune infiltration pattern that is consistent with that of human basal 
tumors83. The UPPL model was derived from mice with directed knockout of Trp53 and 
Pten in the urothelial umbrella cells under the control of the Uroplakin-3a promoter. 
UPPL tumors have papillary histology, decreased immune infiltration, and decreased 
response to PD-1 inhibition relative to BBN tumors. Characterized by gene expression 
profiling, these models reflect human bladder cancer and normal urothelium more 
closely than does the commonly used MB49 model, which appears to more closely 
resemble fibroblasts. These results imply the BBN and UPPL models will prove to be 
valuable resources in studying bladder cancer in immunocompetent animals, and they 
will be a unique resource with which to study molecular subtype-specific biology and 
treatment effects. 
Although dual inactivation of Trp53 and Pten in Upk3a-expressing cells led to 
robust bladder tumor formation, inactivation of these same genes in K5-expressing cells 
did not result in any apparent neoplasia or preneoplastic changes. Although we had set 
out with the goal of answering whether inactivation of Trp53 and Pten in K5-expressing 
basal and intermediate urothelial cells was permissive for tumorigenesis, we are 
hesitant to conclude too much from our negative findings given the significant technical 




(systemic tamoxifen by gavage) and K5-expressing cells (local 4-OHT administration 
into the bladder). Nonetheless, at face value, our results suggest that dual inactivation 
of Trp53 and Pten are sufficient to initiate bladder tumors in Upk3a-expressing but not 
K5-expressing urothelium. 
The immune microenvironments of the mouse models also reflect patterns seen 
in human disease, with increased overall immune infiltration seen in the BBN basal-like 
model83. In parallel with the active immune response, BBN tumors showed increased 
expression of genes associated with immunosuppression, which is presumably an 
adaptive response to suppress and/or evade antitumor immunity. In the BBN (basal-
like) model, we noted increased memory polarization, which is complimented by 
significantly higher expression of EM T-cell immune gene signatures in human basal 
versus luminal tumors among TCGA BLCA samples (Supplementary Fig. S9). These 
patterns mirror those observed in our prior study of human bladder cancer83 and imply 
that tumor immunobiology and mechanisms of resistance to immunotherapy may differ 
by tumor molecular subtype. Importantly, there were a number of aspects noted in the 
described mouse models that have not been as yet examined in human tumors. In the 
BBN (basal-like) model, we noted increased T-cell clonotype sharing, suggesting the 
presence of an active antigen-driven response in these tumors. In contrast, UPPL 
(luminal-like) tumors showed decreased overall immune infiltration along with an 
increased frequency of naïve T cells, consistent with immune exclusion and lack of 
antigen experience, respectively. 
Our study also highlights several limitations of the widely used MB49 murine 




urothelial cytokeratins, lack of EpCAM expression, and a profound skewing toward 
having undergone epithelial-to-mesechymal cell transition. Compared with BBN and 
UPPL tumors, MB49 had a wide transcriptomic distance from both normal murine 
urothelial cells and more closely resemble immortalized fibroblasts. These results 
suggest that although MB49 may be adequate (or in some cases preferred) for studying 
some aspects of bladder cancer biology (e.g., the post-EMT state), the models reported 
in our study should gain wide use in the translational bladder cancer research 
community, both for their subtype specificity and increased fidelity to human bladder 
cancer gene expression profiles. 
Although recent work highlights the mutational faithfulness of the BBN model to 
human bladder cancer106 one limitation of the UPPL1541 and BBN963 models is the 
lack of driver mutations that are also known drivers in human basal-like and luminal-like 
bladder tumors. Major bladder cancer driver mutations such as MLL, FGFR3, and 
ARID1A are not mutated in either model, and suspected driver mutations in our BBN963 
line such as TCF4, FGFR2, and ITK are not seen at high frequencies in human disease 
(Supplementary Fig. S10). This limitation is not unique to our models, as it is also a 
feature of MB49. As RNA transcription is downstream of genetic events such as 
mutations and gene fusions and upstream of protein translation, we feel the 
transcriptomic fidelity of our models to human bladder cancer is evidence that these 
models can be used to faithfully study bladder cancer biology in general and subtype-
specific biology in particular. As both BBN and UPPL tumors exist as transplantable cell 
lines syngeneic with the C57BL/6 background and are able to grow both 




as CRISPR/Cas9 may be used to manipulate these tumors should researchers desire to 
study effects of specific mutations in the context of subtype-specific tumors. A second 
limitation of the UPPL model, especially for tumor immunology studies, is accounting for 
the potential effect of PTEN inactivation on the immune microenvironment. PTEN has 
been found to promote nuclear import of the transcription factor Interferon Regulatory 
Factor 3 (IRF3), thereby positively regulating type I IFN induction107. PTEN loss has 
also been associated with impaired T-cell tumor ingress and T-cell mediated cytotoxicity 
in a preclinical model of melanoma where human tumor cell lines engineered with PTEN 
silenced and to express the murine MHC class I molecule H-2Db were injected into 
immunocompromised mice followed by transfer of murine antigen-specific T cells and 
antigen-presenting cells 7 days later108. Thus, it is possible that the UPPL model may be 
skewed toward an immune evaded or suppressed phenotype due to PTEN loss. 
In the ImVigor 210 study, Rosenberg and colleagues showed that a subset of 
luminal tumors were more likely to respond to PD-1 axis inhibition using an anti–PD-L1 
antibody85. We report here that response to monotherapy using an mAb against PD-1 
was effective in the BBN but not the UPPL model. This represents a potential 
discrepancy between our murine models and their homonymous human subtypes; 
however, that conclusion is tempered by two considerations: (i) Our group's luminal 
versus basal predictor is different from that used by the ImVigor investigators, and 
unfortunately despite publication the ImVigor RNA-seq data have yet to be made public, 
and (ii) the subset of luminal tumors more likely to respond was also more heavily 




marked them as basal by our classifier and/or represent a subset of luminal tumors not 
modeled by UPPL. 
The BBN model exhibited a mixed response to anti–PD-1 therapy, which allowed 
us to evaluate differences in the tumor immune microenvironment between responders 
and nonresponders. Responsive tumors showed higher degrees of CD8+-to-CD4+ T-
cell infiltration and memory-to-regulatory polarization of the tumor-infiltrating T cells. The 
former finding is consistent with prior results in human bladder cancer85, whereas the 
latter is to our knowledge the first report of memory T-cell polarization associating with 
response to immune checkpoint inhibition in bladder cancer. This is consistent with the 
hypothesis that tumor clearance is augmented by generation of T-cell memory. 
Although multiple T-cell immune gene signatures were strongly correlated with tumor 
mass in responders, we observed an overall lack of TCR clonotype sharing increase in 
tumor-infiltrating T cells in responders compared with nonresponders. In addition, 
significant changes to the B-cell clonotype sharing and diversity were observed, 
suggesting B cells may play an important role in the response to checkpoint inhibitor 
therapy. Presumably, this pattern of TCR and BCR expression could be explained by 
several hypotheses: (i) that effector T-cell clones capable of promoting antitumor 
immunity are only present in responders but their frequencies are too low to result in 
discriminating differences in global T-cell diversity changes, or (ii) that effector T-cell 
clones capable of promoting antitumor immunity are present in both responders and 
nonresponders, but the presence of specific B-cell clones is necessary to mediate their 
function. Ongoing studies are evaluating pretreatment tumor features and on-treatment 




therapy, as well as to test novel combinations of immunotherapy agents. Thus, this 
model provides a novel mixed-response platform to study efficacy and mechanisms of 
immunotherapy in bladder cancer. 
2.2 Immuno-PET imaging of tumor-infiltrating lymphocytes using Zirconium-89 
radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic 
tumors. 
 2.2.1 Introduction 
Successful clinical trials using blocking antibodies to the T-cell co-inhibitory 
receptors CTLA-4 and PD-1 have driven the recent emergence of interest in cancer 
immunotherapy, leading to accelerated approval timelines for several 
immunotherapeutic agents across multiple tumor indications85,109–114. However, the 
magnitude of interaction between the immune system and tumors varies greatly both 
within and across tumor types, resulting in differences in the response to checkpoint 
immunotherapy. Many of these alterations depend on the presence of impaired tumor 
antigen-specific effector T cells, which have been positively associated with treatment 
efficacy115,116. Thus, one hypothesis has been that the presence of T cells within the 
tumor microenvironment is critical to the success of checkpoint immunotherapy. 
The ability to monitor T cells within the tumor microenvironment and the immune 
response over the course of therapy may allow for early determination of the treatment 
efficacy117,118. Flow cytometry, quantitative polymerase chain reaction, Vβ 
spectratyping, high-throughput sequencing, and immunohistochemistry are among the 
techniques that have provided useful information about antitumor T-cell immunity. 




greatly limiting the ability to monitor intratumoral T-cell accumulation in vivo or in real 
time. With the expanding implementation of immunotherapies, tools to monitor immune 
cell activity become increasingly crucial for guiding clinical decision-making and 
elucidating treatment options. Additionally, immune cell monitoring can be applied to 
chimeric antigen receptor (CAR) T cell based therapies, which have demonstrated 
clinical efficacy in human B cell cancers, providing a measure of both patient and donor 
T cell location and activity118. Non-invasive imaging of T cells and tumor-infiltrating 
lymphocytes will be an attractive means of detecting T cell infiltration and tracking the 
response to therapy119. Non-invasive monitoring could therefore change how therapies 
are applied and assessed, to the benefit of patients119. 
Positron emission tomography (PET) and single-photon emission computed 
tomography (SPECT) have been successfully used to obtain clinical images of immune 
cell populations117,120. Other techniques such as ex vivo cell labeling and radiolabeled 
metabolic probes have also been used to non-invasively image lymphocytes. However, 
these approaches are not specific for T cells, have toxic effects, or simply fail to detect 
lymphocytes infiltrating within the tumor121. Immuno-PET is an emerging technique that 
combines the specificity of monoclonal antibodies (mAb) with the high sensitivity and 
quantitative potential of PET to non-invasively identify disease, stage, and response to 
therapy. Immuno-PET targeting of lymphocytes can provide spatial and temporal 
information that is currently unavailable using the standard techniques121. Antibodies 
with high affinity and specificity can be conjugated to radionuclides, and PET imaging 
can be used to non-invasively monitor and quantify mAb distribution in real time122. 




for immuno-PET clinical studies due to its physical and biological characteristics123. In 
addition, 89Zr is a residualizing isotope, which prevents the isotope from leaving the 
target after internalization of labeled antibody124. Thus, 89Zr-immuno-PET is a powerful 
tool to study antigen-antibody interactions. 
Recent reports have demonstrated that antibody fragments radiolabeled with 
64Cu can non-invasively detect CD8+ cytotoxic T lymphocytes in mice using immuno-
PET125. In a similar fashion, zirconium-89 radiolabeled cys-diabodies were successfully 
used to non-invasively detect CD4+ T-cell repopulation in wild-type mice and a model of 
immune reconstitution following hematopoietic stem cell transplantation121. Furthermore, 
89Zr radiolabeled cys-diabody detected increased CD8+ tumor-infiltrating lymphocytes 
in an animal model of colon carcinoma126. This work demonstrated that immuno-PET 
targeting of CD4 and CD8 has the potential to non-invasively detect helper/regulatory 
and cytotoxic T-cell populations in vivo. 
One limitation of the use of antibodies specific for CD4 and/or CD8 for imaging is 
the limited information obtained regarding the breadth of the T cell response. A more 
inclusive cell surface protein expressed by T cells is the pan T-cell marker CD3, which 
is found at all stages of T-cell development. The specificity of the CD3 antigen for T-cell 
lineage cells and its presence at all stages of T-cell development make CD3 a rational 
candidate for detecting pan-T-cell populations in vivo. 
Antibodies specific for CD3 can have substantial effects on the function of CD4+ 
and CD8+ T cells in vivo, including induced T cell activation and expansion127–129. 




cells in vivo116,129. Therefore, while anti-CD3 mAb can be used to tag T cells, its effects 
in vivo are variable and depend on dosage, isotype, surface antigen density on target T 
cells, and antigen internalization/modulation of the target cell population127–132. 
Previously, zirconium-89 labeled anti-CD3 indicated a strong correlation between anti-
CTLA-4–treated mice and tumor volume133. However, the immunological effects of 
radiolabeled anti-CD3 mAb at the doses used for PET imaging are still unknown. It is 
therefore important to elucidate the immunomodulatory effects of this novel compound 
to determine if it has the potential to polarize T cells toward an activated and potentially 
anti-tumor phenotype when used as a component of immuno-PET imaging. 
We hypothesized that 89Zr radiolabeled anti-CD3 mAb has potential for immuno-
PET detection of tumor-infiltrating T lymphocytes in mice bearing syngeneic tumors 
without changing overall lymphocyte numbers or viability. 
 2.2.2 Results 
89Zr-DFO-anti-CD3 reagent generation and evaluation 
Full details of DFO-conjugation, radiolabeling and subsequent chemical analysis 
can be found in the supplementary information (S1 File). Briefly, the conjugation 
reaction between murine anti-CD3 mAb and DFO yielded 1.1 chelating group per 
protein molecule based on MALDI-TOF mass spectrometry ([m/z (DFO-anti-CD3)–m/z 
(anti-CD3)]/ M.W (DFO) = 148438–147606/752 = 1.1). The DFO-anti-CD3 was isolated 
and purified with chemical purity higher than 98%. Non-reduced SDS-PAGE for both 
DFO-anti-CD3 conjugate and unmodified anti-CD3 showed similar bands with apparent 




change in apparent molecular weight between the heavy chains of the DFO-anti-CD3 
conjugate and unmodified anti-CD3. This further confirmed the low degree of DFO 
conjugation to anti-CD3 determined by MALDI-TOF-MS. The 89Zr-DFO-mAb 
conjugates were isolated using size exclusion chromatography (SEC) with radiolabeling 
yields > 85% and specific activities >185 MBq/mg (>5 mCi/mg). Following SEC 
purification, the radiochemical purity of 89Zr-DFO-anti-CD3 was higher than 97%. SE-
HPLC chromatograms, MALDI-TOF MS spectrums and SDS-PGE can be seen in 
supplementary info (S1, S2 and S3 Figs). To ensure the stability of our antibody 
conjugate in mouse serum, we performed an in vitro 72h serum stability assay. The 
radiochemical purity of 89Zr-DFO-CD3 remained higher than 98% at 72h post-
incubation in C57BL/6 mouse serum. This corresponds with the lower uptake of 89Zr-
DFO-CD3 in bone seen in the μPET/CT and ex-vivo biodistribution studies (S4 Fig). To 
demonstrate that labeling of antiCD3 did not alter the biological activity of the protein, a 
saturation binding assay was performed, resulting in a binding affinity of 89Zr-DFO-
antiCD3 of 14.17 ± 3.75 nM and saturation plateau, indicating fully preserved 
immunoreactivity (S5 Fig). 
Biodistribution of 89Zr-DFO-anti-CD3, 89Zr-DFO-IgG2b, and 89Zr-DFO-IgG in healthy 
C57BL/6J mice 
In order to evaluate in vivo targeting of 89Zr-DFO-anti-CD3, a biodistribution 
study was performed on 6 healthy C57BL/6J mice. Mice were intravenously injected via 
tail vein with 825.1 ± 14.8 kBq (22.3 ± 0.4 μCi, ~4 μg, 100 μL) of 89Zr-DFO-anti-CD3, or 
89Zr-DFO-IgG2b or 89Zr-DFO-IgG as isotype and non-isotype specific matched heavy-




(BE0002), was also radiolabeled with 89Zr and evaluated in vivo to ensure that the Fc 
region was not responsible for uptake in target organs. The biodistribution of generic 
89Zr-IgG in C57BL/6J was likewise performed in order to determine nonspecific binding 
from organs involved with antibody clearance and elimination. T cells reside in the 
spleen, lymph nodes, thymus, and bone marrow; therefore those organs were 
harvested and measured for radioactivity134. The liver and blood were additionally 
harvested to monitor antibody clearance through the hepatobiliary pathway. Finally, the 
contrast ratio of tissue to blood was evaluated to determine in vivo imaging potential. 
Biodistribution results are shown in Figure 2.8 and Table 2.1. 89Zr-DFO-anti-CD3 
showed the highest uptake in the spleen followed by the axillary lymph nodes (ALN) at 
72h post-injection. Very low concentrations of 89Zr-DFO-anti-CD3 were measured in 
the blood and bone marrow at 72h post-injection. 
 
Figure 2.8. Scatter dot plots from the ex-vivo biodistribution study of 89Zr-DFO-anti-CD3, 
89Zr-DFO-IgG2b, and 89Zr-DFO-IgG in untreated C57BL/6J mice. Each dot represents 
a unique mouse. Six mice (n = 6) were analyzed in each of the 3 groups for a total of 18 
mice. Horizontal lines represent mean ± standard deviation. All tissue uptake data were 
normalized by the weight of the tissue being measured. All measurements were taken at 
72 hours after injection of antibody. P-values were calculated in Table 2.1 using 






Table 2.1. Results from the ex-vivo biodistribution of 89Zr-DFO-anti-CD3, 89Zr-DFO-
IgG2b, and 89Zr-DFO-IgG in C57BL/6J mice (n = 6 per group). 
 
To evaluate whether the uptake in target organs may be due to the interaction 
between 89Zr-DFO-anti-CD3 and T-cells, the biodistributions of both isotype control 
(89Zr-DFO-IgG2b) and IgG control (89Zr-DFO-IgG) were also tested in healthy 
C57BL/6J mice (n = 6 per group). At 72h post injection, the blood concentration of 89Zr-
DFO-anti-CD3 was minimal (0.9% ID/g) when compared to 89Zr-DFO-IgG2b (10.61%) 
and 89Zr-DFO-IgG (20.31%) controls. Indicating rapid clearance and/or uptake of 89Zr-
DFO-anti-CD3 (Figure 2.8, Table 2.1). Moreover, localization of 89Zr-DFO-anti-CD3 to 
T cell rich organ like spleen, and lymph nodes showed significantly higher accumulation 
than the controls. Finally, liver uptake for 89Zr-DFO-anti-CD3 was significantly lower 
than 89Zr-DFO-IgG2b and 89Zr-DFO-IgG. Whole counts of the thymus did not show 
large statistical differences, however, when the thymus to blood ratio was considered; 
the 89Zr-DFO-anti-CD3 was statically higher than either of the two controls. High 




observed for 89Zr-DFO-anti-CD3 confirmed high accumulation in tissue known to have 
high T cell counts. 
PET/CT studies of 89Zr-DFO-anti-CD3 in healthy C57BL/6J mice 
Following the promising results from the biodistribution study, a microPET/CT 
study was performed on six healthy C57BL/6J mice (n = 6) to evaluate immuno-PET 
imaging potential of T cells with 89Zr-DFO-anti-CD3. Healthy C57BL/6J mice were 
intravenously injected via tail vein with 5.6 ± 0.2 MBq (153.4 ± 4.1 μCi, ~25μg, 100 μL) 
of 89Zr-DFO-anti-CD3. High-contrast images were obtained at 72h post-injection 
(Figure 2.9A), where spleen, lymph nodes, and thymus were clearly visualized with low 
background. 
 
Figure 2.9. Micro-PET/CT images of 89Zr-DFO-anti-CD3 in C57BL/6J mice 72h post-
injection (coronal view). (A) Maximum intensity projection of 89Zr-DFO-anti-CD3 
injected into a healthy, immune-competent mouse. The radiolabeled antibody 
accumulated in the following lymphoid organs: cervical lymph nodes (CLN), thymus (T), 




PET/CT (coronal slice) of 89Zr-DFO-anti-CD3 in C57BL/6J mice bearing BBN975 
tumors and (C) a coronal slice of isotype control 89Zr-DFO-IgG2b in C57BL/6J mice 
bearing BBN975 tumors. Six mice (n = 6) in each of the 3 groups were imaged using 
PET/CT. SUV color bar on the left-hand side of the figure corresponds with subfigure A; 
SUV color bar on the right-hand side of the figure corresponds to subfigures B and C. 
Additional scans can be seen in the supplementary information. 
PET/CT and ex-vivo biodistribution studies of 89Zr-DFO-anti-CD3 and 89Zr-DFO-IgG2b 
in C57BL/6J mice bearing syngeneic tumors 
Next, we tested the ability of 89Zr-DFO-anti-CD3 to image tumor infiltrating T 
cells found in C57BL/6J mice bearing BBN975 syngeneic tumors. We compared 89Zr-
DFO-anti-CD3 versus the isotype control 89Zr-DFO-IgG2b using 6 mice for each group 
(2 groups, n = 6). Each group of C57BL/6J mice bearing BBN975 tumors were 
intravenously injected with 6.0 ± 0.1 MBq (162.5 ± 1.8 μCi, ~25μg, 100 μL) of 89Zr-
DFO-anti-CD3 or 89Zr-DFO-IgG2b. Immuno-PET scans of 89Zr-DFO-anti-CD3 showed 
high uptake in spleen, lymph nodes, and tumor (Figure 2.9B). Conversely, the isotype 
control (89Zr-DFO-IgG2b) did not show tumor uptake in microPET/CT scans (Figure 
2.9C). The isotype control also showed higher background than that for 89Zr-DFO-anti-
CD3 due to large amount of antibody-conjugate that remained in circulation. 
To further validate the microPET/CT scans, an ex-vivo biodistribution study of 
89Zr-DFO-anti-CD3 and 89Zr-DFO-IgG2b in C57BL/6J mice bearing BBN975 
syngeneic tumors were performed immediately following each PET scan (Figure 2.10). 
The results are summarized in Figure 2.10 and Table 2.2. Similar to the healthy-mouse 
study, the 89Zr-DFO-anti-CD3 had a significantly lower concentration in blood than the 
isotype control (89Zr-DFO-IgG2b). Also, 89Zr-DFO-anti-CD3 showed higher uptake in 




Liver uptake was significantly higher for 89Zr-DFO-IgG2b than for 89Zr-DFO-anti-CD3. 
Although there was a not statistical difference in tumor uptake between 89Zr-DFO-
IgG2b and 89Zr-DFO-anti-CD3, the tumor-to-blood ratio of 89Zr-DFO-anti-CD3 was 
11.5-fold higher than that for 89Zr-DFO-IgG2b. 
 
Figure 2.10: Scatter plots from the ex-vivo biodistribution study of 89Zr-DFO-anti-CD3 in 
C57BL/6J mice bearing BBN975 tumors.  Each dot represents a unique mouse. Six mice 
(n = 6) were analyzed in each of the 2 groups for a total of 12 mice. Horizontal lines 
represent mean ± standard deviation. All tissue uptake data were normalized by the 
weight of the tissue being measured. All measurements were taken at 72 hours after 






Table 2.2. Results from the ex-vivo biodistribution studies of 89Zr-DFO-anti-CD3 and 
89Zr-DFO-IgG2b in C57BL/6J mice bearing BBN975 tumors (n = 6 per group). 
 
Immunological effects of DFO-anti-CD3 in C57BL/6J mice 
To assess the immunological effects of antibodies used in the context of T-cell 
imaging, flow cytometric analysis of splenocytes from mice dosed with 25 μg of DFO-
anti-CD3, 25 μg of native anti-CD3, or PBS control was performed. Administration of 
antibody showed no significant differences in lymphocyte count or viability compared to 
PBS control (Figure 2.11). These metrics demonstrate that this dose of DFO-anti-CD3 
does not result in net-depletion of the splenic pan-lymphocyte population, of which T 
cells are a major component. To ensure free DFO did not significantly influence the T 
cell population within our studies, we performed a control experiment comparing T cell 
phenotypic subpopulation frequencies in free DFO versus PBS control treated animals. 




animals (0.4265 nmol), with no significant changes observed in any T cell population 
relative to PBS control (S7 Fig). 
 
Figure 2.11: Effects of DFO-anti-CD3 and unconjugated anti-CD3 treatment on total 
lymphocyte numbers and viability in the spleen of C57BL/6J mice. Y-axis corresponds to 
absolute event counts for each respective subfigure. 
DFO-anti-CD3 decreases the naïve CD8+ population and increases central/effector 
memory CD8+ populations 
Since changes in the frequency and enumeration of peripheral lymphocytes were 
not observed following DFO-anti-CD3 injection, we therefore determined if the DFO-
anti-CD3 altered the distribution of CD8+ and CD4+ T-cell sub-populations135. 
Specifically, naïve, total memory, central memory, and effector memory sub-populations 
were analyzed within the total CD8+ or CD4+ T-cell pools. The effect of DFO-anti-CD3 
resulted in a modest increase in the total CD8+ T cell population compared to the PBS 
control (16.22% vs 13.07%, p < 0.05, Table 2.3, S1 Table). There was a small but 




group compared to unmodified anti-CD3 treated animals (16.22% vs 12.45%, p < 0.05, 
Figure 2.12, Table 2.3, S1 Table). 
 
Figure 2.12: Representative gating (left) and immunological effects (right) of DFO-anti-
CD3 on CD8+ T-cell phenotype distribution. Effects of DFO-anti-CD3 and unconjugated 
anti-CD3 treatment on frequency of total, naïve, memory, central memory, and effector 
memory CD8+ T-cells in the spleen of C57BL/6J mice are shown. Total CD8+ 




Naïve, memory, central memory, and effector memory CD8+ percentages are with 
respect to total CD8+ populations. For all samples, statistical significance was determined 
via Kruskal-Wallis with a significance cutoff of * (P ≤ 0.05), ** (P ≤ 0.01), *** (P ≤ 0.001), 
or **** (P ≤ 0.0001), with n = 6 in all groups. Error bars represent standard deviation from 
the mean. 
 
Table 2.3. Effects of DFO-anti-CD3 and unconjugated anti-CD3 treatment on frequency 
of total, naïve, memory, central memory, and effector memory CD8+ T-cells in the 
spleen of C57BL/6J mice are shown. 
 
When comparing population changes between the DFO-anti-CD3 treated group 
versus the PBS control (S1 Table), we observed a significant decrease in naïve CD8+ T 
cells both in percentage (32.68% vs 70.48%) and total count (2.32x106 vs 3.68x106). A 
corresponding increase in memory CD8+ T cells by percentage (48.77% vs 22.75%) 
and count (3.41x106 vs 1.21x106) was also observed. A deeper look into the central 
memory and the effector memory populations identified significant changes when 
comparing DFO-anti-CD3 treated mice against PBS treated mice. Specifically, there 
was a significant increase in the central memory population (43.72% vs 17.50%, p < 
0.001) and a significant increase in the effector memory population (15.66% vs 7.23%, 




animals trended similarly to the respective cell populations in DFO-anti-CD3 treated 
animals. 
DFO-anti-CD3 decreases total CD4+ T cells and may decrease naïve, central memory, 
and effector memory populations 
Following interrogation of the CD8+ T-cell populations, we next looked at the 
effects of DFO-anti-CD3 on splenic CD4+ T cells. In contrast to the increases observed 
in the CD8+ T-cell population, total CD4+ T cells significantly decreased in the DFO-
anti-CD3 group when compared against a PBS control (9.02% vs 21.43%, p < 0.001, 
Table 2.4, S1 Table). There were no significant differences in the percentages of naïve, 
total memory, central memory, or effector memory CD4+ T-cell sub-populations 
between the DFO-anti-CD3 and PBS groups (Fig 2.13, Table 2.4, S1 Table). However, 
all of these populations trended toward a decrease in absolute count for the DFO-anti-
CD3 group likely due to the lower initial total CD4+ count. Changes in all CD4+ 
populations trended similarly between DFO-anti-CD3 and unconjugated anti-CD3 





Figure 2.13: Representative gating (left) and immunological effects (right) of DFO-anti-
CD3 on CD4+ T-cell phenotype distribution. Effects of DFO-anti-CD3 and unconjugated 
anti-CD3 treatment on frequency of total, naïve, memory, central memory, and effector 
memory CD4+ T-cells in the spleen of C57BL/6J mice. Total CD4+ percentages and 
counts are with respect to all live singlets within the lymphocyte gate. Naïve, memory, 
central memory, and effector memory CD4+ percentages are with respect to total CD4+ 
populations. For all samples, statistical significance was determined via Kruskal-Wallis 
with a significance cutoff of * (P ≤ 0.05), ** (P ≤ 0.01), *** (P ≤ 0.001), or **** (P ≤ 0.0001), 





Table 2.4. Effects of DFO-anti-CD3 and unconjugated anti-CD3 treatment on frequency 
of total, naïve, memory, central memory, and effector memory CD4+ T-cells in the 
spleen of C57BL/6J mice. 
 
 2.2.3 Discussion 
We report a non-invasive immuno-PET imaging study in which 89Zr radiolabeled 
anti-CD3 antibody was used to detect T-cell distributions in healthy mice and tumor-
infiltrating T lymphocytes in an immune-competent animal model bearing syngeneic 
tumors. Our method for targeting CD3 in vivo provides a sensitive and specific imaging 
technique for detecting peripheral and tumor infiltrating T lymphocytes. To the best of 
our knowledge, we are the first to elucidate the immunological effects of an anti-CD3 
ImmunoPET-agent on systemic T cell populations. Our results demonstrate that the 
CD3 antigen is a rational target to non-invasively study T cell populations in vivo. 
Further development of 89Zr-DFO-anti-CD3 mAb may be used to evaluate tumor-
infiltrating T cells cancer patients and predict their response to therapy. 
The design of an 89Zr-anti-CD3 immunoPET-agent required the conjugation of a 




chelator because its complex with Zr4+ has high chemical and biological stability137. In 
addition, the radiolabeling of 89Zr with DFO-conjugates takes place at room 
temperature, which is convenient for protein-based conjugates138. The chemical and 
radiochemical properties of our conjugate were consistent with other 89Zr-DFO-mAb 
radioimmunoconjugates previously reported138–140. 
The 89Zr-DFO-anti-CD3 conjugate demonstrated a remarkable ability to target 
and detect tumor-infiltrating and peripheral T cells in an immune-competent syngeneic-
tumor model. Absolute tumor signal was similar between 89Zr-DFO-anti-CD3 and the 
isotype control, but the 89Zr-DFO-anti-CD3 showed rapid clearance from the blood and 
yielded a tumor to blood ratio that was 11.5 times higher than the control. The 
combination of swift clearance and rapid protein recognition between 89Zr-DFO-anti-
CD3 and CD3+ T cells resulted in the clear visualization of tumor-infiltrating and 
peripheral T cells by microPET/CT. 
Investigation of the immunological effects of anti-CD3 and DFO-anti-CD3 on total 
lymphocyte frequency, number, and viability showed modest and non-significant 
differences compared to the PBS control. A deeper look at the immunological effects of 
DFO-anti-CD3 on CD4+ and CD8+ T-cell populations noted a more dramatic difference. 
For CD4+ T cells, DFO-anti-CD3 decreased the total count and percentage of the total 
CD4+ pool. This decrease was observed across all CD4+ sub-populations. The 
implication of this could be a decrease in a CD4+ T-cell mediated anti-tumor response, 
with a potentially diminished cellular (Th1/Th17) or humoral (Th2) immune function. 
There could also be a potential decrease in the CD4+ regulatory T cell population, in 




needed to identify how DFO-anti-CD3 affects each of these subpopulations, and to 
determine whether the overall skew is in favor of an anti-tumor immune response. 
Conversely, the immunological effects of DFO-anti-CD3 on CD8+ T-cells showed 
a significant increase in the total CD8+ pool. Our experiments suggest that DFO-anti-
CD3 caused phenotypic skewing of CD8+ T cells from naïve into central memory (CM) 
and effector memory (EM) populations. Both CM and EM cells are able to recognize 
and target tumors for cytolysis and to yield progeny effector cells that drive a robust 
cytotoxic response115. The potential benefit of this increase in memory T cell 
populations is underscored by the association between tumor infiltration of memory T 
cells and better patient prognosis in several cancers. It is therefore possible that the 
systemic effects of DFO-anti-CD3 may increase activation of antigen-specific T cells, 
thereby increasing the number of tumor infiltrating T cell. This increase would further 
improve imaging capabilities and could provide secondary therapeutic effects. Further 
studies are needed to confirm this effect, most notably within the tumor 
microenvironment. Additionally, survival studies are needed to provide direct evidence 
that DFO-anti-CD3 treatment could have dual roles as both an imaging and therapeutic 
agent. 
Overall, DFO-anti-CD3 demonstrated no significant change in total T cell count, 
but a depletion of CD4+ T cells and subsequent increase of CD8+ memory T cells. 
Coincidentally, a higher CD8+ to CD4+ T cell ratio has been associated with better 




An anti-CD3 antibody was successfully radiolabeled with 89Zr via DFO chelating 
agent. 89Zr-DFO-anti-CD3 was found to specifically bind to T-cells populations in 
healthy mice and was able to detect tumor-infiltrating T lymphocytes in C57BL/6J mice 
bearing syngeneic tumors. DFO-anti-CD3 showed no change in overall T lymphocyte 
numbers or viability, but had diminished CD4+ T-cell counts and polarization of the 
CD8+ T-cell pool towards a memory phenotype. These studies showed that DFO-anti-
CD3 could have beneficial immunomodulatory properties favoring a more anti-tumor 
phenotype. Translation of this CD3-based immunoPET-agent to the clinic could provide 
actionable information about the tumor immune microenvironment in cancer patients, all 
while avoiding unwanted and invasive medical procedures. 
 2.2.4 Materials and methods 
Synthesis and characterization of 89Zr-DFO-anti-CD3 
An anti-CD3 antibody was modified with p–isothiocyanatobenzyl desferrioxamine 
(DFO) and radiolabeled with Zr-89 following a previously described method138. A 
detailed description of the synthesis, radiolabeling and characterization of 89Zr-DFO-
anti-CD3 can be found in the supplementary information (S1 File). 
89Zr-DFO-antiCD3 in vitro binding affinity assay 
Immunoreactivity of 89Zr-DFO-antiCD3 was tested by binding saturation assay. 
C57BL/6J murine splenocytes (1.5x106) in microtubes were incubated with increasing 
concentrations of 89Zr-DFO-antiCD3 (0.4–112 nM). Triplicate microtubes were used for 
each measuring point. After incubation, the suspension was centrifuged at 2000 x g for 




were measured for radioactivity using an automatic γ-counter. Binding affinity (Kd) was 
calculated GraphPad Prism software (GraphPad Software, Inc., California, USA). 
Animal model 
All animal studies were reviewed and approved by the University of North 
Carolina Animal Care and Use Committee (IUCAC). C57BL/6J mice (male, 4–6 weeks 
old, Charles River Laboratories) were used in all of the experiments. Syngeneic bladder 
tumors in C57BL/6J mice were induced using continuous exposure of 0.05% N-Butyl-N-
(4-hydroxybutyl) nitrosamine (BBN) in drinking water144,145. Tumor progression and size 
were monitored in the bladder by ultrasonography. Once the bladder tumors reached 5–
10 mm in diameter, they were harvested and dissociated. Portions of the tumor were 
resuspended in growth media and plated to a 60mm plastic plate. By repeating 
passage, syngeneic bladder cancer cell lines, including BBN975, were successfully 
established and the expression of EpCAM was confirmed by flow cytometry. For 
immuno-PET and biodistribution assays, each C57BL/6J mouse was injected with 10 
million BBN975 cells subcutaneously in the right flank. When tumors reached 50–100 
mm3, typically 20–30 days post tumor injection, immuno-PET and biodistribution assays 
were performed. All animals were humanely sacrificed under CO2 asphyxiation followed 
by cervical dislocation, accordingly with UNC Institutional Animal Care and Use 
Committee (IACUC) protocol. 





Three groups of healthy C57BL/6J mice (n = 6) were intravenously injected via 
tail vein with 825.1 ± 14.8 kBq (22.3 ± 0.4 μCi, ~4 μg, 100 μL) of 89Zr-DFO-anti-CD3, 
89Zr-DFO-IgG2b, or 89Zr-DFO-IgG. Anti-mouse CD3 mAb (BioXCell InVivoMab, clone 
17A2) was chosen because of its availability and extensive references. Rat IgG 2b 
(clone BE0090) was purchased from BioXCell and Rat IgG (clone 02902) was 
purchased from Life technologies. Three days post-injection, we harvested blood, liver, 
spleen, axillary lymph node, thymus, and bone. The tissues were weighed and 
measured for radioactivity using a Capintec CRC-55tW dose calibrator and well counter. 
Whole tails were also measured for radioactivity to eliminate the variability of injections. 
Radioactivity measurements from tissues were decay-corrected back to the time of 
injection. The percent of injected dose per gram of tissue (%ID/g) were calculated using 
these decay-corrected radioactive counts. 
microPET/CT studies of 89Zr-DFO-anti-CD3 in healthy C57BL/6J mice 
Healthy C57BL/6J mice were intravenously injected via tail vein with 5.6 ± 0.2 
MBq (153.4 ± 4.1 μCi, ~25μg, 100 μL) of 89Zr-DFO-anti-CD3. At 72 hours post injection 
the mice were anesthetized with 2% Isoflurane/Oxygen and statically scanned by CT 
and PET for 30 min. CT imaging was performed at 40kV, 140uA, 360 projections per 
bed. MicroPET energy window 250–700 keV was used for the experiment. The CT and 
PET scans were co-registered using AMIDE imaging software. 
microPET/CT and ex vivo biodistribution studies of 89Zr-DFO-anti-CD3 and 89Zr-DFO-




Two groups of C57BL/6J mice bearing BBN975 tumors (n = 6) were 
intravenously injected with 6.0 ± 0.1 MBq (162.5 ± 1.8 μCi, ~25μg, 100 μL) of 89Zr-
DFO-anti-CD3 or 89Zr-DFO-IgG2b. At 72h post injection, the mice were anesthetized 
with 2% Isoflurane/Oxygen and statically scanned by CT and PET for 30 min. After 
PET/CT scanning, we collected blood, liver, spleen, axillary lymph node, thymus, bone, 
and tumor from the treated mice. All tissues were weighed, and measured for 
radioactivity. The percent of injected dose per gram of tissue (%ID/g) and tumor-to-non 
tumor tissue (T/nT) ratios were calculated. The CT and PET scans were co-registered 
using AMIDE imaging software. 
Tissue dissociation 
Spleens were homogenized using the GentleMACs Dissociator and the samples 
were passed through a 70 µM cell strainer, followed by homogenization with a 5 mL 
syringe plunger. The samples were centrifuged for 7 minutes at 1200 RPM, 4°C, 
decanting the supernatant. The remaining pellet was resuspended into 1 mL of ACK 
lysis buffer (150 mM NH4Cl, 10 mM, KHCO3, 0.1 nM Na2EDTA in DPBS, pH 7.3) for 2 
minutes at room temperature before quenching with 10 mL of cold media. The samples 
were centrifuged for 7 minutes at 1200 RPM, 4°C, resuspended in 10 mL of cold media, 
and passed through a 40 μM cell strainer. Cell counting was performed by running a 
diluted aliquot of sample on a MACSQuant flow cytometer, counting lymphocytes as 





Samples were washed and resuspended in cold DPBS, normalized by count, and 
transferred onto a 96 well V-bottom plate at 1 million lymphocytes per well. Cells were 
resuspended in FVS510 viability stain (1:1000 dilution in 100 μL DPBS) for 40 minutes 
on ice. Wells not receiving viability staining were resuspended in DPBS. Cells were 
washed twice in staining buffer (0.02% NaN3, 2% BSA in DPBS), resuspended in 50 μL 
Fc block (1:50 dilution in staining buffer), and incubated on ice for 15 minutes. Antibody 
master mix was added to samples at 50 μL per sample with final antibody 
concentrations of: CD3e PE (1:100; 145-2C11), CD8a APC-H7 (1:100; 53–6.7), CD4 
FITC (1:200; RM4-5), CD44 PerCP-Cy5.5 (1:200; IM7), CD62L BV421 (1:200; MEL-14), 
NK1.1 APC (1:100; PK136), CD14 APC (1:100; rmC5-3), CD19 APC (1:100; 1D3). (All 
mAbs from BD Biosciences). Cells were incubated on ice for 45 minutes and washed 
twice with staining buffer. Cells were fixed in 2% paraformaldehyde overnight. The 
following morning, a minimum of 100,000 events were collected for each sample on a 
BD LSRFortessa flow cytometer. 
Flow cytometry analysis 
FlowJo flow cytometry software Version 10 was used for analyses of all flow 
cytometric data (S8A Fig). Lymphocytes were identified on the 2-dimensional scatterplot 
of forward scatter (FSC)-area by side scatter (SSC)-area, followed by discrimination of 
singlet cells through FSC-area by FSC-height. Live cells were next identified by 
negative signal from viability staining. From this population of lymphocytes, T cells were 
identified as events which were CD19, CD14, and NK1.1 negative and either CD4 or 
CD8 positive. This strategy for T cell identification was used in place of CD3 staining 




DFO-antiCD3 treated animals (S8C and S8D Fig), presumably due to competitive 
binding of treatment and staining antibodies. Within CD4+ and CD8+ T cell populations, 
cells were identified as naïve (CD44-, CD62L+), central memory (CD44+, CD62L+), or 
effector memory (CD44+, CD62L-) (S9 Fig). 
Statistical analysis 
Data are shown as mean ± standard deviation. Differences between multiple 
groups were tested for significance using Kruskal-Wallis test followed by a Bonferroni 
corrected Mann-Whitney U-test or Dunn’s multiple comparison post-test to compare 
differences between two groups (GraphPad, Prism 5). Non-parametric statistical 
analysis between two groups was performed using Mann-Whitney U-test (GraphPad, 
Prism 5). P values ≤ 0.05 were considered significant. 
Supplemental material 
All supplemental figures and tables cited in Chapter 2.2 are listed according to 










CHAPTER 3: Role of human endogenous retroviruses in the tumor immune 
microenvironment 
3.1 Introduction 
Human endogenous retroviruses (hERVs) are remnants of exogenous 
retroviruses integrated into the primate genome over evolutionary time17. hERVs share 
genomic similarities to other retroviruses, including the presence of functional and 
remnant 5′ and 3′ long terminal repeats (LTRs), and gag, pro, pol, and env genes. 
Subsets of recently integrated hERVs still maintain limited translation under 
physiological and pathological conditions18,19,38,146,147, including evidence for modulation 
of melanoma, lymphomas, leukemias, and ovarian, breast, prostate, urothelial, and 
renal carcinomas18,20–25,27,148. Although studies have identified the role of specific 
hERVs in the pathogenesis and progression of these cancers, to date there have been 
a limited number of pan-cancer studies elucidating the landscape and impact of hERV 
expression. A recent study by Rooney et al. analyzed features associated with genes 
important for immune cytolytic activity, finding that one of these associated features was 
expression of a small subset of hERVs41. While this study provided evidence that hERV 
expression associated with an immune phenotype, the exploration of hERVs was limited 
by a small reference set, no reported mechanism of association or prognostic impact of 
hERV expression, and no confirmation of a hERV-specific immune population within 
any tumor type. Thus, the role of hERVs in modulating the tumor immune 




identification of full-length, intact hERVs from sequencing data. To fully understand the 
role of hERVs in antitumor immunity, a more comprehensive database containing 
greater numbers of individual full-length hERVs is required. Understanding patterns of 
hERV expression will allow for greater knowledge of the impact of hERVs on tumor-
immune interactions, the design of new prognostic models based on hERV signatures, 
and further identification of tumor-specific hERV epitopes for targeted tumor 
vaccinations. 
Currently, a limited repertoire of tools are available for hERV quantification. 
There exist several databases of hERV elements, including HERVd, which contains 
hERV-like elements, and their genomic locations that have been used for analysis of 
RNA-Seq data35,149,150. Additionally, there are several tools for identification of intra- and 
intergenic hERV-like elements37, related transposable elements151, and interspersed 
repeats (RepeatMasker) among human transcripts34. While these resources provide 
methods to quantify expression of hERV-like elements among transcripts, they do not 
provide quantification based on an intact, full-length hERV proviral reference. This 
capability to distinguish and quantify individual hERVs provides a useful tool to classify 
hERVs into distinct groups based on biological associations in various cancers. 
Recently, Vargiu et al. compiled a database of 3,173 intact, full-length hERV 
sequences and developed a comprehensive method for classifying these sequences 
into 11 superfamilies (Supplemental Table 1)38. Using this database as a reference, we 
designed a computational workflow for identifying the expression of specific hERVs from 
RNA sequencing (RNA-Seq), hervQuant, and quantified hERV expression within the 




specific hERVs with immune and clinical features. Among all cancer types 
encompassed within the pan-cancer dataset, clear cell renal cell carcinoma (ccRCC, 
designated by TCGA as KIRC) contained the greatest number of prognostic hERVs. 
Thus, we explored two mechanisms by which hERV expression may influence the 
tumor immune microenvironment in ccRCC: (i) activation of RIG-I–like pathway 
signaling and (ii) hERV epitope-triggered T and B cell activation. Using biological 
classes of hERV signatures derived from these two mechanisms, we further 
demonstrated the ability of hERV expression to predict patient survival in a multivariate 
regression model, independent of traditional clinical staging and molecular subtyping. 
Last, we used a publicly available ccRCC ribosome profiling (Ribo-Seq) dataset152 to 
screen for translation of tumor-specific hERV epitopes, validated their capacity to bind 
HLA in vitro, and demonstrated the presence of tetramer-positive epitope-specific T 
cells within ccRCC tumors. We found tumor-specific hERV expression to be associated 
with clinical response to PD-1 axis inhibition in ccRCC patients, suggesting that hERV 
expression may provide a biomarker for immunotherapy responsiveness and hERV viral 
proteins may provide targetable, tumor-specific epitopes. The information gained from 
hERV expression profiling gives new insight into the role of hERVs within tumor-immune 
microenvironment interactions and provides evidence for hERV expression–based 
molecular models for patient prognosis and responsiveness to immunotherapy. 
3.2 Results 
Expression and association of hERVs in TCGA pan-cancer.  
TCGA pan-cancer hERV expression was determined using hervQuant, described 




For consistency, only samples sequenced by Illumina NextSeq at 2 × 50 bp were 
analyzed, resulting in complete removal of ESCA, GBM, OV, and STAD and partial 
removal of COAD, UCEC, and READ subtypes (see Supplemental Table 2 for tumor 
abbreviations). All 3,173 reference hERVs were expressed in at least one sample, 
encompassing all 11 superfamilies and 3 lineages (Supplemental Table 1). Relative 
hERV expression patterns were strikingly homogenous across all cancer types (Figure 
3.1B and Supplemental Figure 3). Among all cancer types, TGCT demonstrated the 
greatest mean and median hERV expression, while LIHC, ACC, and UVM ranked last 
(Supplemental Figure 4). To identify similar hERV expression patterns across models, 
we calculated the Euclidean distance of mean hERV expression between each cancer 
type (Figure 3.1B and Supplemental Figure 5). Tumor types with lowest overall hERV 
expression (LIHC, ACC, UVM) were closely related by unsupervised clustering and 
shared very low similarity with all other tumor types. Two large clusters comprised 10 
(PCPG, SKCM, CHOL, SARC, THYM, DLBC, PRAD, THCA, KICH, and LGG) and 8 
(LUAD, PAAD, BLCA, CESC, MESO, UCEC, UCS, and BRCA) cancer types. While 
several cancer types demonstrated similar hERV expression patterns based on tissue 
location (UCEC and UCS, HNSC and LUSC, KIRC and KIRP, and READ and COAD), 
the clustering observed between various tumor types suggests that hERV expression 
may be conserved among cancers across a variety of tissues. Notably, two tumor types 
with immune-privileged tissues of origin (TGCT and UVM) demonstrated lower 
similarities to all other cancers. Lack of immune interactions within these native tissues 
may potentially result in unique hERV expression profiles in these tumors, suggesting 




presence of related tumor immune responses. 
 
Figure 3.1: Human endogenous retrovirus expression and association in TCGA pan-
cancer dataset. (A) Schematic of the hervQuant workflow. (B) hERV expression displayed 




dataset. Tumor groups shown in the middle ring, with colors representing clusters 
determined from a cut-tree (height = 140) of hierarchical clustering of Euclidean distance 
of mean hERV expression between each cancer type. Innermost lines represent hERV 
expression pairwise Euclidean distance ≤40 between tumor types. Opacity and width of 
inner lines increase with greater similarity. (C) Volcano plot of association (GLM) between 
read-normalized hERV expression and the mean of the methylation β coefficient, with 
GLM coefficient along the x axis and –log10 FDR-corrected P value along the y axis. (D 
and E) Association (GLM) between read-normalized hERV expression and (D) IGS 
expression and (E) survival among TCGA pan-cancer dataset. FDR- (D) or Bonferroni-
corrected (E) P represented by intensity of color and direction of coefficient represented 
by color (red, positive; blue, negative). Color bar displays hERV superfamily and 
canonical clade classifications. (D) Rows and columns are ordered by number of 
significantly positive associations. (E) Survival analysis filtered by hERVs and tumor types 
with at least 1 significant comparison. See Supplemental Table 2 for number of samples 
per TCGA cancer cohort. 
Overexpression of specific hERVs within tumors has been attributed to 
epigenetic demethylation of genes associated with provirus expression, which can be 
triggered through the use of epigenetic modulatory agents27,28,153–156. hERV expression 
was highly associated with Illumina Methylation450K-derived methylation patterns, with 
the majority of hERVs significantly associated with demethylation (2,639 hERVs with 
generalized linear model [GLM] FDR-corrected P ≤ 0.05; 2,205 with coefficient <0; 434 
with coefficient >0; Figure 3.1C). 
We next examined the association between hERV expression and immune 
features, age, and survival among tumor types. We first performed multivariable linear 
regression of hERV expression by cancer type with 46 immune gene signatures (IGS) 
previously described in the literature83,100,101,157–159 (Figure 3.1D and Supplemental 
Figure 6). A small population of hERVs demonstrated near ubiquitous positive or 
negative association with all IGS, with the majority of hERVs showing a split association 
pattern. Included among IGS that demonstrated positive association with the majority of 




cells known to have antitumor effector function, including effector and central memory T 
cells and NK cells. Additionally, a signature of anti–PD-1 (aPD1) responsiveness 
(IPRES_aPD1_responder) was positively associated with hERV expression in 79.2% 
(1,472 of 1,858) of significantly associated hERVs, while a signature for nonresponder 
tumor biopsies (IPRES_aPD1_nonresponder) was negatively associated with all hERV 
expression in 83.0% (1,679 of 2,024) of significantly associated hERVs8. We next 
examined the association between hERV expression and age, controlling for tumor 
type, and observed that the majority of significantly associated hERVs demonstrated 
negative association between expression and patient age (GLM FDR-corrected P < 
0.05; 150 with coefficient <0; 13 with coefficient >0; Supplemental Figure 7). To 
elucidate whether hERV expression associated with clinical outcome, we performed 
Cox’s proportional hazard regression (CoxPH) for hERV expression across all cancer 
types. Association of survival with mean hERV expression identified 3 tumor types with 
prognostic mean hERV expression (KICH, COAD, and KIRC). In all 3 tumor types, 
mean hERV expression was negatively prognostic (Supplemental Figure 8). 
Additionally, we examined Kaplan-Meier survival curves for each TCGA cancer type 
split by upper versus lower 50th percentile mean hERV expression, and observed 5 
cancer types with significant separation of survival curves (Supplemental Figure 9; 
BLCA, COAD, KICH, KIRC, and PCPG; log-ranked P < 0.05). Among these 5 cancer 
types, KIRC was the most associated with survival. All cancer types except BLCA 
demonstrated shorter survival in patients with greater mean hERV expression. To 
perform a more detailed analysis, we associated survival with expression of each 




tumor type in which several hERVs have been shown to be actively translated27,31,32,42, 
constituted 25.1% of all significantly prognostic hERVs, with over 1.5× more significant 
hERVs than the next highest cancer, LGG (KIRC: 362; LGG: 230; Figure 3.1E). To 
elucidate the immune mechanisms behind this enrichment of prognostic hERVs in 
ccRCC, we focused on this cancer type for the remainder of our analyses. 
hERV expression in ccRCC demonstrates evidence of immune stimulation through RIG-
I–like signaling. 
Several groups have demonstrated that activation of select endogenous retroviral 
elements can trigger signaling through innate immune sensors, including double-
stranded RNAs (dsRNA) that subsequently signal through cytosolic RIG-I–like 
receptors28,156. To elucidate a more comprehensive role for hERVs in the RIG-I–like 
pathway in ccRCC, we studied the association between hERV expression and genes in 
the RIG-I–like receptor signature (Molecular Signatures Database)160, observing marked 
separation of genes into 2 groups by hierarchical clustering (Figure 3.2A). We defined 2 
hERV groups (1 and 2; Supplemental Table 3) based on the ratio between each hERV’s 
mean linear regression coefficients within each gene cluster (>1 or < 1) and validated 
their definitions using principal component analysis (Figure 3.2B). While both groups 
demonstrated significant positive association between hERV expression and genes that 
activate the RIG-I-like pathway, group 2 hERVs demonstrated a significant positive 
association with several key antagonist genes downstream of NF-κB signaling (most 
notably NFKBIB), along with a significant negative association to key agonistic genes in 
NF-κB signaling (e.g. TBK1, TANK, and AZI2). CoxPH of hERV expression within 




the majority of group 1 and 2 hERVs providing association with longer and shorter 
overall survival, respectively (Figure 3.2C). In addition, group 2 and non-prognostic 
group 1 hERVs (CoxPH Bonferroni-corrected P > 0.05) demonstrated a significant 
positive association with the majority of IGS (93%, 57%, and 60%, respectively), while 
prognostic group 1 hERVs (Bonferroni-corrected P ≤ 0.05; majority associated with 
longer overall survival) largely demonstrated a negative association with IGS (33%), 
including those for T cells, B cells, dendritic cells, macrophages, and NK cells (Figure 
3.2D and Supplemental Figure 11). Despite these negative association patterns with 
IGS observed in prognostic group 1 hERVs, TCGA KIRC samples with greater 
expression of these hERVs had decreased ratios of Treg to CD8+ IGS (Treg IGS 
divided by the mean of 3 CD8+ IGS) compared with any other hERV group, suggesting 
the immune infiltrate associated with prognostic group 1 hERVs was less 
immunosuppressive than that of non-prognostic group 1 and group 2 hERVs 
(Supplemental Figure 12). Additionally, prognostic group 1 hERVs demonstrated 
positive association with signatures for Th17 T cells, which have been associated with a 
more favorable prognosis in ccRCC161. Overall, this analysis provided the first evidence 
to our knowledge for biologically distinct hERV groups that differentially interact with 
innate immune sensing, with differential downstream prognostic and immunological 





Figure 3.2: Mechanism of hERV-mediated RIG-I–like pathway signaling in ccRCC. (A) 
Heatmap of association (GLM) between hERV expression and RIG-I–like pathway–
associated genes. FDR-corrected –log10(P value) represented by intensity of color, and 




and 2 (orange) hERVs are represented by color along the left-side color bar. (B) PC1 
versus PC2 from PCA of association matrix in A between hERV expression and RIG-I–
like pathway–associated genes from for group 1 and 2 hERVs. Percentage of variance 
for principal component 1 (PC1) and PC2 is shown in parentheses along each axis. (C) 
Volcano plot of CoxPH analysis of UQN hERV expression as a predictor of survival, with 
Bonferroni-corrected –log10(P value) displayed as a function of hazard ratio for each 
hERV. Dashed horizontal line represents FDR-corrected P = 0.05. (B and C) Groups 1 
and 2, and other hERVs defined from A (group 1: blue; group 2: orange; neither: gray). 
(D) Heatmap of association (GLM) between expression of IGSs with group 1 and 2 hERV 
signatures (average expression), split by either significant or nonsignificant association 
with patient prognosis. FDR-corrected P values represented by intensity of color, and 
direction of coefficient represented by color (red, positive; blue, negative). 
hERV expression in ccRCC demonstrates evidence of B cell activation.  
In addition to innate immune sensor signaling, hERVs can trigger antitumor 
immunity through tumor-specific expression of viral epitopes. In cancer patients, high 
antibody titers have been known to develop against hERV proteins with specificity of 
expression within the tumor, with little else known regarding the role of this B cell 
response30. To determine whether hERVs show evidence of an adaptive immune 
response in ccRCC, we identified T/B cell clonotype repertoires in TCGA KIRC using 
MiXCR and filtered on T/B cell receptors (TCRs/BCRs; defined as shared CDR3 amino 
acid sequence) observed in ≥10% of patients162. These filtering criteria resulted in no 
shared TCR clonotypes, suggesting potentially low sensitivity of detection for MiXCR-
derived TCR data in RNA-Seq data. In contrast, 437 shared BCRs were identified, of 
which 397 were significantly associated with expression of ≥1 hERV (Figure 3.3A, left). 
Within this pool, 4 clones had significant positive association with the expression of 
1,207 hERVs, suggesting a potential hERV epitope–driven B cell response (Figure 
3.3A, right, and Supplemental Table 3). Differential superfamily distribution patterns 
were observed between BCR-associated and non-BCR-associated hERVs, suggesting 




(HERVERI, HML, HSERVIII, and HERVW9; FDR-corrected χ2 test P ≤ 0.05; 
Supplemental Figure 13). Furthermore, multiple sequence alignment (Clustal Omega) of 
proviral sequences from these BCR-associated hERVs identified large regions of high 
sequence identity (Supplemental Figure 14). Filtering on sequence identity of ≥25% of 
all BCR-associated hERVs with a sequence length ≥21 base pairs (the approximate 
minimal length necessary for immunoglobulin CDR3 region specificity)163, we observed 
8 regions of conserved DNA similarity (Figure 3.3B). NIH Retrovirus Protein BLAST 
(https://www.ncbi.nlm.nih.gov/genome/viruses/retroviruses/) of these sequences 
showed similarity to known hERV env genes in 8 of 8 sequences, with additional 
similarity to other retroviral genes in 2 of 8 sequences. While suggestive of potentially 
targetable antigens within the hERV env region, CoxPH demonstrated significantly 
higher hazard ratios among BCR-associated compared with non-BCR-associated 
hERVs (Welch’s t test P = 2.4 × 10–3; Figure 3.3C). Differential expression analysis 
(DESeq2) of BCR-associated hERVs demonstrated a balanced proportion of hERVs 
with both higher tumor–to–matched normal and matched normal–to–tumor expression 
(tumor: n = 542; matched: n = 72; Figure 3.3D), suggesting an overall lack of tumor 





Figure 3.3: hERVs associated with expression of BCR clonotypes are negatively 
prognostic in ccRCC. (A) Heatmap of association (GLM) between hERV expression and 
expression of B cell clonotypes, displaying all TCRs and BCRs that demonstrate 




with highest numbers of significantly associated hERVs (right, underscored by black box 
to the bottom left). FDR-corrected P values represented by intensity of color and direction 
of coefficient represented by color (red: positive, blue: negative). (B) Multiple sequence 
alignment of areas of DNA identity in ≥25% of hERVs (all hERVs significantly associated 
with the top 4 B cell clones) and ≥24 base pairs in length (minimum BCR epitope length). 
Base pair sequences displayed by color (A: blue; T: red; C: green; G: yellow; gap: gray) 
and sequence below. y axis order is conserved in all plots. (A and B) Color bars at left 
show superfamily and canonical clade classification. (C) Hazard ratios among all hERVs 
significantly associated to the top 4 B cell clones (left) or non-BCR-associated hERVs 
(right) within TCGA KIRC, with Welch’s t test P value displayed. Data represent median 
(middle line), with boxes encompassing the 25th to 75th percentile, whiskers 
encompassing 1.5× the interquartile range from the box, and outliers shown by dots. (D) 
Waterfall plot displaying the log2 fold change in mean expression of hERVs associated 
with the top 4 B cell clones in the tumor compared with matched normal tissue. FDR-
adjusted P value significance (P ≤ 0.05) from DESeq2 analysis displayed in red (positive 
fold difference), blue (negative fold difference), and gray (nonsignificant). 
hERV signatures of innate and adaptive immune activation provides prognostic value in 
ccRCC.  
Currently, clinical stage is the most robust prognostic variable for ccRCC. While 
molecular features such as M1–M4 molecular subtyping have been shown to be 
potentially prognostic, no molecular markers have been widely adapted for clinical 
decision making in ccRCC, making identification of a robust molecular marker for 
prognosis an appealing goal164. Throughout this study, we identified pools of hERVs 
with evidence of both RIG-I–like–mediated innate immune activation and inhibition, as 
well as B cell–mediated adaptive immunity (Figure 3.4A,B). To provide evidence that 
these classes can be used to generate a model of clinical outcome in ccRCC, we 
derived signatures corresponding to the mean expression of prognostic hERVs (CoxPH 
Bonferroni-corrected P ≤ 0.05) within each class. According to log-rank test, Kaplan-
Meier overall survival curves for patients within the upper versus lower 50th percentiles 
for each of the 3 signatures were significantly different (RIG-I–like upregulated [up]: P = 




× 10–5; Figure 3.4C). Patients with both higher expression of RIG-I–like down and BCR-
associated signatures had significantly shorter overall survival, while those with higher 
expression of the RIG-I–like up signature had longer overall survival. Recent analyses 
also provided metrics for disease-specific survival (DSS) and progression-free interval 
(PFI) in TCGA KIRC, additionally with an underpowered reporting of disease-free 
interval (DFI)165. Of these metrics, DSS and PFI trended similarly to curves observed 
with overall survival, providing further evidence that these hERV signatures are 
specifically associated with disease burden (Supplemental Figure 15). We performed 
multivariable CoxPH modeling with clinical stage and with or without molecular subtype 
(M1–M4) and hERV signatures as predictors for patient outcome in TCGA KIRC. 
Comparing a full model against an all-but-one-feature model, all 3 signatures provided 
significant prognostic value in addition to stage and molecular subtype, with the RIG-I–
like down signature contributing nearly as much prognostic power as traditional staging 
and each of the 3 signatures providing greater prognostic power than molecular 
subtyping (Figure 3.4D and Supplemental Table 4). To establish whether these hERV 
signatures were prognostic in other tumors, we performed univariable CoxPH for each 
signature within all TCGA cancer types (Figure 3.4E). Among these 3 signatures, BCR-
associated hERVs were additionally prognostic in COAD and LGG, while RIG-I–like 
down hERVs were additionally prognostic in BLCA, COAD, KIRP, LGG, and LIHC, 
suggesting these additional cancer types may have hERV–immune microenvironment 
interactions similar to those in ccRCC. Included among these cancer types were KIRP 




hERV expression patterns (Supplemental Figure 5), and LGG, which contained the 
second greatest number of prognostic hERVs after KIRC (Figure 1E). 
 
Figure 3.4: Immune-related hERV signatures are prognostic for patient overall survival. 




an anti-tumor immune response. (B) Venn diagram showing the number hERVs 
significantly associated (GLM, FDR-corrected P < 0.05) with genes corresponding to the 
upregulation (blue) or downregulation (orange) of the RIG-I–like pathway or positively 
associated (GLM, FDR corrected P < 0.05) with expression of B cell clones (green). (C) 
Kaplan-Meier survival curves for TCGA KIRC patients split by the upper (blue) and lower 
(red) 50th percentile of expression for each of the 3 hERV group signatures represented 
in A. (D) Change in multivariable CoxPH log-likelihood ratios in TCGA KIRC using clinical 
stage and/or M1–M4 molecular subtyping and the 3 classes of hERV groups represented 
in B as predictors for survival. Stacked bars show the change in likelihood ratio for each 
feature when removed from the full model, as well as the χ2 test P value for each hERV 
group signature when removed from the full model (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001). 
(E) Univariable CoxPH coefficients for hERV signatures as a predictor for overall survival 
among each cancer type. FDR-corrected P value represented by red asterisks (*P ≤ 0.05). 
hERVs demonstrate evidence of tumor-specific presentation of targetable viral epitopes.  
Previous studies have identified select tumor-specific hERV epitopes in ccRCC 
that trigger in vitro antitumor responses with limited in vivo efficacy31,32,42. Studies 
regarding neoantigens have suggested that a large number of potential epitopes are 
required for screening in order to identify a few clinically relevant peptides with 
significant in vivo antitumor efficacy15,70,166,167. We examined hERV expression patterns 
between tumors and matched normal tissue within TCGA KIRC and observed that 
normal samples clustered together (Supplemental Figure 16). The majority of hERVs 
were heavily upregulated in tumor compared with matched normal samples, leading us 
to hypothesize that there may be many more differentially expressed and targetable 
hERVs within tumor than previously described. In an attempt to expand the potentially 
targetable hERV epitope pool in ccRCC, we first ranked hERVs based on fold change in 
expression between tumor and matched normal samples (Supplemental Figure 17)168. 
Notably, CT-RCC hERV-E (HERVERI/gammaretrovirus-like, designated as hERV 2256 
in the reference database, also known as ERVE-4), one of the few hERVs 
demonstrated to be capable of eliciting a vaccine-inducible CD8+ T cell response, 




same hERV was previously described by Rooney et al. (ERVE-4) and was found to be 
significantly upregulated in ccRCC and associated with a signature of cytotoxicity41. To 
ensure that our analyses were consistent with these previously published findings, we 
performed linear regression between CT-RCC hERV-E and IGS expression including 
the Rooney signature for cytotoxicity (CYT), and observed a significant association 
between expression of this hERV and the majority of IGS in our set, including CYT 
(Supplemental Figure 18). 
Similar to the pattern observed in CT-RCC hERV-E, hERVs that were 
overexpressed within tumors were ubiquitously positively associated with IGS, while 
those that demonstrated overexpression within matched normal tissue demonstrated a 
mixed association pattern (FDR-corrected P ≤ 0.05; Figure 3.5A), suggesting that 
preferential hERV expression in the tumor may facilitate immune activation. 
Interestingly, none of the top 10 hERVs by tumor versus normal expression were 
significantly associated with TCR/BCR clonotype expression or with survival. Given that 
(i) these hERVs were significantly associated with immune activation and (ii) there is 
evidence of functional epitopes and public hERV-specific T cells in at least one of these 
hERVs (CT-RCC hERV-E), the inability to computationally detect TCRs/BCRs 
significantly associated with these hERVs suggests we lacked the sensitivity necessary 
to identify these hERV-specific TCR/BCR clones. This lack of detectable public adaptive 
immune response is also characteristic of neoantigens, which despite failing to show 
association with TCR/BCR expression and survival in the absence of immunotherapy in 






Figure 3.5: hERVs demonstrate evidence of targetable epitope expression in ccRCC. (A) 
Association (GLM) of the 10 most positively (left) and negatively (right) differentially 




expression. FDR-corrected P values represented by intensity of color and direction of 
coefficient represented by color (red: positive, blue: negative). (B) Read coverage from 
ccRCC Ribo-Seq data for hERV 4700, demonstrating read coverage of coding regions 
for gag (red), pol (blue), and env (green) genes. (C) Percent identity between all reading 
frames of translated amino acid sequences from the reference gag (red), pol (blue), and 
env (green) sequences for hERV 4700 with known hERV proteins in the NIH retroviral 
protein BLAST database. (D) Exchange efficiency for HLA-A*02:01 monomer UV 
exchange of predicted hERV 4700 epitopes. (E) Left: RT-qPCR (responders: n = 7; 
nonresponders: n = 6) log2 expression of hERV 4700 gag, pol, and, env sequences. 
Right: hervQuant-derived (responders: n = 10; nonresponders: n = 10) hERV 4700 
expression in Nivolumab-treated (aPD1-treated) ccRCC tumor biopsies. Statistical 
analysis performed using Mann-Whitney U test (*P ≤ 0.05, **P ≤ 0.01, NS: P > 0.05). Data 
presented as values (dots) and median (middle line), with boxes encompassing the 25th 
to 75th percentile and whiskers encompassing minimum to maximum values. 
Tumor-specific transcription is necessary for epitope generation but is not 
sufficient without downstream translation. Since the majority of hERVs are 
translationally inactive, we ran hervQuant on a publicly available Ribo-Seq dataset 
comprising several regions from 2 ccRCC and matched normal kidney nephrectomy 
samples (4 regions per tumor; 2 regions per matched normal)152. To filter for hERVs 
with the strongest evidence of differential expression by both Ribo-Seq and RNA-Seq, 
we ranked hERVs by the sum of RNA-Seq and Ribo-Seq fold change in expression in 
tumor versus normal samples (Supplemental Figure 19). Despite evidence of translation 
in the literature, CT-RCC hERV-E did not demonstrate coverage by Ribo-Seq in this 
ccRCC dataset, suggesting the relative insensitivity of Ribo-Seq– compared with RNA-
Seq–based hERV identification. However, analysis of the GWIPS database169 
containing aggregate data from >30 Ribo-Seq datasets provided evidence for 
translation of CT-RCC hERV-E in several human lymphoblastic cell lines but minimal 
translation in all other sets, including normal human tissues, suggesting that CT-RCC 
hERV-E had the capacity for translation within tumor-like tissues (Supplemental Figure 




tumor versus normal expression by RNA-Seq, was identified as the most differentially 
expressed hERV with greatest evidence of translation. Additionally, hERV 4700 was 
expressed at low levels in matched normal tissues from all other tumor subtypes 
(Supplemental Figure 21) and demonstrated additional evidence of translation among 
GWIPS tumor cell line samples (Supplemental Figure 22). Although Ribo-Seq coverage 
of hERV 4700 within ccRCC samples was relatively low, coverage patterns were similar 
to those observed by RNA-Seq (Figure 3.5B). Areas of coverage within the hERV 4700 
proviral reference corresponded to viral gag (red), pol (blue), and env (green) genes. 
Protein-BLAST of these regions translated across each reading frame provided high 
sequence similarity with known reference hERV sequences across all 3 frames of pol 
and env, and frame 2 of gag (Figure 3.5C and Supplemental Figure 23). Using the 
longest sequence identified within each protein reading frame, we performed 
NetMHCPan4.0 epitope prediction, identifying 30 predicted HLA-A*02:01 binders 
(binding affinity ≤500 nM; Supplemental Table 5)39. To ensure these predicted epitopes 
were hERV specific, we searched for overlap between amino acid sequences of each 
peptide with known human proteins in the GENCODE hg19 protein-coding transcript 
translated sequences, observing no overlap between epitopes and non-hERV proteins. 
Using an HLA-A*02:01 monomer UV exchange assay and HLA ELISA readout170–175, 
we validated the binding of 30 of 30 predicted epitopes to HLA-A*02:01 with exchange 
efficiencies ranging from 16.1% to 73.1% (Figure 3.5D). 
hERV epitopes associate with aPD1 response with evidence of epitope-specific T cells 




To explore whether hERV 4700 expression is predictive for patient response to 
aPD1 therapy, we performed quantitative real-time PCR (RT-qPCR) quantification of 
hERV 4700 with 2 of each gag-, pol-, and env-specific primer/probe sets on ccRCC 
tumor biopsy RNA in aPD1-treated patients (responders: n = 7, nonresponders: n = 6; 
Figure 3.5E and Supplemental Tables 6–8). We observed greater mean RT-qPCR 
signal in aPD1 responders in all primer/probe sets (Mann-Whitney U test P < 0.05; 
Supplemental Table 9), as well as hervQuant-derived hERV 4700 expression from the 
same set with added samples (responders: n = 10, nonresponders: n = 10; Mann-
Whitney U test P = 0.0455), suggesting that transcription of hERV 4700 is associated 
with greater responsiveness to immunotherapy. Additionally, multivariable linear 
regression (GLM) provided perfect fit of primer/probe sets as a predictor for response. 
To demonstrate the presence of an anti–hERV 4700 T cell immune response in ccRCC, 
we performed tetramer staining of an HLA-A*02:01 ccRCC tumor sample using the 30 
MHC tetramers described above (Figure 3.6A,B). Using a stepwise approach, we first 
screened the tumor using 5 pools of 6 tetramers, which demonstrated that pool 4 had 
the largest tetramer-positive CD8+ T cell population (11.3% tetramer-positive). Running 
the 6 individual tetramers, we observed tetramers 2 and 3 to have the greatest staining, 
which corresponded to peptides derived from frame 2 of the gag (10.9% positive) and 
pol (13.5%) protein regions, respectively. We validated the presence of these T cell 
populations in 3 additional ccRCC tumors (gag: 10.9%–24.8%; pol: 13.5%–22.3%), as 
well as observing staining within the range of negative control tetramers in 4 healthy 
donor peripheral blood mononuclear cells (PBMC) samples (gag: 0.12%–1.51%, pol: 




our epitope prediction method and provide evidence for the presence of hERV 4700–
specific T cells within ccRCC.
 
Figure 3.6: hERV 4700 epitope–derived HLA-A*02:01 tetramers identify the presence of 




for identification of CD8+ epitope-specific T cells in ccRCC tumor. (B) Epitope gating for 
5 pools of 6 tetramers (top), as well as staining of individual tetramers from pool 4 (bottom) 
in ccRCC. (C) Percent tetramer-specific CD8+ T cells for epitopes identified in B (tetramer 
2: NSWQEMVPV; tetramer 3: MVGPWPRPV) in ccRCC tumors (n = 4) and healthy donor 
PBMC samples (n = 4). Dots represent values for each sample, with bars representing 
the mean across each group. Negative controls for gating definitions include tetramer 
fluorescence-minus-one (FMO) (A) and nonspecific HLA-A*02:01-negative tetramer (B 
and C). Data presented in Figure 6 represent results from 4 independent experiments. 
3.3 Discussion 
We report here a hierarchical analysis of hERV–immune microenvironment 
interactions within the TCGA pan-cancer dataset, integrated with Ribo-Seq data, RNA-
Seq data from immunotherapy-treated patients, and functional biological assays, to 
provide insight into hERV immunobiology in cancer. Our broad survey of hERV 
expression and association patterns provided multiple lines of evidence that hERVs 
shape the tumor immune microenvironment in several cancer types. Conditioning on 
cancer type, we observed that gene signatures of immune responsiveness (aPD1-
responsive signature, effector immune cells) were positively associated with hERV 
expression, suggesting that hERVs may either directly interact with antitumor immunity 
through immune activation or provide a biomarker for an active antitumor immune 
response. In agreement with this view, we observed that hERVs were significantly 
prognostic in multiple cancer types, with the greatest enrichment of prognostic hERVs 
observed in ccRCC. Interestingly, BLCA was the only cancer type in which greater 
average hERV expression resulted in significantly longer survival times. This finding 
suggests potentially different hERV-mediated tumor immunobiology in BLCA and should 
be further explored in future studies. For IGS and CoxPH analyses, hERV expression 
data were normalized either (i) to total RNA-Seq read count (reads per million; RPM) to 




(UQN) of hERV reads within each sample to determine the impact of relative hERV 
proportions (Supplemental Tables 10 and 11). IGS patterns of association were strongly 
conserved between hERV expression by UQN and read normalization. We observed 
variability in hERV association patterns with 3 CD8+ T cell signatures derived from 
different publications (CD8_T_Cell, CD8_Cluster, CD8)100,101,159, with CD8_T_Cell 
showing an association pattern different from the other 2 signatures. The CD8_T_Cell 
signature contained a set of 8 genes that accounted for its variation from the other 2 
signatures — HAUS3 (cytokinesis and mitosis), SF1 (pre-mRNA splicing), SFRS7 (pre-
mRNA splicing), ZNF91 (protein coding), ZNF609 (protein coding), THUMPD1 (gene 
expression/rRNA processing), MYST3 (histone acetyltransferase), and CDKN2A (cell 
cycle regulator) — all of which are nonspecific to CD8+ T cells in function 
(Supplemental Figure 25). Nevertheless, we included the CD8_T_Cell signature within 
all analyses (including Treg-to-CD8+ ratio) because it remains a commonly used 
signature for CD8+ T cells within the literature. 
In contrast to IGS, CoxPH analysis with UQN hERV data contained a greater 
number of positively prognostic hERVs compared with read-normalized data, 
suggesting that the proportional expression of hERVs may also influence overall 
survival. We additionally observed that the majority of hERVs were associated with 
younger patient age. Since most tumor types show an association between older age 
and worse outcome, and the majority of significantly prognostic hERVs were associated 
with worse outcome, these results suggest that the association between hERVs and 




Due to the diverse tumor-immune interactions observed among different cancer 
types, we narrowed down further the role of hERVs upon the tumor immune 
microenvironment to one cancer type. We focused on ccRCC to further study the role of 
hERVs in shaping the tumor immune microenvironment because (i) it contained the 
greatest number of prognostic hERVs and (ii) hERV proteins are known to be 
expressed and immunogenic in ccRCC27,31,32,42. 
Within ccRCC, we considered the potential for hERVs to impact both arms of the 
immune system. The role of hERVs in triggering an innate immune response is 
underscored by several recent reports noting that epigenetic-modifying agents that 
promote greater DNA demethylation — decitabine (methyltransferase inhibitor) and 
abemaciclib (CDK4/6 inhibitor)28,156 — increased expression of retroviral elements and 
triggered subsequent antitumor responses through innate sensor signaling, including 
induction of RIG-I–like pathway detection of viral dsRNAs. While these previous reports 
demonstrated only the proinflammatory nature of selected hERV elements, we were 
surprised to find two strikingly distinct patterns of association between hERV expression 
in ccRCC and expression of genes associated with the RIG-I–like family. The 
implication of this clustering pattern (along with the significantly different patterns of 
association between these hERV groups with survival and IGS expression) is that 
hERVs may play both agonistic and antagonistic roles in innate sensor immunity. 
Potentially, group 2 hERVs (RIG-I–like down) may interfere with RIG-I–like signaling 
through a currently unknown mechanism, ultimately skewing the tumor immune 
microenvironment in favor of an immunosuppressive phenotype with greater Treg–to–




Next, we studied the role of hERVs in triggering an adaptive immune response 
through hERV-mediated immune activation of retroviral epitope-driven T and B cell 
responses. MiXCR analysis of TCGA KIRC failed to identify TCR clones that were 
shared across at least 10% of samples, suggesting that while hERV epitopes have the 
capacity to trigger a T cell–driven antitumor response31,32,42, we lacked the sensitivity to 
computationally identify public hERV-specific TCR clones. In agreement with this, 
comparison of MiXCR-derived TCR expression with previously described TCRs derived 
from amplicon-based adaptive TCR repertoire profiling in 3 TCGA KIRC samples 
demonstrated low total TCR counts of MiXCR data with low frequencies of overlapping 
clones (Supplemental Figure 26). In contrast, we observed a large pool of shared 
BCRs. It is important to note that BCR repertoires are likely more completely sampled 
from RNA-Seq data than are TCR repertoires, as we observed increased BCR 
sequence reads, consistent with the greater transcription of immunoglobulin mRNA from 
cells of the B cell lineage compared with TCR mRNA transcription from activated T 
cells. Thus, our study had greater power to detect BCR than TCR repertoire 
associations. Multiple sequence alignment of BCR-associated hERVs demonstrated 
clustering of proviral sequences by superfamily, suggesting that a B cell response 
generated against shared hERV epitopes is likely to occur within one or several closely 
related superfamilies. The higher hazard ratios among BCR-associated hERVs may be 
related to the lack of tumor specificity for these hERVs. The majority of IGS in ccRCC, 
including those for B cells, have been shown to be associated with worse prognosis105. 
While the mechanism for this finding is currently undetermined, a potential contributor to 




epitopes shared by hERVS upregulated within the surrounding normal tissues. Further 
investigation should be performed to study the importance of this potential anti-hERV B 
cell response in ccRCC. 
Evidence for hERV-mediated activation of the innate and adaptive immune 
responses suggests that expression of these proviruses within tumors may contribute to 
immune editing of tumor cell populations. Highly immunogenic hERVs with the capacity 
to be recognized by endogenous T and B cell responses are likely cleared by the 
immune system or otherwise expressed under a heavily immunosuppressed 
microenvironment. There may also exist additional hERV epitopes that generate 
immune responses too weak to promote antitumor immunity. These two groups can 
both be potentially targeted for immune activation through the use of nonspecific (e.g., 
checkpoint blockade therapy, innate immune agonists) or epitope-specific (vaccination, 
adoptive T cell therapy) immunotherapies. Further time-course immune profiling studies 
should be performed to study the mechanisms of hERV-mediated immune surveillance 
in a developing tumor. 
With evidence of hERV-mediated activation of both innate and adaptive immune 
responses, we sought to examine whether these responses could be used to develop a 
model for patient prognosis in ccRCC. Apart from molecular subtyping, no molecular 
markers have improved the prognostic capabilities of current clinical predictive systems 
in ccRCC, suggesting the potential for development of hERV-based signatures as a 
biomarker for survival. In attempt to identify such a prognostic biomarker, we created 
hERV signatures derived from our previous analysis of hERV interactions with the 




model that provided significantly greater prognostic power than M1–M4 molecular 
subtyping and levels of prognostic information similar to those of traditional clinical 
staging. Additionally, while these hERV signatures were derived and optimized for 
ccRCC, we showed 2 signatures to provide prognosis in several other tumor models 
related to ccRCC by hERV expression patterns, level of prognostic hERVs, and tissue 
of origin, implying that additional hERV signatures for patient prognosis can be 
independently developed for other cancer types. 
Last, we sought to develop a screening method for detection of hERVs actively 
undergoing translation. The implication of such a tool is the potential for development of 
immune response biomarkers and antitumor T cell vaccine therapies, similar to those 
developed in neoantigen-based vaccine studies. Our analysis of tumor-specific hERVs 
in ccRCC identified CT-RCC hERV-E as the second highest differentially expressed 
hERV by RNA-Seq expression. This particular hERV has been well described in the 
literature as a ccRCC tumor–specific provirus with evidence of hERV-specific T cell 
responses31,32,42. Within our Ribo-Seq analysis, we were underpowered to detect 
evidence of CT-RCC hERV-E translation among 2 ccRCC samples. However, our 
analysis of the GWIPS database provided evidence for the translation of CT-RCC 
hERV-E in human tumor cells but not in normal blood, fibroblasts, or muscle tissue. This 
conforms to the view that CT-RCC hERV-E has the capacity for translation under tumor-
specific conditions and suggests that deeper Ribo-Seq coverage in ccRCC may be 
needed to increase the sensitivity of our computational screening to broaden the set of 
potentially targetable hERV epitopes. Our analysis of CT-RCC hERV-E RNA-Seq 




this hERV as being upregulated in ccRCC and associated with a gene expression index 
of cytotoxicity41. We observed the same significant association with their cytotoxicity 
signature and additionally identified a large proportion of other IGS strongly associated 
with its expression. Among these, the most significantly associated was the Treg 
signature, suggesting that expression of CT-RCC hERV-E may be also associated with 
immunosuppression. This strong association with immunosuppressive signatures 
suggests CT-RCC hERV-E may be another potential marker of response for 
immunotherapies such as aPD1 checkpoint blockade therapy. 
RNA-Seq analysis of hERV 4700 demonstrated preferential expression within 
ccRCC, with modest expression in normal kidney and liver. This preferential expression 
underscores the potential for hERV 4700–targeted immunotherapies, with the caveat 
that a particularly robust anti–hERV 4700 immune response could potentially result in 
on-target/on-tissue and on-target/off-tissue toxicity. We provided additionally validation 
for the transcription of this hERV through RT-qPCR and hervQuant analysis of an 
aPD1-treated ccRCC dataset, and showed that expression of hERV 4700 is associated 
with responsiveness to immunotherapy. 
Ribo-Seq screening provided evidence for translation of hERV 4700, supporting 
translation of epitopes that we further validated to bind MHC. Additionally, tetramer 
staining of predicted hERV 4700 epitopes in 4 ccRCC tumors demonstrated the 
presence of infiltrating T cells with receptors specific for gag- and pol-derived epitopes, 
supporting the idea that (i) hERV 4700 may act as a direct target in ccRCC, whereby 
aPD1 could trigger an antitumor response against hERV 4700–derived epitopes, and (ii) 




These same T cell populations were scarce to absent in healthy donor PBMCs, 
confirming the specificity of these T cells in ccRCC tumors. Tetramer-specific T cell 
frequencies were particularly high among ccRCC tumors (NSWQEMPV, 10.9%–24.8%; 
MVFPWPRPV, 13.5%–22.3%), suggesting that as much as 40% of tumor-infiltrating 
CD8+ T cells may be specific for these 2 hERV 4700 epitopes. We recognize that these 
frequencies are particularly high for a tumor-infiltrating population, and several caveats 
exist for our analyses. First is the potential for T cell cross-reactivity against these 
tetramers, as well as peptide impurities that recognize other infiltrating T cell 
populations. Additionally, tetramer-positive populations contained a large range of 
fluorescence intensities, suggesting these T cells do not necessarily comprise a single 
clone but likely several different clones with different TCR affinities. Future studies to 
characterize the TCR sequences and phenotypic characteristics of these tetramer-
positive populations should be performed to further elucidate the role of these 
populations and determine the basis for these and other potential caveats. 
In addition to hERV 4700, we observed 172 other hERVs that were differentially 
expressed between aPD1 responders and nonresponders by hervQuant profiling 
(Wilcoxon’s test, P < 0.05), suggesting that a more comprehensive set of hERV 
expression signatures may exist for the development of an aPD1 response biomarker in 
ccRCC (Supplemental Figure 27). Of these hERVs, 6 demonstrated overlap with the 
RIG-I–like down signature, one with the BCR-associated signature and 34 with all 
prognostic hERVs, suggesting relatively low overlap between the set of predictive and 
prognostic hERVs. Overall, hervQuant is the first described method to our knowledge 




validation should be performed to confirm the capacity of these potential hERV epitopes 
as therapeutic vaccine targets and to develop a robust hERV-based biomarker for 
immunotherapy response in ccRCC. 
In summary, we describe a computational workflow, hervQuant, for robust 
quantification of individual hERVs using RNA-Seq data. The data gained through 
hervQuant provide insights into the pan-cancer landscape of hERV expression and 
immune modulation. Within ccRCC, we found a distinct group of hERVs that were 
inversely associated with RIG-I–like signaling genes, prognosis, and IGS expression. 
Additionally, we examined the interaction between hERV expression in ccRCC and 
activation of B cell clonotypes, and demonstrated the capacity of the above-mentioned 
hERV classes to provide a multivariable model of patient prognosis that significantly 
outperforms traditional clinical staging and molecular subtype prognosis models in 
ccRCC. We provide evidence for a new method of hERV epitope prediction based on 
differential hERV expression in the tumor, Ribo-Seq screening for translation, 
computational epitope prediction, in vitro validation for HLA binding, and in vivo 
detection of epitope-specific T cells in a ccRCC tumor. Importantly, we observed that 
hERV sequences identified through this approach were significantly associated with 
aPD1 responsiveness in ccRCC tumors, supporting continued research into hERVs as 
biomarkers and therapeutic targets for immunotherapy. With the recent increasing 
interest in the role of hERVs in modulating the tumor immune microenvironment, we 
believe the work presented here substantially expands our understanding of hERV 
biology and opens the way for future development of technologies to exploit hERV 





Alignment and quantification of hERV expression from RNA-Seq data.  
hERV genomic coordinates were derived from a previously a published study by 
Vargiu et al.38. Full-length hERV sequences were masked for low complexity reads (9 or 
more repeating single nt; 7 or more repeating double nt; 4 or more repeating nt patterns 
of 3; 3 or more repeating nt patterns of 4; 2 or more repeating patterns of 5; 2 or more 
repeating nt patterns of 5) and compiled alongside human hg19 transcriptome reads 
into a reference file for downstream alignment. RNA-Seq FASTQ files were aligned to 
the hERV reference using STAR v2.5.3 (multimaps ≤10, mismatch ≤7)176. BAM output 
files were filtered for reads that mapped to hERV reference using SAMtools (v1.4)177, 
then quantified using Salmon v0.8.2 (Quant mode, –1 ISF)178. Raw expression matrices 
were either normalized to hERV counts per million total FASTQ reads and log2 
transformed, or normalized to the upper quartile hERV expression value among non-
zero values within each sample and log2 transformed (Supplemental Tables 12–14). 
Only TCGA pan-cancer samples sequenced with Illumina HiSeq 2 × 50 bp were 
analyzed. See the supplemental material for optimization details and input parameters. 
RNA-Seq expression, IGS analysis, and survival analysis.  
MapSplice-aligned, RSEM-quantified RNA-Seq expression matrices and survival 
data were downloaded from FireBrowse (http://firebrowse.org/). Expression matrices 
were merged between all cancer types, upper quartile normalized within each sample, 
and log2 transformed. IGS were derived from previously described 




gene within the signature. TCGA LAML samples were omitted from analysis in order to 
prevent skewing of IGS patterns. 
TCR/BCR alignment.  
MiXCR (v2.1.1) was used for identification of TCR and BCR sequences with 
TCGA KIRC162. Following suggested run methods provided by MiXCR’s documentation 
for RNA-Seq data (https://mixcr.readthedocs.io/en/latest/rnaseq.html), paired-end 
FASTQ files were run through alignment in RNA-Seq mode, 2 rounds of contig 
assembly, extension of incomplete CDR3s, assembly, and export. Data were 
subsequently converted into an expression matrix, dropping all clones (defined as 
conserved amino acid CDR3 sequence) with expression in fewer than 10% of all TCGA 
KIRC samples, and scaled to counts per billion total FASTQ reads. 
HLA-A*02:01 monomer UV exchange and β2-microglobulin ELISA.  
Epitope prediction was performed with the NetMHCpan 4.0 Server interface, 
defining predicted HLA binders as those with binding affinity ≤500 nM39. Predicted 
hERV epitopes were synthesized through New England Peptide array technology. 
Monomer exchange reaction was carried out using the BioLegend Flex-T HLA-A*02:01 
monomer UV exchange protocol174. Peptide exchange efficiency was performed using 
the BioLegend HLA class I ELISA protocol175. 
RT-qPCR validation of hERV 4700. 
Expression levels of hERV 4700 were assessed by RT-qPCR in a collection of 




patients; 9 samples) and nonresponders (n = 6 patients; 6 samples). RT-qPCR was 
performed on all available samples, with no further selection process. Total RNA 
isolation was performed using the RNAeasy FFPE Kit (QIAGEN). DNAse treatment was 
performed during RNA isolation using RNase-free DNase I (QIAGEN). RNA quality and 
concentration were assessed using a NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies). 
First-strand cDNA synthesis was performed using 250 ng total RNA, random 
hexamers, and the SuperScript IV Reverse Transcriptase Kit (Life Technologies). RT-
qPCR was performed on a CFX96 Touch Real-Time PCR Detection System (Bio-Rad) 
using TaqMan Universal PCR Master Mix (Applied Biosystems). RT-qPCR primer and 
probe sequences are shown in Supplemental Table 7. All analyses were performed in 
triplicate, and relative RNA levels were determined using hypoxanthine 
phosphoribosyltransferase 1 (HPRT1) as an endogenous internal control (Applied 
Biosystems, catalog 4333768). A HeLa control RNA sample was included for inter-plate 
calibration. hERV 4700 expression levels were calculated using the ΔΔCt method. 
Expression levels for 2 sample pairs derived from the same patients were averaged for 
statistical analyses in Figure 3.5E. 
Flow cytometric analysis.  
Tetramer and cell surface staining was performed as described previously179. 
Briefly, viably frozen, histologically subtyped ccRCC tumor samples were thawed and 
stained for HLA-A2 (BD Biosciences; clone BB7.2, allophycocyanin [APC]). Separately, 




then stained using approximately 10 μg/ml tetramer (phycoerythrin [PE]) or Beckman 
Coulter iTAg MHC class I human–negative tetramer control on ice for 30 minutes. Cells 
were then washed and incubated on ice with 5 μg/ml biotin-conjugated anti-PE antibody 
(BioLegend; PE001) for 20 minutes, followed by 2 washes, then further incubation with 
5 μg/ml streptavidin, R-PE conjugate (SAPE) for 10 minutes on ice. Cells were then 
washed and stained for viability using BD fixable viability dye FVS700 according to the 
manufacturer’s directions. Last, cells were Fc blocked using mouse immunoglobulin 
(MilliporeSigma, catalog I5381) for 10 minutes, followed by surface staining for 20 
minutes on ice with the following markers: anti-CD45 (BD Biosciences; clone HI30, 
BV510), anti-CD3 (BD Biosciences; clone UCHT1, FITC), anti-CD8 (Beckman Coulter; 
SFCI21THy2D3 [T8], APC), anti-CD4 (BD Biosciences; clone RPA-T4, BV421), anti-
CD14 (BD Biosciences; clone MϕP9, PerCP Cy 5.5), anti-CD19 (BD Biosciences; clone 
HIB19, PerCP Cy5.5), and anti-CD56 (BD Biosciences; clone BI59, PerCP Cy5.5). 
A minimum of 1,000,000 events were collected for each sample on a BD 
LSRFortessa flow cytometer. FlowJo flow cytometry software version 10 was used for 
analyses of all flow cytometric data. Tumors were derived from viably frozen 
nephrectomy samples from UNC Chapel Hill and Vanderbilt University hospital patients 
with clear cell histology. Healthy donor PBMCs were screened by and purchased from 
Gulf Coast Regional Blood Center, Houston, Texas, USA. 
Data availability.  
TCGA analyses were performed on data collected and generated by the TCGA 




TCGA raw data can be accessed in the database of Genotypes and Phenotypes 
(dbGaP, accession phs000178). Ribo-Seq analysis was performed on data collected by 
Loayza-Puch et al. and can be accessed in the NCBI’s Gene Expression Omnibus 
database (GEO GSE59821)152. hervQuant expression matrices for TCGA pan-cancer 
(UQN and RPM) and aPD1-treated ccRCC (raw reads) RNA-Seq datasets are available 
in Supplemental Tables 12–14. The GWIPS ribosomal profiling database is available at 
https://gwips.ucc.ie/. The hervQuant workflow reference and instructions are available 
for download at https://unclineberger.org/vincent/resources 
Statistics.  
GLM using the R “glm” package was used for all univariable regression, unless 
otherwise stated. Univariable and multivariable CoxPH was performed with the R 
“survival” package. Multiple sequence alignment was performed with Clustal Omega 
through the R “msa” package180. Differential hERV expression was calculated using the 
DESeq2 R package168. For all CoxPH analyses, P value correction was performed 
using Bonferroni’s correction to maintain a conservative cutoff of significance. For all 
other analyses, 5% FDR multiple testing correction for P values was performed unless 
otherwise stated. Welch’s t test was performed for statistical calculation in Figure 3.3C. 
Log rank test was performed for statistical calculation in Figure 3.4C, with no multiple 
testing correction. Multivariable CoxPH and χ2 test were performed for statistical 
calculation in Figure 3.4D, with no multiple testing correction. Mann-Whitney U test was 
performed for statistical calculation in Figure 3.5E, with no multiple testing correction. P 




Study approval and sample acquisition.  
The present studies in humans were reviewed and approved by the Vanderbilt 
University Human Research Protections Program, and the University of North Carolina 
at Chapel Hill IRB and the Office of Human Research Ethics (CB 7097). Subjects 
provided written informed consent prior to their participation in the study. Biopsy 
samples were collected according to a protocol approved by the Vanderbilt University 
IRB (no. 160979), and the UNC IRB approved the biorepository protocol (LCCC 1212). 
Patients were identified through an IRB-approved protocol and identified using a 
pharmacy-based list. Line of treatment for each patient varied. The response was first 
determined by chart review of clinicians’ notes and then confirmed by the authors of this 
article based on RECISTS 1.1 imaging criteria. 
Supplemental material 
All supplemental figures and tables cited in Chapter 2.2 are listed according to 








CHAPTER 4: Design and delivering of neoantigen-based therapeutic vaccines 
4.1 Machine learning model for prediction of neoantigen immunogenicity 
 4.1.1 Introduction 
T cells are a key driver of anti-tumor immune response through recognition of 
antigenic tumor peptides presented on cell surface major histocompatibility complex 
(MHC) proteins. These peptides include tumor neoantigens, which are derived from 
mutation-containing proteins that generate novel immunogenic epitopes, as well as minor 
histocompatibility antigens (mHA), which are variants within the same MHC allele arising 
from single nucleotide polymorphisms, most commonly in the setting of hematopoietic 
stem cell transplants.  Despite the ability of these antigen-based therapeutic tumor 
vaccines to promote tumor-specific T-cell responses in a number of pre-clinical models70–
72, clinical efficacy remains to be demonstrated14,15.  
Among significant challenges impeding clinical translation of neoantigen/mHA 
therapies includes the ability to select the subset of immunogenic antigens from all 
possible computationally-predicted neoantigens.  Unlike murine pre-clinical models 
where in vivo/ex vivo methods to screen for immunogenicity exist, no such benchtop 
prediction method for immunogenicity is currently available in humans.  As such, the 
development of an algorithm for predicting the immunogenicity of computationally-




While there are robust methods to predict for the binding affinity of potential peptide 
epitopes across multiple species39,181, these methods are insufficient to determine 
whether an immune response will be generated against said epitope in vivo.  In the case 
of neoantigens and mHA, where most predictions are based on SNV/SNP mutations, 
predicted binders share high sequence identity to native protein sequences.  This high 
sequence identity results in greater potential for central tolerance compared to epitopes 
derived from non-self-proteins (such as viral antigens).   
While a subset of predicted neoantigens/mHA are capable of promoting an 
effector T cell response, it isn’t currently clear whether specific features of the predicted 
antigen sequence predicts for immunogenicity.  Here, we correlate peptide-intrinsic 
features of predicted murine neoantigens and mHA with immune response in the 
vaccine setting.  Using a gradient boosting method with cross-validation, we design a 
novel model to predict for neoantigen/mHA peptide immunogenicity based on peptide-
intrinsic characteristics.  We predicted for the immunogenicity of predicted neoantigens 
in the BBN963 basal-like bladder model and mHA in the P815 (BALB/c host, DBA/2 
recipient) mastocytoma transplant model and demonstrated the capacity of epitopes 
with high predicted immunogenicity to control tumor growth better than those with low 
predicted immunogenicity and untreated control.  Lastly, using our model on predicted 
class I neoantigens among the TCGA pan-cancer dataset, we observed high 
association between highly immunogenic neoantigens and MSI-high driven immune 
features in colon adenocarcinoma (COAD) and a strong negative association between 
MYC amplification and highly immunogenic neoantigen numbers in lung 




 4.1.2 Results and Discussion 
 
Identification, screening, and computational processing of murine neoantigens 
Neoantigens and mHA were predicted in six murine tumor models (B16F10, 
BBN963, MB49, UPPL1541, P815, and T11) spanning the murine b and d haplotypes 
(Figure 4.1A).  Neoantigen prediction was performed as previously described182.  
Briefly (Figure 4.1B), whole exome sequencing was performed on tumor and matched-
normal tail or liver DNA, along with whole transcriptome sequencing of tumor RNA.  
Tumor mutations were called using UNCeqR183, filtering for SNV mutations with at least 
5x coverage by RNA-seq.  Translated 8-11mer (class I)  or 15mer (class II) peptides 
were derived across three open reading frames, and then predicted for MHC binding 
affinity using NetMHCPan3.0184.  Minor mismatch antigens were predicted similarly in 
the P815 model (derived from DBA/2 background) against the BALB/c histocompatible 
host.  Predicted binders were filtered by binding affinity < 500nM, with top binding 
epitopes synthesized using New England Peptide array technology.  To screen for 
immunogenicity, animals were vaccinated on days zero and seven with pools of eight 
peptides.  Splenocytes from vaccinated animals were collected on day 14 and plated in 
triplicate onto an IFN-γ capture ELISpot alongside one antigenic peptide contained 
within the vaccine.  Immunogenicity was defined as the average number of spots 






Figure 4.1: Summary of tumor antigen prediction and identification of peptide-intrinsic 
features.  (A) Number of MHC class I and II neoantigens/mHA per tumor model contained 
within the study. (B) Schematic of neoantigen/mHA prediction and ELISpot validation 
workflow. (C) Summary of major classes of peptide-intrinsic features identified for each 
antigen, including amino acid sequence and characteristics at I) each absolute position, 





With the goal of identifying peptide-intrinsic features that associate with 
immunogenicity, we derived a set of features for each peptide, including the amino acid 
sequence and characteristic (via R package aaComp: Tiny, Small, Aliphatic, Aromatic, 
Nonpolar, Polar, Charged, Basic, and Acid) at each absolute position (Figure 4.1C: I), 
relative site (Figure 4.1C: II), at the site of mutation (Figure 4.1C: III), and at the first 
three, middle, or last three sequences of each peptide (Figure 4.1C: IV).  We began our 
analysis by performing univariable and multivariable generalized linear model (GLM) 
regression between these sets of peptide-intrinsic features with immunogenicity, 
independently for class I and class II peptides. 
Associations of immunogenicity in class I MHC epitopes 
Univariable regression between intrinsic peptide features and immunogenicity in 
class I antigens demonstrated 38 significant features (FDR-correlated p-value < 0.05; 
Figure 4.2A).  Among these features, the most strongly positively associated with 
immunogenicity were changes at the mutation position into a small amino acid 
(“Mutated_position_change_of_Small_feature”), valine at relative site 2 
(“Relative_site_2_V”), and basic amino acids at the mutated position of the reference 
epitope (“Reference_AA_at_mutated_position_Basic”), while the most strongly 
negatively correlated were small amino acids at the mutated position of the reference 
epitope (“Reference_AA_at_mutated_position_Small”), changes in the mutated position 
into a basic amino acid (“Mutated_position_change_of_Basic_feature”), and polar 





Figure 4.2: Linear regression analysis between peptide-intrinsic features and tumor 
antigen immunogenicity.  (A and C) Volcano plot representing GLM coefficient (x-axis) 
and –log10(FDR p-value) (y-axis) for each peptide-intrinsic feature as a predictor for 
immunogenicity in (A) class I and (C) class II neoantigens/mHA.  Dashed line 
represents FDR p-value = 0.05. Spot color represents –log10(p-value) magnitude and 




Spearman correlation between each significantly correlated feature from (A and C) for 
(B) class I and (D) class II neoantigens/mHA, respectively.  Significantly correlated 
features are shown in color, with coefficient direction and magnitude represented by 
color. (E) ELISpot-derived immunogenicity scores for class I neoantigens/mHA 
classified as predicted high (>100) or low (<100) immunogenic by multivariable GLM 
regression, with significant features from (A) as independent variables.  
We additionally looked for co-correlation among the 38 significant features, 
observing relatively low numbers of significantly co-correlated features (Figure 4.2B).  
Significant features which demonstrated strong co-correlation were expectedly related, 
such as 1) charged or basic amino acid residues at the mutated position of the 
reference peptide, 2) valine or small amino acids at absolute position 11, and 3) valine 
or small amino acid at the last position, and valine at relative site 8.  Thus, these 
significant peptide-intrinsic features largely provided predictive power independently of 
one-another, suggesting a multivariable model may outperform univariable regression.  
To increase confidence of our multivariable model, we performed univariable GLM with 
1000-fold bootstrapping with 2/3rd resampling and kept features which were significant 
in >50% of iterations.  Nine significant features from bootstrapping were inputted into a 
multivariable GLM regression model, observing significant linear fit between the actual 
immunogenicity and the predicted immunogenicity generated from the complete model 
(coefficient 0.48, p < 0.0001).  Within the multivariable model, five significant features 
(“Relative_site_2_V” p < 0.0001; “Relative_site_5_K” p = 0.0035; “Last_position_V” p = 
0.0050; “Absolute_position_3_Y” p = 0.0045; 
“Mutated_position_change_of_Small_feature” p = 0.0087) primarily drove the fit, with 
antigens classified by this model as predicted high (>100) or low (<100) immunogenicity 
demonstrating significant differences in actual immunogenicity scores (Wilcoxon p < 




Hd haplotypes, we observed the immunogenicity for each of these five significant 
features split categorically by haplotype, which generally demonstrated the same 
pattern between both haplotypes.   
Correlates of immunogenicity in class II MHC epitopes 
Among class II epitopes, 15 peptide-intrinsic features were significantly 
correlated with immunogenicity (Figure 4.2C).  Among the most positively associated 
features included changes in the mutation position into a non-polar amino acid 
(“Mutated_position_change_of_NonPolar_feature”), valine at position 1, tyrosine at 
position 6, and basic amino acid at position 2.  Interestingly, the strongest negatively 
associated feature was changes in the mutation position into a small amino acid 
(“Mutated_position_change_of_Small_feature”), which was positively associated in 
class I epitopes.  Additionally negatively associated features included changes in the 
mutation position into a polar amino acid 
(“Mutated_position_change_of_Polar_feature”), and small/tiny amino acids at the 
mutated site.  Among significant features, four features corresponding to small or tiny 
amino acids at the mutational site were strongly co-correlated, with all other features 
demonstrating moderate to low co-correlation (Figure 4.2D).  Multivariable GLM 
regression using these 15 features demonstrated significant linear fit between actual 
and predicted immunogenicity (coefficient 0.73, p < 0.0001), with two significant 
features “Absolute_position_1_V” and “Mutated_position_change_of_Small_feature” 
primarily driving the fit (p = 0.0044 and 0.0036, respectively). 




To design a predictive model for neoantigen and mHA immunogenicity, we split 
our class I epitope database into an exploration (75% of epitopes, n = 157) and 
validation (25% of epitopes, n = 53) sets (Figure 4.3A).  Class II modeling was not 
attempted, due to the low number of epitopes available within our database (n = 68).  
This lower class II epitope count is a result of i) fewer sequences with predicted binding 
affinity < 500 nM among class II epitopes, but additionally ii) lack of class II prediction in 
the P815 model.  The consistently lower number of predicted class II epitopes suggests 
either that there are indeed fewer biologically relevant class II neoantigen/mHA 
compared to class I antigens, or that the binding affinity threshold should be changed 
for class II predictions to include those with higher predicted nM scores than the 500 nM 
cutoff currently implemented.  Currently, no studies have examined optimal predicted 
binding affinity cutoffs for class I and II neoantigens, with 500 nM widely used as the 
cutoff for both classes. 
In order to reduce noise within our model, we collapsed immunogenicity counts 
with absolute values less than or equal to the absolute value of the most negative count 
to zero. Within the exploration set, we used a 10,000-fold bootstrapping (2/3rd 
resampling) approach, comparing multivariable GLM, elastic net, random forest, 
gradient boosting, and linear and radial support vector machine methods.  Input 
variables for each model included either all peptide-intrinsic features or a subset of 
features that demonstrated significant univariable correlation in >50% of 1000-fold 
bootstrapping iterations (2/3rd resampling) within the exploration set.  Performance for 
each model and each set of input variables was determined by r-squared values, 




tested models.  Among the pre-filtered models, gradient boosting outperformed all other 
methods and was selected for our final model.  The class I validation set was run 
through the final model, demonstrating significant correlation between the actual 
immunogenicity by ELISpot and the predicted immunogenicity by modeling (p = 0.013, 
coefficient = 0.30, Figure 4.3B).  Among peptides with predicted immunogenicity above 
the 75th percentile, 5 of 17 epitopes (29.4%) were identified as true-positives (actual 
immunogenicity above background) while 2 of 13 epitopes (15.4%) within the bottom 
25th percentile were false-positives.  This high true-negative rate is particularly important 
in the setting of filtering for a large pool of predicted tumor antigens, as it allows for 





Figure 4.3: Performance and validation of gradient boosting model approach for 
predicting neoantigen/mHA immunogenicity.  (A) Schema of cross-validation approach 
used for GBM model building. (B) Performance of final GBM model in validation set, 
showing actual (x-axis) versus predicted (y-axis) immunogenicity scores.  Size of each 
point represents number of antigens at each coordinate.  Red line represents line of 
best fit, with p-value of fit shown above the graph.  (C and E) Schema for in vivo 
validation experiments, with tumor vaccine studies performed in (C) BBN963 basal-like 
bladder cancer and (E) P815 mastocytoma syngeneic transplant models.  (D and E) 
Kaplan-Meier survival curves for (C and E) respectively, for animals treated with 




or bone marrow only control (grey).  Statistics performed with log-ranked testing (**: p < 
0.01; ***: p < 0.001) 
In vivo validation of class I immunogenicity prediction model 
To demonstrate our final model could be used to increase the likelihood of 
identifying a clinically relevant, immunogenic epitope for anti-tumor vaccine response, 
we performed vaccine studies using two models within our validation set: BBN963 
basal-like bladder model (solid tumor) and P815 mastocytoma (liquid tumor, syngeneic 
transplant model).  BBN963 epitopes were predicted neoantigens in the C57BL/6 
background, while P815 epitopes were selected for mHA in the BALB/c background 
against a DBA/2 host. 
In BBN963, three predicted high and two predicted low immunogenicity 
neoantigens were identified.  Animals were vaccinated with 30 µg of one of these 
peptides (or no-peptide control) alongside 50 µg poly(I:C) as adjuvant, challenged with 
tumor at 12 days after vaccination, and given a 30 µg peptide booster on day 21 after 
initial vaccination (Figure 4.3C).  We observed significantly better survival among 
animals vaccinated with a predicted high immunogenicity peptide than predicted low 
immunogenicity peptide (log-rank p < 0.001) or no-peptide control (log-rank p < 0.01; 
Figure 4.3D), while predicted low immunogenicity peptide and no-peptide control 
groups did not demonstrate significant difference in survival.   
In P815, there were a total of two predicted high and three predicted low 
immunogenicity graft-vs-tumor mHA.  BALB/c donor animals were vaccinated with a 
pool of predicted high or low immunogenicity peptides (100 µg each peptide) or no-
peptide control, alongside 50 µg poly(I:C) as adjuvant on days 0 and 7.  DBA/2 recipient 




3x106 BALC/c bone marrow cells, and 3x105 P815 tumor cells on day 14; and given a 3rd 
booster vaccine on day 21 (Figure 4.3E).  Animals given predicted high immunogenicity 
T cells survived for longer than those given predicted low immunogenicity T cells, both 
of which survived for longer than no-peptide control T cells (Figure 4.3F).  Additionally, 
we observed significantly lower tumor burden in high immunogenicity versus low 
immunogenicity animals by luciferase imaging by day 26 (Wilcoxon test of total 
luminescence p < 0.05; Figure 4.4), without significant differences in weight loss or 
clinical score.  In summary, these experiments demonstrate the clinical relevance of our 
immunogenicity prediction model, with significant differences observe between 
predicted high and low immunogenicity epitopes.  These experiments used 
neoantigen/mHA in both the prophylactic and therapeutic setting, rather than strictly 
treating animals after tumor injection.  This method was selected due to the intrinsic low 
efficacy of free-peptide vaccines, whereby differences in therapeutic efficacy may not be 
observed between predicted high and low immunogenicity antigens.  As such, while 
these experiments provide evidence for the clinical relevance of our computational 
model, development of more robust therapeutic vaccine platforms are necessary for 





Figure 4.4: Luciferase imaging of luc-P815 tumor burden in DBA/2 recipients. 
 
Correlates of predicted immunogenicity in human class I epitopes 
While this immunogenicity prediction model was designed and validated in 
mouse, we hypothesized that similar rules of immunogenicity may exist among human 
neoantigens.  To test this hypothesis, we ran predicted class I neoantigens from the 
Cancer Genome Atlas (TCGA) database through our final model, generating 
immunogenicity scores for each epitope.  As expected, we observed strong correlation 
between the number of highly immunogenic neoantigens (HIN) identified by our model 
(>95th percentile) with number of total neoantigens (Pearson correlation p < 0.0001).  
From our validation experiments in BBN963 and P815 models, we observed that 




vaccine setting than predicted low immunogenicity peptides.  As such, we reasoned that 
while HIN count and total neoantigen burden were highly co-correlated, the most highly 
immunogenic neoantigens were the key drivers of immunity.  Thus, we performed 
regression studies between HIN count and immune features without controlling for total 
neoantigen burden.   
We observed significant association between HIN count and immune gene 
signatures of IFN-γ, cytotoxicity, CD8 and total T cells, and B cells among the TCGA 
pan-cancer dataset (Figure 4.5A).  When analyzed by tumor type, the majority of these 
significant associations were encompassed by the colon (COAD) and lung (LUAD) 
adenocarcinoma cancer types (Figure 4.5B).  Within COAD, there was strong positive 
association between HIN count and T-cell and cytotoxicity signatures.  To identify 
potential drivers of this pattern, we looked for co-expression of HIN count and MSI 
status, observing MSI-high COAD tumors having significantly higher HIN counts (Figure 





Figure 4.5: Correlative analysis of predicted neoantigen immunogenicity in TCGA human 
dataset.  (A) Volcano plot representing GLM coefficient (x-axis) and –log10(FDR p-value) 
(y-axis) between numbers of highly immunogenic neoantigens and immune gene 
signatures in TCGA pan-cancer dataset. (B) Heatmap representing GLM regression 
between numbers of highly immunogenic neoantigens and immune gene signatures for 
each TCGA cancer subset.  Color represents direction of coefficient (red: positive; blue: 




immunogenic neoantigens (x-axis) versus MSI score (y-axis) for TCGA COAD dataset. 
(D) Volcano plot representing GLM coefficient (x-axis) and –log10(FDR p-value) (y-axis) 
between numbers of highly immunogenic neoantigens and cancer driver mutations in 
TCGA LUAD dataset.  (A and D) Dashed line represents FDR p-value = 0.05. 
In contrast, LUAD largely demonstrated negative association with immune gene 
signatures of PD-1 responsiveness, T and B cells, and several innate immune cell 
signatures.  We examined the association between whole-exome sequencing derived 
oncogene/tumor suppressor copy numbers with HIN count, which demonstrated 
significant negative association with the MYC gene (FDR p-value < 0.01; Figure 4.5D).  
Among MYC amplified tumors, there was significantly greater expression of genes 
corresponding to cell cycle gene patterns, as well as enrichment of downstream genes 
to the MYC pathway (gene set enrichment analysis and DAVID gene ontology analysis), 
suggesting MYC amplification provides a strong pro-tumorigenesis signal.  Additionally, 
there was a decrease in sharing of MiXCR-derived T-cell receptor sequences in MYC 
amplified tumors, providing evidence that decreased neoantigen burden may negatively 
impact the anti-tumor immune response in LUAD.  A potential explanation for this 
pattern between MYC amplification and lower HIN count is a result of decreased 
selective pressures for accumulation of mutations in MYC-driven LUAD cancers, where 
further mutations in oncogene/tumor-suppressors are not necessary for oncogenesis.  
 In summary, we demonstrate that peptide-intrinsic features are associated with 
neoantigen and mHA immunogenicity.  We provide here a description of a machine 
learning algorithm for predicting neoantigen immunogenicity, validated with therapeutic 
vaccine experiments.  Analysis of human cancer data reveals that the number of 
predicted high immunogenicity neoantigens is associated with immunological and 




of-concept for computational prediction of SNV/SNP-derived neoantigen/mHA 
immunogenicity, demonstrating the potential of applying such a method on human data 
to improve clinical selection of tumor antigen targets for therapeutic vaccine 
development. 
 4.1.3 Materials and methods 
Neoantigen and mHA prediction and ELISpot immunogenicity studies 
 Neoantigen and mHA predictions were performed using protocol previously 
described in section 2.1.2: Neoantigen prediction.  ELISpot immunogenicity studies 
were performed according to protocol previously described in section 2.1.2: 
Vaccine/ELISPOT assay for neoantigen immunogenicity 
Linear regression and computational modelling 
 Intrinsic peptide features were derived from custom scripts, as well as from the R 
package Peptides.  Univariable and multivariable linear regression was performed with 
a general linear method (GLM) using the R package glm.  Multivariable models, 
including the final gradient boosting model, were built from the R package caret, with 
custom scripts to perform cross-validation.   
Peptide treatment studies 
 Biological validation treatment studies were performed as summarized in Figure 
4.3C,D.  Briefly, BBN963 treatment studies began with pre-tumor vaccination with 30 µg 
of a single peptide (or no-peptide control) and 50 µg poly(I:C) adjuvant, injected in 100 
µL PBS intradermally in the flank of 8-10 week old female C57BL/6 mice (Charles 
River).  Twelve days after vaccination, 1x107 BBN963 cells were injected in 100 µL PBS 




µg of the initial respective peptide with no poly(I:C) adjuvant.  This booster was 
delivered in 100 µL PBS intradermally in the skin directly adjacent to the tumor.  
Animals were monitored for tumor growth and survival every 2-3 days for the remainder 
of the study, with UNC Institutional Animal Care and Use Committee (IACUC) defined 
endpoints of area >200 mm2 or ulceration >5 mm in the longest diameter.   
For P815 treatment studies, 8-12 week old male BALB/c donors (Jackson 
Laboratory) were vaccinated on days 0 and 7 with 100 µg total peptide (3-4 pooled 
equimolar peptides, or no-peptide control) and 50 µg poly(I:C) adjuvant in 100 µL PBS 
intradermally in the flank.  DBA/2 recipients were treated with 800 rad total body 
irradiation on day 13.  On day 14, splenic-derived T cells and bone marrow cells were 
isolated from donor BALB/c animals, and recipient DBA/2 animals were given tail-vein 
IV injections of 3x106 T cells, 3x106 bone marrow cells, and 3x105 P815-luciferase tumor 
cells (or bone-marrow only control).  DBA/2 recipients were given a booster vaccine on 
day 21 (100 µg total peptide, 50 µg poly(I:C)), with animals monitored every 2-3 days for 
survival, with UNC IACUC defined endpoints of bilateral hind-limb paralysis.  Luciferase 
imaging studies were performed on days 8, 13, 22, 26, and 35 after transplant, using an 
IVIS imaging system on animals given intraperitoneal luciferin. 
4.2 Neoantigen-delivering nanoparticles for therapeutic tumor vaccines 
 4.2.1 Introduction 
Tumor-specific vaccine targets are currently under development for patient-
specific tumor therapies.  Neoantigens are largely patient specific variant peptides that 
can be recognized by T cells to direct tumor killing185–187, and they are an appealing target 




and can recognize the restricted expression of neoantigens by the tumor cell188–192.  
Despite the ability of neoantigen-based therapeutic tumor vaccines to promote tumor-
specific T-cell responses in a small number of pre-clinical models, clinical efficacy 
remains to be demonstrated14,49,70–72.  A key challenge arising in the field of tumor-vaccine 
therapy is the development of a vaccine platform to allow for optimal immune response 
against the vaccine target antigens.  Most neoantigen studies rely upon free-peptide 
vaccination, which are sub-optimally immunogenic compared to other delivery vehicles 
such as nanoparticle (NP)-based platforms due to factors such as exogenous proteases 
and poor uptake by antigen-presenting cells68. 
To address the challenges of neoantigen delivery, we have developed a NP 
vaccine platform for the delivery of neoantigen peptides.  NPs are an effective platform 
for a diverse range of cancer immunotherapies68, as exemplified by recent development 
of a tumor-lysate delivering NP system which significantly delayed tumor growth and 
increased survival in B16F10 melanoma model tumor-bearing mice75.  This NP platform 
was hypothesized to derive therapeutic efficacy from capture of neoantigen-containing 
proteins that promote anti-tumor immunity, as evident by the most efficacious NP 
formulation contained the highest number of captured neoantigen-containing proteins.  In 
addition, we recently demonstrated the efficacy of a dual checkpoint inhibitor/T-cell 
stimulatory antibody (αPD-1/αOX-40) delivering NP platform, which caused tumor 
regression and long term survival in >30% of B16F10 melanoma tumor-bearing mice 
when used in combination with radiation therapy, outperforming dual free-antibody 
(Appendix V)193.  This study demonstrated the effectiveness of immunotherapy co-




delivery of the antigen and an immune adjuvant.  Based on these preliminary studies, we 
believe vaccination with a similar neoantigen-delivering NP (ndNP) platform will generate 
robust anti-tumor immune responses over conventional free-peptide based vaccines.  In 
this study, we describe an ndNP platform with improved efficacy and immune activation 
over conventional free-peptide vaccination. 
 4.2.2 Results and Discussion 
Neoantigen prediction and NP design 
Neoantigen prediction and validation was performed in the B16F10 melanoma 
model, as described previously (Chapter 2.1, Materials and methods).  From the total 
pool of ELISpot-validated neoantigen peptides, we selected the top two MHC class I 
and class II epitopes for treatment experiments.  In additional, we also tested four 
neoantigens previously identified and validated by Min et al. using a tumor antigen 
capture NP approach75.  This pool of neoantigens was compared to a previously 
described neoantigen sequence with therapeutic efficacy in B16F10 (B16-M30: 
PSKPSFQEFVDWENVSPELNSTDQPFL) in a publication from Kreiter et al70.  To look 
for evidence of neoantigen presentation on the B16F10 tumor cell, T cells were isolated 
from respective neoantigen vaccinated C57BL/6 mice and expanded ex vivo in a 
neoantigen-pulsed dendritic cell co-culture.  These enriched neoantigen-experienced T 
cells were co-cultured against B16F10 cells, with anti-tumor response measured via 
IFN-γ capture ELISpot (Figure 4.6).  Compared to a non-specific (SIINFEKL) T cell 
control, we observed IFN-γ signal above backround in 7 of 9 tested neoantigen 






Figure 4.6: IFN-γ ELISpot in a co-culture assay of neoantigen-experiences T cells and 
B16F10 tumor cell.   
 
For the delivery platform, PLGA-PEG-NH2 was selected for the NP matrix, with a 
redox-sensitive succinimidyl 3-(2-pyridyldithio)propionate (SPDP) linker conjugated to 
the polymer amine group.  Subsequently, c-terminus modified neoantigens containing a 
cysteamide functional group was attached to the SPDP moiety of the polymer, resulting 
in an oxidation-sensitive neoantigen peptide release mechanism.  This ndNP chemistry 
was designed such that neoantigen epitopes would be released upon cellular uptake in 




Therapeutic vaccine treatment studies 
We next conducted a treatment study to demonstrate the feasibility of our 
proposed neoantigen-delivery nanoparticle (ndNP) platform (Figure 4.7). Treatments in 
B16F10-bearing mice began on day 4 after tumor injections (7.5x104 cells, s.c.), when 
tumors were just palpable, with vaccination and anti-PD-1 therapy given according to 
Figure 4.8 timeline.  ndNPs were loaded with the STING agonist DMXAA as adjuvant.  
Mice were given either ndNP containing our eight validated neoantigens (NP-mix 
peptide; n = 10), ndNPs containing the previously published B16-M30 reference 
neoantigen peptide70 (NP-ref peptide; n = 5), free DMXAA with either free neoantigen 
peptides (Free mix peptide; n = 10) or free reference neoantigen peptide (Free ref 
peptide; n = 10), DMXAA-only NP control (DMXAA-NP; n = 5), free DMXAA only control 
(n = 5), blank NP with no-peptide/no-DMXAA control (NP void, n = 5), anti-PD-1 only 
control (PD1 only; n = 5), or PBS only control (PBS; n = 5).  Peptide and DMXAA 
adjuvant loading concentrations, as well as size, polydispersion index (PDI), and zeta 
potential characteristics of each NP group is shown in Table 4.1.   
 
Table 4.1: Characterization of neoantigen-delivering nanoparticle formulations and 





Tumor growth was significantly delayed in ndNP treated animals, with ndNP 
containing our predicted neoantigens outperforming all other treatment groups and 
controls (Welch’s t-test tumor volume p < 0.05 by day 20).  Based upon Luminex studies 
taken from peripheral bleeds on day 10, we observed increases in pro-inflammatory 
cytokines in ndNP-mix peptide treated animals, which were significantly differentially 
clustered from all other groups by hierarchical clustering (Figure 4.9). 
 
Figure 4.7: Tumor growth curves for B16F10 bearing mice treated with neoantigen 
delivering nanoparticles or free neoantigenic peptide.  X-axis represents days post tumor 











Figure 4.9: Heatmap of Luminex cytokine z-scores measured in day 10 plasma levels 
from animals in Fig. 2 treatment study.  Samples (columns) are ordered by hierarchical 
clustering by z-score of cytokine levels (rows), with boxes around the dendrogram 
representing significance via the R package pvclust. 
 
Overall, these studies provide proof-of-principle for the superiority of a NP-based 
neoantigen vaccine platform over current standard free-peptide vaccines, suggesting 
the ndNP platform may allow for the use of a greater range of neoantigens that 
otherwise may not be substantially immunogenic as free-peptides.  This improved 
clinical efficacy is associated with increases in peripheral levels of pro-inflammatory 
cytokines and chemokines, suggesting the combination of multiple neoantigens, 




than free-peptide/DMXAA vaccine.  Currently, the mechanism behind the enhanced 
immunogenicity and efficacy of this ndNP platform remains unknown.  Potential 
hypotheses include 1) enhanced DC uptake due to particle size and charge 
characteristics, 2) decreased peptide degradation, and 3) co-localization of peptide and 
DMXAA adjuvant.  Future studies will be performed to elucidate the mechanism of 
enhanced efficacy, including experiments to analyze the necessary cell populations 
(e.g. cell depletion studies, in vitro/ex vivo phenotyping of cell populations, 
transcriptomics analysis of tumor and lymph node infiltrating populations) and NP 
characteristics (e.g. separation of peptide- and DMXAA-delivering NP, alteration of NP 
chemistry to modulate loading, size, and charge characteristics).  Compared to 
published peptide (200µg per peptide194) and DMXAA (500µg195) treatment doses, 
current peptide and adjuvant dosing is relatively low in NP groups (Table 4.1), 
suggesting optimization of NP chemistry to improve loading efficiency and capacity may 
further increase the efficacy of ndNP treatment.  In future studies, we will study methods 
to improve ndNP loading and comprehensively elucidate the immunological mechanism 
for improved ndNP efficacy. 
 4.2.3 Materials and methods 
Neoantigen and mHA prediction and ELISpot immunogenicity studies 
 Neoantigen and mHA predictions were performed using protocol previously 
described in section 2.1.2: Neoantigen prediction.  ELISpot immunogenicity studies 
were performed according to protocols previously described in Chapter 2.1.2: 






 Peripheral blood was collected from cheek bleeds of tumor bearing animals on 
day 10 after tumor injection, allowing blood to clot.  After clotting (>15 minutes), samples 
were spun at 13,000RPM for 15 minutes on a desktop centrifuge, collecting remaining 
serum.  Serum samples were flash frozen on dry ice and stored at -80°C until use.  
Luminex studies were performed using the Bio-Plex Pro Mouse Cytokine 23-plex assay 
(Bio-rad, #m60009rdpd), according to manufacturer protocol.  Subsequent analyses 
were performed using custom scripts, showing hierarchical clustered, z-score 
normalized cytokine concentration values for each serum sample. 
ndNP synthesis and treatment studies 
 PLGA-PEG-NH2 (m.w. 17kDa), succinimidyl 6-[3(2-
pyridyldithio)propionamido]hexanoate (LC-SPDP), and N,N-Diisopropylethylamine 
(DIPEA) were combined at a 1:4:10 molar ratio, respectively, in DMF solvent.  Reaction 
was left overnight at room temperature under normal atmosphere.  Product was 
subsequently precipitated with a cold mixture of methanol and diethyl ether (1:1 volume) 
and dried under vacuum.  The dried precipitant was mixed with c-terminus cysteamide 
modified neoantigen peptide at a 1:2 molar ratio, respectively, in DMF solvent.  
Reaction was left at room temperature for 48 hours under N2 atmosphere.  Conjugated 
polymer product was precipitated in a mixture of cold methanol and diethyl ether (0.5 – 
0.8:1 by volume) and dried under vacuum.  Peptide conjugation efficiency was 
confirmed using the Pierce Quantitative Fluorometric Peptide Assay, according to 




 Nanoparticle formation was performed using nanoprecipitation.  DMXAA was 
dissolved in acetone at 1 mg/mL, and peptide-polymer conjugate dissolved in DMF at 
10 mg/mL.  DMXAA and peptide-polymer solutions were combined at 1:100 by mass.  
This mixture was added dropwise into water (1:3 organic to water by volume) and 
stirred aggressively by magnetic stir plate.  This solution was left for 4 hours at room 
temperature under ventilation to allow for evaporation of organic solvent.  Subsequent 
formed particles are washed three-times in DI H2O in an Amicon Ultra Centrifugal Filters 
(50 mL, 100,000 NMWL).  Particle size and charge were confirmed using dynamic light 
scattering and zeta potentiometry, respectively.  DMXAA loading was quantified using 
UV-Vis spectroscopy absorption at 345 nM.  Washed NP was added to DPBS at 100 µL 
per dose before final injection. 
 For treatment studies, peptide dosage was normalized to 100 µg across all 
treatment groups (except peptide-free controls), and DMXAA dose was 130 µg in Ref 
NP group and 70 µg in all other treatment groups (except DMXAA-free controls).  Total 
polymer mass ranged 7-13 mg per treatment.  All vaccine treatments were given as 
intradermal injections in the skin directly adjacent to the tumor.  Anti-PD-1 co-therapy 






CHAPTER 5: Future Directions and Conclusion 
The works presented here represent a multidisciplinary approach to study the 
role of the adaptive immune system in modulation of the tumor immune 
microenvironment.  The focus of these studies is to 1) develop biologically relevant 
models and tools to elucidate the microenvironment of various cancer subtypes, 2) 
elucidate the mechanism of action for existing immunotherapies (i.e. anti-PD-1 therapy), 
3) improve upon the efficacy of current anti-tumor vaccine targets (i.e. neoantigens and 
mHA), and 4) identify novel tumor specific antigen targets for biomarker and therapeutic 
vaccine development (i.e. hERV antigens).  In addition to these studies, we are 
performing ongoing projects to follow up on the findings presented above.  
To develop a deeper understanding of the biological features associated with the 
anti-PD-1 mixed response phenotype in BBN963, we are performing single cell 
transcriptomics and CyToF proteomics analyses on tumor infiltrating lymphocytes.  For 
single cell RNA-seq (scRNA-seq) analysis of BBN963 tumors, tumor bearing animals 
were treated with anti-PD-1 therapy and monitored for response.  Primary responders (n 
= 3) and non-responders (n = 3) to therapy were selected, with tumor infiltrating 
lymphocytes enriched from the tumor using gradient centrifugation.  These cells were 
then run through a 10x Chromium Controller, with downstream library preparation 
performed according to the 10x 3’ gene expression profiling kit.  These samples are 
currently under analysis, with the aim of elucidating transcriptional differences 




bulk RNA-seq and Luminex studies on pre-treatment peripheral blood samples in 
BBN963 tumor bearing animals, we observed increases in gene signatures associated 
with five different toll-like receptor (TLR) pathways as well as increases in pro-
inflammatory cytokines/chemokines (IL-1a, IL-1b, IL-2, MIP-1a, RANTES) and 
decreases in IL-5 in samples that subsequently respond to anti-PD-1 therapy.  
Altogether, this suggests response to anti-PD-1 therapy may be dictated by the 
presence or absence of pre-treatment systemic inflammation levels.  Analysis of 
scRNA-seq data from post-treatment tumor samples will allow us to observe the 
subsequent immune differences in these tumors, painting a clearer picture of the 
connection between pre-treatment and post-treatment patterns of response to 
checkpoint inhibitor therapy. 
In addition, we have been developing a murine CyToF mass cytometry panel in 
collaboration with the UNC Flow Cytometry core facility.  This 35-40 marker panel will 
be used to identify and phenotype the various tumor infiltrating leukocytes in anti-PD-1 
responsive and non-responsive tumors.  From initial studies using a flow cytometric 
panel, we have observed that the time to which a tumor develops resistance to anti-PD-
1 therapy is correlated with a decrease in total CD45+ immune infiltration, but an 
increase in the relative frequencies of exhaustion-associated cell phenotypes (Tregs, 
terminally differentiated CD4 and CD8 T cells, PD-1 expressing T cells, myelocytic and 
granulocytic MDSCs, dendritic cells, and macrophages) to stem-like cell phenotypes 
(naïve and central memory CD4 and CD8 T cells, B cells, and total CD4 and CD8 T cell 
frequencies).  Altogether, this suggests that longitudinal development of resistance to 




remaining infiltrating immune cells displaying a more exhausted phenotype.  Future 
CyToF studies will allow us to comprehensively study this pattern, including analysis of 
various other checkpoint inhibitor (CTLA-4, LAG-3, TIM-3), costimulatory (OX-40, 
CD80/86), and innate M1/M2 (Arg-1, Ym-1) markers.   
Our analysis on the role of hERVs in modulation of the tumor immune 
microenvironment primarily focused on ccRCC; however, several other tumor types 
displayed similar patterns of significant association between hERV expression versus 
patient outcomes and immune signatures.  Apart from ccRCC (TCGA KIRC), low grade 
glioma (LGG) demonstrated the second greatest number of significantly prognostic 
hERVs.  As such, we have begun correlative analyses in LGG to study the impact of 
hERV expression on the cancer disease process.  Initial findings show differential hERV 
expression patterns among IDH1/2 mutant and wild-type LGG tumors – a key driver of 
oncogenesis in LGG – with IDH1/2 mutant tumors showing significantly lower overall 
hERV expression than IDH1/2 wild-type tumors.    
Lastly, our analysis on the design and delivery of neoantigen-based cancer 
vaccines has demonstrated our capacity to use computational methods to improve 
neoantigen prediction, as well as using a nanoparticle delivery platform to improve 
vaccine immunogenicity and outcomes.  Our computational analysis provided an initial 
in silico approach for selectively filtering out high-immunogenicity murine neoantigen 
epitopes, providing a promising strategy for application in human neoantigen selection.  
Future directions for this work include increasing the sample size available for model 
design, which would allow for further increases in predictive power.  Furthermore, 




computational approach can predict for clinical outcome similarly to what was observed 
in our pre-clinical validation experiments. 
Our initial studies on a nanoparticle neoantigen vaccine approach demonstrated 
significantly better survival and tumor growth control than free-peptide controls.  Paired 
with this efficacy, peripheral inflammatory cytokine and chemokine levels were 
preferentially upregulated in our ndNP treated group, suggesting a strong immune 
component to the ndNP’s mechanism of action.  In future studies, we plan to 1) improve 
the peptide and adjuvant loading efficiencies of the ndNP platform and 2) 
comprehensively elucidate the mechanism of action for ndNP’s increased efficacy over 
free-peptide vaccines.  The first of these goals is being actively pursued by members of 
the lab of Andrew Wang, looking at potentially novel synthesis techniques to both 
increase synthesis efficiency and absolute peptide/adjuvant loading capacity of ndNPs.  
Considering the current vaccination dose of our ndNPs is relatively low for both peptide 
(~100ug) and DMXAA adjuvant (~70ug) but still shows significant survival benefit, we 
expect an optimized strategy will further bolster our ability to cure tumor bearing 
animals.  In order to elucidate the mechanism of action for ndNPs, we will rely upon flow 
cytometric and RNA-seq approaches to compare the immune infiltrate between free-
peptide and ndNP treated animals.  These well validated approaches will provide a 
jumping-off point for more detailed studies to confirm the role of various immune 
populations in response to ndNP therapy.  We hypothesize to observe the importance of 
both innate and adaptive immune arms, with APC populations such as DCs being 
necessary for neoantigen uptake and presentation, pro-inflammatory innate populations 




immunity, and presence of antigen-specific T cells necessary to carry out anti-tumor 
effector function.  Previous studies have suggested that the majority of anti-tumor T 
cells in neoantigen treated animals are derived against class II MHC epitopes, despite 
the fact that CD8+ CTLs have been historically thought to be the most important 
component in the anti-tumor immune response.  It remains to be seen if ndNP therapy 
differentially modulates the CD4 and CD8 arms of the T cell response in a manner 
unique from free-peptide vaccination. 
The ultimate goal for all of these studies is to apply the knowledge and 
techniques described here for treatment of human cancers.  With the advent of 
universal immunotherapy treatment strategies such as checkpoint blockade therapy, 
immuno-oncology has become an integral portion of our management of various 
cancers.  Our work in chapter 2 highlights the immune correlates of responsiveness to 
anti-PD-1 therapy in basal-like bladder cancer, and development of these biologically 
faithful cancer models provides an avenue to further understand the effects of 
checkpoint blockade inhibitors and tumor-antigen vaccine therapies.  Current clinical 
studies in melanoma suggest that similar to checkpoint blockade therapy, not all 
patients respond to neoantigen vaccine therapy, with no clear explanation for resistance 
to therapy.  Future directions for the field will include expanding tumor-specific antigen 
vaccine therapy to other cancer types.  As such, elucidation of neoantigens in our BBN 
and UPPL models provides us with the capacity to better understand how to most 
effectively deliver these vaccines in bladder cancer, as well as how to overcome 




The future of immuno-oncology is largely focused on the use of tumor-specific 
antigen targets to drive anti-tumor adaptive immune responses.  With conventional SNV 
neoantigens showing promise in pre-clinical and clinical trials, we are now striving to 
expand the targetable epitope landscape of cancers, increase the power of current 
targets, and understand how these adaptive immune therapies synergize with existing 
universal immunotherapies.  Our work in chapter 3 provides a method for genomic 
identification of tumor-specific hERV antigenic targets, which may allow for a novel 
class of TSA targets for therapeutic leverage in ccRCC and other cancer types.  
Currently, our results suggest that a large proportion of ccRCC TILs may already be 
hERV-specific, suggesting that these tumor-specific T cells may be terminally 
exhausted and not able to carry out effector function.  Future studies will include 1) 
understanding the mechanism of immune suppression for hERV-specific T cells within 
ccRCC tumors, and how we may reverse this exhaustion to re-awaken their effector 
function, and 2) leveraging tumor-specific hERV antigens for therapeutic purposes, 
including development of a robust hERV-related biomarker for immunotherapy 
responsiveness and application of hERV antigens for vaccine and cellular therapies.  
With evidence of enhanced vaccine efficacy through the use of a NP delivery platform 
presented in chapter 4, hERV and other TSA targets may additionally benefit from the 
use of a nano-delivery system alongside neoantigens.  In summary, the studies 
presented in this dissertation were pursued with the goal to understand and improve 
anti-tumor immunotherapeutics, with the hope that they may one day improve our 





APPENDIX 1: RNA-seq Analysis of the Tumor Microenvironment 
1. Introduction  
Over the last several decades, we have observed a marked increase in the use 
of next-generation sequencing methods, including whole exome/genome sequencing 
and whole transcriptome profiling, allowing for characterization of a wide variety of 
sample types throughout a broad set of scientific disciplines.  The field of 
immunogenomics grew from a convergence of genomics and data science approaches 
applied to immunological questions, largely driven by cancer biologists and 
immunologists seeking to understand the tumor immune microenvironment from large 
next generation sequencing datasets such as those of The Cancer Genome Atlas 
(TCGA).  Immunogenomics is largely focused on the immune response in the context of 
malignancy, within which the complex tumor-immune microenvironment can be 
dissected with the use of transcriptomic analysis of tumor and tumor-infiltrating 
lymphocytes.   
The initial evaluation of the tumor microenvironment was performed using cDNA 
microarray technology.  However, microarray technology is limited by 1) transcript-
specific probes that do not allow novel transcripts to be queried, 2) limited range for the 
detection of low abundant transcripts, and 3) inability to alter the process to improve this 
detection.  The use of microarray technologies has largely been replaced by whole 
transcriptome RNA-seq methods, which circumvent the issues associated with 
microarray analysis.  Using RNA-seq, investigators are able to identify tens of 
thousands of genes within a single tumor-derived sample.  The use of RNA-seq to 




of the tumor microenvironment from archival tissues196,197.  Additionally, RNA-seq can 
be used in combination with or lieu of pathological approaches to subtype cancers198.  
Among immunogenomic advancements aided through the use of RNA-seq include 
correlative analyses of responders versus non-responders to immunotherapy182, design 
of biomarkers for predicting patient prognosis and response to therapies199,200, and 
characterization of the antigen spectrum of a tumor and subsequent targeting of these 
antigens (neoantigens71,201, cancer testes antigens190, tumor associated antigens202, 
etc.).  These analyses have allowed for a greater understanding of the tumor-immune 
microenvironment, with recent advancement in of single-cell sequencing technologies 
providing even further granularity in deconstructing the complicated cellular immune 
microenvironment. 
Evaluation of the tumor-immune microenvironment with RNA-seq can frequently 
provide data orders of magnitude larger than conventional immunological techniques 
such as flow cytometry (which require fresh sample processing) or other assays that are 
not accessible from FFPE material.  As a result, consistency and automation of the 
RNA-seq workflow is necessary.  In this chapter, we will provide a summary of our 
RNA-seq workflow, which is broken down into the following steps: 1) tissue collection 
and isolation of RNA, 2) library preparation and sequencing, 3) data processing and 
quality control, 4) alignment and quantitation, and 5) analysis of data.  Lastly, it should 
be noted that the field of RNA-seq analysis is rapidly progressing, with more accurate 
methods constantly in development.  While we have provided examples and 
recommendations for analysis software in the chapter, the fluid nature of this field may 




technologies.  As such, the reader should examine recent developments in the field and 
make adaptations as these newer technologies are made available.  
2. Materials 
2.1. Tissue collection, RNA isolation, and QC 
 PCR Workstation 
 Life Technologies RNaseZap RNase Decontamination Wipes 
 Sigma-Aldrich RNaseZap spray 
 Absolute Ethanol, molecular biology grade 
 Roche High Pure RNA Paraffin Kit 
 Qiagen QIAshredder 
 Qiagen RNEasy Mini Kit 
 Qiagen RNEasy Micro Kit 
 2-Mercaptoethanol 
 Qiagen TissueRuptor II  
 Qiagen TissueRuptor Disposable Probes 
 15mL polypropylene (PP) centrifuge tubes 
 Qiagen DNase RNase-Free DNase Set 
 Molecular Biology Grade Water 
 DNA low-bind tubes 
 Qubit BR RNA assay kit 
 Qubit HS RNA assay kit 
 ThermoFisher Qubit 4.0 Fluorometer 




 Agilent RNA ScreenTape 
 Agilent RNA ScreenTape Sample Buffer 
 Agilent RNA ScreenTape Ladder 
 ThermoFisher NanoDrop OneC  Microvolume UV-Vis Spectrophotometer 
2.2. Library preparation and sequencing 
2.2.1. Library preparation kits: 
 mRNA: 
 KAPA Stranded mRNA-Seq Kit 
 Illumina Truseq Stranded mRNA 
 Nugen Universal Plus mRNA-seq 
 Takara Smart-Seq v4 Ultra Low Input RNA Kit for Sequencing  
 Total RNA: 
 Illumina Truseq Stranded Total RNA 
 KAPA Stranded RNA-Seq Kit with RiboErase 
 Nugen Ovation Universal RNA-Seq with Any Deplete 
 Nugen Ovation Solo RNA-Seq System with Any Deplete 
 Takara SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input 
Mammalian 
 FFPE: 
 Illumina Truseq Stranded Total RNA 
 Kapa Stranded RNAseq with RiboErase 
 Nugen Ovation RNA-Seq FFPE System with AnyDeplete 




 Illumina Truseq RNA Exome 
2.2.2. Quantification 
 KAPA library quantification kit 
2.2.3. Nucleotide Concentration 
 Qiagen RNeasy MinElute Cleanup Kit 
 KAPA Pure Beads  
 Beckman Coulter Agencourt RNAClean XP 
2.2.4. Depletion Kit 
 Nugen AnyDeplete 
2.3. Data processing and quality control, alignment and quantification, and 
analysis of data 
2.3.1. Computer: Our analyses are performed on a computing cluster 
comprised of many interconnected, individual machines.  If your analyses 
are limited to a small number of samples (tens), a high-powered computer 
running a Unix-based operating system (>8 cores, >32 Gb RAM) may be 
able to run most analyses mentioned below.  However, if greater 
computational power is required and a computing cluster is not available, we 
recommend the use of Google Compute Engine (which we have historically 
used for certain high-requirement jobs). 
2.3.2. Workspace: If running analyses on multiple computing clusters or outside 
computing engines, we recommend consultation with a data scientist and 
use of a containerization method such as Docker (https://www.docker.com) 




for greater ease, as all parametrization and dependences are packaged 
together within the Docker environment. 
2.3.3. Software: The following programs are recommended for analyses 





 STAR aligner 
 Picard tools 
 Salmon quantifier 
 Samtools 
 Differential gene expression software (DESeq2, limma+voom, NOISeq, 
edgeR) 
 Gene set analysis software (GSEA, ssGSEA, GSVA) 
 TCR/BCR inference tool (MiXCR, V’DJer) 
 MHC inference tool (PHLAT, HLAProfiler) 
 MHC binding affinity predictor (NetMHCPan4.0, NetMHCIIPan) 
 Viral/ERV quantification software (Virdetect, hervQuant) 
3. Methods 
3.1. Isolation of total RNA and QC 




RNA isolation is critical to the success of RNA-sequencing and as a result 
maximizing yield and purity of RNA is crucial.  The time needed for tissue collection 
needs to be minimized to prevent RNA degradation.  The collection of tissue in this 
protocol is optimized for a specific amount of RNA; the addition of a greater amount of 
tissue may paradoxically reduce the yield of RNA.  Please remember to perform all 
isolations with an extraction agent in a fume hood with gloves and eye protection.    
RNA may be extracted from fresh or flash frozen samples or FFPE material.  A number 
of extraction methods exist and an isolation strategy should be chosen based on the 
starting material and RNA subpopulation of choice203,204.  Beta-mercaptoethanol (2-ME) 
is commonly added to quanidium-based lysis buffers to improve RNA isolation from 
whole tissues samples abundant in RNases205, and should be added in the 
manufacturer’s recommended amount when using commercially available kits (e.g. 
Qiagen RNEasy micro/mini).  When freezing RNA or material for subsequent RNA 
extraction, nuclease free, tight-closure tubes such as Eppendorf DNA LoBind tubes are 
recommended to prevent contamination from RNases.  The volume of lysis buffer 
needed per sample should be determined empirically based on cell type and number or 
tissue type and mass, using the manufacturer’s recommendations as a general 
guideline.  For total RNA isolation, we routinely use the Qiagen Rneasy Mini kit when 
processing tissue or when starting with larger cell numbers and the Rneasy Micro Kit 
when starting with fewer than 500,000 cells.   
Given that RNA is easily degradable and potentially prone to contamination, 




 Optimally, an RNA-only workspace with a molecular biology hood (to prevent 
contamination from debris in the air) should be used during extraction and 
reverse transcription, with a separate workspace for DNA-related molecular 
biology.  Additionally, having a separate space for different species may prevent 
cross-contamination between different experiments. 
 To further prevent cross-contamination, reagents used for handling RNA should 
remain in the RNA-only workspace and used exclusively for handling RNA.  
Ensure all reagents are RNAse free and/or molecular biology grade. 
 Use disposable, sterile RNase-free plasticware that does not require pre-
treatment and barrier pipette tips. 
 The workspace should be cleaned with an RNAse removing material, such as 
Sigma RNaseZap Rnase decontamination solution.  
 RNAse-free gloves and gowns should be work to prevent contamination from 
skin cells during handling of RNA. 
 As a general rule, RNA and DNA should be kept on ice while handling (unless 
otherwise stated by a protocol), working as quickly as possible.  Keep UV-light 
sources away from nucleic acids to prevent degradation. 
For FFPE slides, it is recommended to have a pathologist score the slides to 
ensure the material taken for RNA extraction is the tissue of choice (ex. tumor), and to 
control for estimated cellular heterogeneity when comparing experimental groups207.  
Numerous commercially available FFPE extraction kits have been compared208–210 or 




the Roche High Pure RNA Paraffin Kit for manual RNA extraction or the Maxwell 16 
LEV RNA FFPE Purification Kit for automated extraction. 
See note 1 
3.1.2. Collection/Suspension/Lysis using Qiagen reagents  
i. When starting with fresh tissue, the material should be sectioned into small 
pieces (<20 mg).  If starting with a single cell suspension, the cells should first 
be washed in PBS, pelleted, and the supernatant removed.  
ii.  RLT lysis buffer (component of Qiagen RNEasy kits) supplemented with 1% 
(v/v) beta-mercaptoethanol is then added to each cell pellet or 20 mg piece of 
tissue and vortexed.  The sample resuspended in RLT can then be flash 
frozen with either liquid nitrogen or an ice bath using dry ice and 70-100% 
ethanol.  If no lysis buffer is available, the tissue or cell pellet can be frozen 
dry and lysis buffer added upon thawing.   
iii. Fresh tissue in RLT or thawed tissue in RLT can be homogenized with the 
tissue disrupter (e.g. Qiagen TissueRuptor II) according to the manufacturer’s 
instructions.  We typically homogenize tissue in a nuclease free 50 mL conical 
using the Qiagen TissueRuptor II at full speed for 30 seconds.   
iv. Homogenized tissue should then be transferred to a QIAshredder before 
proceeding to the Rneasy Mini Kit.  If the starting material is a single cell 
suspension, the cells in RLT can be transferred directly to a Qiashredder for 
homogenization prior to using the RNeasy Mini Kit for large cell numbers or 
Rneasy Micro Kit for smaller cell numbers.  When starting with fewer than 




homogenize in place of using a Qiashredder in order to minimize nucleic acid 
loss.   
v. The Qiagen Rneasy kits can be used as directed and variations are available 
that include an extra step utilizing a genomic DNA eliminator column (Rneasy 
Plus kits) or on-column DNA digestion with Dnase (Qiagen Rnase-Free 
Dnase Set).  
vi. Molecular biology grade water should be used for eluting RNA and should be 
pipetted directly onto the column filter.  During this step, care should be taken 
not to touch the filter or the sides of the column with the pipette tip.  The 
elution volume should be chosen carefully based on the amount of input 
material.  If the eluent is too dilute, the RNA may need to be concentrated in 
order to perform QC.   
RNA should be stored at -80° C and should always be aliquoted to avoid 
unnecessary freeze-thaw cycles. 
3.1.3. QC 
Three methods of quality control should be used for the most comprehensive 
measure of RNA quality:  
i. Qubit or similar method for high sensitivity fluorometric quantification 
ii. Spectrophotometer (Nanodrop or similar) for purity assessment 
iii. Fragment analyzer (Tapestation, LapChip, etc.) measuring electrophoretic 
mobility to determine RNA integrity 
Ideally, 2 µL of sample should each be used for Qubit quantification and 




is within the working range of the instrument since many of the corresponding 
instrument kits have minimum and maximum cutoffs beyond which the reading is 
unreliable.  Follow the temperature requirements of the reagents required to operate the 
QC instruments, as the readings are often temperature sensitive. 
Some RNAseq library preparation methods will be more sensitive to 
contamination than others.  Nanodrop measures contaminants and reports the ratio of 
absorbance of a sample at 260 and 280 nm and the ratio at 260 and 230 nm.  A 
260/280 ratio of 2.0 ± 0.02 is generally accepted as pure RNA while expected 260/230 
values are typically in the range of 2.0-2.2206,212.  Many library prep methods 
recommend a 260/280 and 260/230 ratio of at least 1.7.  A low 260/280 ratio indicates 
contamination, often with protein or extraction solutions such as phenol, while low 
260/230 rations indicate presence of compounds that absorb light at 230 nM such as 
EDTA, carbohydrates, and/or phenol.  RNA integrity number (RIN; electropherogram-
based quality metric), devised by Agilent213,214, and the DV200 metric (the number of 
nucleic acid fragments greater than 200 nucleotides long), developed and 
recommended by Illumina215, are two measures commonly reported by fragment 
analyzers to assess RNA degradation.  Fully intact RNA has a RIN score of 10, while 
partially degraded RNA and strongly degraded RNA will have a RIN of 5 and 3, 
respectively. 
3.2. Library preparation 
Two factors largely determine which RNA-seq library preparation kit one should 
use: quality and quantity of the starting material. Some recommendations for kits can be 




those listed below, these are recommendations based on standard operating procedure 
at the University of North Carolina at Chapel Hill’s High Throughput Sequencing Facility. 
See notes 2-6. 
3.3. Sequencing 
We use an Illumina sequencing platform for the vast majority of our RNA-seq 
analyses, given the exceptional amount and quality of data provided.  Below is a 
summary of current Illumina platforms (see Table A1.2) and when we would select each 
for sequencing: 
 HiSeq 4000: Used for the majority of our whole transcriptome RNA-seq runs.  
Good cost/performance ratio, but relatively slow run-times compared to NextSeq 
and NovaSeq 6000 instruments.  However, is known to have an increase in 
duplicates compared to the earlier HiSeq2500 due to the patterned flow cell. 
 HiSeq 2500: A less optimal option, as it provides fewer reads without 
considerable decreases in cost.  Typically, the HiSeq 4000 is favored in place of 
the HiSeq 2500, unless library preparation methods are only compatible with the 
HiSeq 2500. 
 Nextseq: Occasionally used when sequencing a small sample set (<8 samples 
per run).  Fast run-times and low instrument costs make this an ideal option for 
groups with relatively lower throughput sequencing experiments.   
 MiSeq: Not used for whole transcriptome RNA-seq due to limited sequencing 
depth, but can be used for TCR/BCR amplicon studies.   
 Novaseq 6000: Likely to replace the HiSeq 4000 as our primary whole 




costs but substantially higher reads per run makes this an ideal option for groups 
with very high run throughputs. 
For the majority of human and murine RNA-seq analyses, paired-end 2x50bp 
sequencing chemistry will provide adequate length for accurate alignment of reads to a 
reference genome.  The exceptions to this are 1) if the focus of one’s sequencing run is 
to identify novel splice variants or resolve genomic regions with many long repeated 
elements, or 2) the reference genome/transcriptome for the derivative organism is not 
well characterized, for which longer reads may be optimal.  The length of sequencing 
can also be influenced by the type of RNA.  It is easier to have longer reads on higher 
quality fresh frozen samples than in FFPE which are inherently fragmented to sizes 
around 130-150 bp. 
3.4. Data processing and quality control 
3.4.1. Read quality metrics 
Before raw sequencing data is converted to downstream formats, several 
sequencing metrics should be considered: 
 Cluster density: Metric for DNA density on sequencing flow cell.  Lower cluster 
density maintains quality but sacrifices data output, while overloading can result 
in poor image resolution and base quality.  Recommended cluster densities vary 
for each Illumina machine and optimal loading concentrations should be 
consulted prior to sequencing.  Improper library quantification can result in 
inaccurate loading concentrations – we typically rely on Nanodrop and fragment 
analyzers to determine library quality but Qubit for concentration calculations.  




libraries with suspected low qualities or contaminations, as it can accurately 
quantify the concentration of libraries specifically, without quantification of non-
library DNA content. 
 Quality score: The quality score per sequencing cycle as well as a histogram of 
quality distribution are provided for each run.  This Q30 (Phred) quality score 
represents the likelihood of error for each particular base call.  Optimally, scores 
should reach 30 (99.9% accuracy) or greater across all cycles and base pair 
positions. 
3.4.2. BCL to FASTQ conversion, demultiplexing 
Conversion from Illumina sequencing instrument generated basecall files (BCL) 
to downstream FASTQ format is performed using the bcl2tofastq software, which 
simultaneously demultiplexes samples based upon sequence index.  To properly 
demulitplex samples, a sample sheet must be provided to the software, containing a 
row for each sample included within the run and the following columns (description 
given after colon): 
 FCID: Flow cell ID 
 Lane: Lane number as an integer 1-8 
 SampleID: ID of the sample 
 SampleRef: Reference used for alignment of the sample 
 Index: Index used for generation of a particular library.  If two indices were used, 
they should be separated by a hyphen (e.g. ACCAGTAA-GGACATGA). See note 
7. 




 Control: “Y” indicates sample is a control; “N” indicates sample is not a control 
 Recipe: What library preparation method was used for this sample 
 Operator: Name/ID of the operator of this sample 
 SampleProject: Name of project under which this sample belongs 
For details of how to install and run bcl2fastq, please refer to the Illumina 
bcl2fastq conversion software support page 
(https://support.illumina.com/sequencing/sequencing_software/bcl2fastq-conversion-
software.html). 
See note 8 
3.5. Pre-alignment QC 
After conversion into FASTQ format, quality control is performed to identify 
potential issues arising from the sample preparation and sequencing process.  
Typically, we perform this using the FastQC software, which provides a simple and fast 
method to identify per base sequence quality, GC content, per base N content, 
sequence length distribution, sequence duplication levels, overrepresented sequences, 
and adapter content.  Commonly used filters for excluding samples from downstream 
analysis in transcriptome profiling experiments include: 1) less than 30 million mapped 
reads in the sample, and 2) mean PHRED base quality <= 35. Other filters are 
additionally applied after sample alignment, as described below. 
See note 9 
3.6. Alignment and quantification 




Many computational methods exist to map RNA-seq data to the reference 
genome, allowing for splice aware alignment of both mRNA and other RNA types 
(rRNA, intronic, and intergenic RNAs)216.  In recent years, our group has transitioned 
from exclusively using Mapsplice to STAR for RNA-seq alignment, which is primarily 
rooted in their equivalent ability to accurately align reads while dramatically improving 
alignment times99,176,217.  Apart from STAR, many other aligners have been compared in 
terms of speed and performance216, demonstrating that the most reliable general-
purpose aligners include STAR, CLC, Novoalign, and GSNAP.  While accuracy of these 
other popular aligners are similar to STAR, runtimes for human-derived data are 
significantly faster by STAR than the other three aligners.   
More recently, tools such as Sailfish, Salmon, and Kallisto allow for extremely 
fast but approximate quantification of genes directly from the FASTQ file, without 
alignment to a reference genome178,218,219.  Sailfish and Salmon make use of a quasi-
mapping approach while Kallisto uses pseudo-alignment for estimated quantification of 
genes.  Both of these methods mathematically similar, k-mer based algorithms, with the 
key difference that quasi-mapping uses suffix arrays while pseudo-alignment 
implements de Brujin graphs.  While these methods can provide very fast and fairly 
accurate estimates of gene expression, they do not perform as well from FFPE derived 
data, do not have the accuracy of genome aligners, and do not generate read-level data 
(BAM/SAM file).  As such, we typically still rely on STAR for alignment of FASTQ files. 
STAR requires a single-ended or pair-end FASTQ file(s) for alignment to the 
reference genome.  Additionally, a reference genome must be supplied and further 




STAR generated genome has not been previously built, reference genome sequences 
(in the form of FASTA files) and optionally an annotation file (in the form of a GTF file) 
need to be input into STAR for generating genome indexes.  While the annotation file is 
not necessary to build the reference genome, it should be included to improve mapping 
accuracy.  Limited STAR genomes are available from the creators of STAR 
(http://labshare.cshl.edu/shares/gingeraslab/www-data/dobin/STAR/STARgenomes/), 
but users are encouraged to generate their own genome indexes using the most up to 
date assemblies and annotations.  The NCI’s Genome Data Commons (GDC) also 
provides references genomes that they use for their harmonization pipelines 
(https://gdc.cancer.gov/about-data/data-harmonization-and-generation/gdc-reference-
files). 
3.6.2. Post-alignment QC 
After alignment, several quality control metrics are collected to ensure results can 
be interpreted without significant bias from technical outliers.  Given that each sample 
set can vary dramatically, there are no strict cutoffs for any of these metrics.  We try to 
determine the presence of technical outliers within the set and remove samples or are 
just aware of the sample quality when interpreting downstream analyses.  The following 
metrics are commonly analyzed: 
 Proportion aligned vs unaligned: Performed to ensure there are not an over-
abundance of unaligned reads among all data. 
 Percent of alignment by region: Comparison of percentage of total bases aligned 
to mRNA versus intergenic, intronic, or ribosomal RNA to ensure the 




measured using output from Picard Tools220.  Typically, we want at least 10% of 
reads to map to mRNA, but the other metrics will vary by library and RNA type 
(See note 10).  
 Number of non-zero genes: Performed to determine coverage among all genes 
and identify low diversity samples. 
 Relative log expression: Analysis of total aligned reads per sample to ensure 
read distributions are similar across samples.  This gives an intuitive view of the 
global variation in relative expression221. 
 Upper quartile comparison: Calculated as 
𝑀𝑒𝑑𝑖𝑎𝑛(𝑎𝑙𝑙 𝑈𝑄 𝑣𝑎𝑙𝑢𝑒𝑠 𝑎𝑐𝑟𝑜𝑠𝑠 𝑐𝑜ℎ𝑜𝑟𝑡)
𝑈𝑄 𝑓𝑜𝑟 𝑎 𝑔𝑖𝑣𝑒𝑛 𝑠𝑎𝑚𝑝𝑙𝑒
, where 
UQ denotes the upper quartile (75th percentile) value among all read counts per 
sample.  This metric provides a scaling factor for each sample representing the 
relative multiplier necessary for UQ read-normalization of that sample relative to 
all other samples in the set.  Alternatively to the above method, DESeq2’s 
sizeFactor function can also be utilized to calculate a scaling factor.  Samples 
with particularly high scaling values generally have lower mRNA mapping and 
normalization of these samples will result in amplification of noise.    
 Principle component analysis: Performed to identify potential technical outliers. 
3.6.3. Quantification methods 
Gene expression profiling experiments require generation of quantified gene 
expression values for all genes represented in the sequencing data.  In recent years, 
the use of RSEM and Cufflinks as quantifiers have widely been replaced by newer, 




of magnitude faster in run time compared to older quantifiers while maintaining similar 
or better accuracies224.   
As mentioned earlier, Sailfish and Salmon can directly quantify FASTQ files 
without genome alignment; however, they can additionally be used downstream of an 
aligner strictly as a transcript quantifier.  We typically pair Salmon quantifier (quant 
mode) downstream of STAR alignment.  Salmon requires an unsorted BAM file as input, 
and we use the transcriptome-space BAM file as input, with an hg38 or mm10 reference 
transcriptome FASTA file as reference. 
3.7. Select methods of analysis 
 Prior to analysis, gene expression matrices are derived through combining the 
raw count data for each sample into a matrix.   
 From this raw matrix, some threshold can be applied to drop lowly expressed 
genes, such as filtering by a minimum read count threshold or dropping all genes 
with zero expression for all samples (i.e. tissue specific genes).  For tumor 
experiments, we typically have relied on dropping all genes which are not 
expressed in >70% of all samples, which provides a conservative cutoff to filter 
out lowly expressed genes but may in some instances introduce bias away from 
these rare genes.   
 Next, this raw, filtered expression matrix is normalized.  Common methods 
include upper quartile normalization (UQN), median normalization, normalizing 
RPKM (Reads Per Kilobase Million), FPKM (Fragments Per Kilobase Million), 
TPM (Transcripts Per Kilobase Million), or relying on a software package such as 




M; TMM)168,225.  These software package normalization methods lead to a more 
stable normalization than the other methods226.  
 If not using DESeq2 VST or edgeR TMM for normalization, the normalized matrix 
is log2(x+1) transformed for a final expression matrix.  
See note 11 
3.7.1. Differential gene expression analysis 
A wide variety of differential gene expression analysis tools exist, with popular 
tools including edgeR, DESeq2, limma and voom, NOISeq, SAMSeq (samr), EBSeq, 
bayseq, sleuth, among others.  Direct comparison of these popular methods suggests 
NOISeq, DESeq2, and limma+voom have the best sensitivity/specificity performance 
metrics, with further suggestions that integration of multiple methods may further 
improve overall performance227.  Another common tool for differential gene expression 
analysis is edgeR, which has been shown to have similar performance compared to 
DESeq2225,228.   
We perform differential gene expression analysis using DESeq2, using a gene 
expression matrix of raw count as input168. This matrix is automatically normalized by 
DESeq2 prior to differential expression analysis.  In the case of Salmon derived 
expression data, counts need to be converted to an integer DESeq2. 
3.7.2. Immune gene signature analysis 
Immune gene signatures are composed of a set of genes, typically specific to an 
immune cell or pathway of interest combined with a method to transform expression 
levels of signature genes into a single score for each sample.  We calculate immune 




where >30% of respective genes demonstrate zero expression in a particular sample 
are not considered for downstream analyses.  The IGS score is calculated as the mean 
of the expression of all genes within a particular signature229.   
Alternatively, genes within each signature can instead be scaled across the cohort, 
taking the median value as the IGS score.  This extra normalization step can help 
reduce biases incurred by highly or lowly expressed genes, but may also reduce 
sensitivity if those genes have a high degree of biological significance.  The following list 
of citations contains gene signatures we regularly use in our analyses: 
 Palmer C et al. BMC Genomics 2006; PMID:16704732159 
 Schmidt M et al Cancer Res 2008; PMID:18593943230 
 Beck et al Clin Cancer Research 2009; PMID:19188147231 
 Rody A et al. Breast Cancer Res 2009; PMID:19272155232 
 Chan et al PNAS 2009; PMID:19666525157 
 Prat A et al Breast Cancer Res 2010; PMID:20813035158 
 Fan C et al. BMC Med Genomics 2011; PMID:21214954233 
 Rody A et al. Breast Cancer Res 2011; PMID:21978456234 
 Bindea G et al. Immunity 2013; PMID:24138885100 
 Iglesia MD et al. Clinical Cancer Research 2014; PMID:24916698101 
 Kardos J and Chai S et al. JCI insights 2016; PMID:2769925683 
 Charoentong P et al. Cell Reports 2017; PMID 28052254235 
 Vesteinn et al Immunity 2018; PMID: 2962829050 
 MSigDB gene sets160 




 Gene Ontology terms 0050852 – GO:0050852; PMID:NA 
3.7.3. Gene pathway analysis 
Gene pathway analyses provide a measure for pathways which have genes 
expressed at levels higher than by chance.  Among immunogenomic-related pathways, 
we typically use MSigDB gene sets for the bulk of our analysis160. Of particular 
relevance includes the C7 immunologic gene sets, C2 curated gene sets, C5 gene 
ontology gene sets, and the hallmark gene sets.  There are several methods for 
performing gene pathway analysis, among which include 1) standard GSEA analysis, 2) 
weighted analysis, and 3) network-based approaches.  Below, we will provide a 
summary and examples for each approach. 
Commonly use pathway analysis tools for standard GSEA analysis include 
GSEA, single sample GSEA (ssGSEA), and GSVA for gene pathway analysis236–238.  
Standard GSEA analysis takes in a discrete and predefined gene set that typically 
represents a biological state, comparing whether RNA-seq or microarray expression 
data between two biological groups show phenotypic differences based upon those 
gene sets.  Additionally, ssGSEA and GSVA are able to generate gene signature 
expression values for each individual sample, which GSEA is not.  Thus, GSEA is only 
able to compare signature expression among pre-defined groups.  While GSEA, 
ssGSEA, and GSVA are among the most popular gene set analysis tools, other gene 
pathway analysis software such as PLAGE, GLOBALTEST, and PADOG have 
demonstrated greater sensitivity and under certain conditions239–242.  As such, the 




set, and thus the chosen method may require optimization and validation for the 
optimization of results.  
Alternatively to standard GSEA, weighted approaches such as GSEAPrerank 
take into account a predefined list of rank-ordered genes to calculate the enrichment 
score243.  The gene’s ranks thus define the weight of its contribution to the enrichment 
score.  This can be particularly useful when the ranking metrics provided by standard 
GSEA are not appropriate for the data, or if the expression data is derived from a non-
standard approach (targeted methods, ChIP-seq, GWAS studies). 
Another method for gene pathway calculation is a network-based approach, as 
exemplified by DawnRank, which ranks potential driver genes based on their impact on 
differential expression of downstream genes in a molecular interaction network244.  
DawnRank performs these analyses on a per-patient basis, allowing for identification of 
personalized driver genes without biases from the rest of the cohort.  It should be noted 
that to call driver mutations, DawRank additionally requires variant call files, which 
typically is derived using DNA data. 
3.7.4. Deconvolution 
The incredibly complex cellular composition of a tumor microenvironment 
underscores the difficult question of how to deconvolute the proportional signals from 
each cell type.  Among cellular deconvolution tools currently available, CIBERSORT 
and TIMER are the most popular for characterization of the tumor 
microenvironment196,197.  CIBERSORT is designed to infer the relative proportion of 
individual immune populations among total leukocytes, while TIMER instead aims to 




limitation of both tools is their reference is derived from peripherally collected leukocytes 
from healthy donors, with the assumption that these transcriptional patterns do not 
substantially differ from their tumor infiltrating counterparts.  At this time, it is not clear 
which of these two methods provides more accurate estimates of tumor infiltrating 
immune populations from bulk RNA-seq data. 
3.7.5. TCR/BCR inference tools 
We have directly compared the performance of several TCR/BCR inference 
tools, including MiXCR, MiTCR, TRUST, and V’DJer162,245–247.  Based on these 
comparisons, our preferred inference method is MiXCR for TCR calling and 
MiXCR/V’DJer for BCR calling.   
MiXCR-based TCR inference is performed according to recommended settings 
from the Mi lab for short-read RNA-seq data 
(https://mixcr.readthedocs.io/en/master/rnaseq.html; subheading “Typical analysis 
workflow”), which typically yields 100 to 102 total clones, depending upon sequencing 
depth and RNA quality.  From the MiXCR export file output, we perform diversity and 
clonotypes sharing calculations through standard diversity calculation formulas (species 
evenness, and diversity indices such as Gini-Simpson or Shannon entropy).  We have 
found that analyses from samples with very few identified clones (101-102) results in 
inaccurate diversity calculations, and thus a minimum clone cutoff should be optimized 
and implemented.  We avoid the use of TRUST because of its identification of a large 
frequency of “non-canonical” CDR3-regions, which can be as short as a single amino-




BCR inference is performed using both MiXCR and V’DJer.  Unlike MiXCR, 
V’DJer uses an assembly-based inference method for calling full length BCR calls from 
fresh-frozen derived RNA.  As a result, V’DJer is able to provide full length BCR 
sequences into the constant region for isoform calling, which allows for single base 
resolution of the BCR.  In a comparison of these two tools, MiXCR was demonstrated to 
have greater sensitivity and less computational intensity compared to V’DJer248, and 
therefore may be more relevant in situations where population-levels statistics are of 
primary interest rather than identification of full length BCR-sequences.  
See note 12 
3.7.6. HLA inference 
HLA typing has historically been performed through the use of PCR, Sanger 
sequencing, or flow cytometric approaches, with next generation sequencing recently 
emerging as a potentially higher throughput and more cost effective approach249.  The 
majority of these approaches rely upon the use of HLA region targeted DNA 
sequencing, preventing the identification of biologically meaningful data outside of HLA 
typing.  Additionally, targeted sequencing requires the use of capture probes, which 
may result in loss of capture for polymorphisms within the MHC genes.  Whole 
exome/genome approaches suffer from their requirement of very high read depth, with 
nearly half a billion sequencing reads necessary for accurate calling250,251. 
As a result of these limitation, RNA-seq derived MHC calling methods have been 
recently developed, which allows for accurate calling of alleles without limiting data for 
uses beyond this purpose.  One example of such a tool is PHLAT, which can use both 




takes a k-mer approach to allow for identification of both common and rare alleles from 
RNA-seq data47. 
3.7.7. Neoantigen prediction 
Several published neoantigen prediction pipelines exist, although they almost all 
require additional tumor-derived whole-exome sequencing data in order to accurately 
call mutations.  As such, we will discuss several neoantigen prediction tools currently 
available, without enumerating on the exact DNA inputs necessary for running the 
software.  A more recent approach comes from Neopepsee, which attempts to increase 
calling accuracy through incorporation of amino acid level immunogenicity information 
derived via a machine learning algorithm trained on a dataset of reported class I MHC 
epitopes known to exhibit a positive T-cell effect252.  Another tool is pVACtools, which 
also integrates DNA and RNA data to call class I and II neoantigens, importantly with 
the inclusion of point mutations, indels, gene fusions, and frameshift mutations derived 
epitopes253.  Lastly, another tool is INTEGRATE-neo, which is a neoantigen prediction 
pipeline with a focus on gene fusion derived epitopes254. 
Most neoantigen calling pipelines work through a similar process, which we have 
simplified below: 
i. Variant calling: Mutations are identified using a variant calling program, with 
DNA-seq and RNA-seq inputs.  DNA sequences corresponding to peptides 
are retrieved and translated in silico into protein sequences. 
ii. Analysis of variant expression: RNA-seq data is used to quantify read 
coverage of all called mutations.  The expression levels of each peptide 




coverage.  Peptides which do not meet a minimum read coverage are filtered 
out. 
iii. HLA typing: For human samples with unknown HLA type, HLA typing 
software is applied as described in the above section. 
iv. Enumeration of possible variant peptides:  Generally, 8-11mers are 
considered for class I epitopes while 15mers are considered for class II 
epitopes.  Several groups rely upon the use of long peptides (closer to 30 
amino acid residues in length), with the idea that these longer peptides will 
allow for better antigen-presenting cell processing and presentation. 
v. MHC binding prediction: Binding affinity to MHC molecules expressed by 
the tumor for all possible peptides generated from mutations is predicted.  
Perhaps the most widely used MHC binding affinity prediction software is 
NetMHCpan (version 4.0) and NetMHCIIpan (version 3.2) for class I and II 
epitopes, respectively 39,181.  Peptides are filtered by their binding affinities 
(IC50 nM) to each allele in the tumor sample’s HLA type.  Peptides with an 
IC50 value of less than 500 nM for at least one allele are typically considered 
predicted neoantigens. 
3.7.8. Viral quantification 
Expression of viral and human endogenous retroviral (hERV) RNA can drive 
immunological phenotypes in cancer52,200.  We have developed tools for quantification 
of vertebrate viral and human endogenous retroviral (hERV) transcripts from RNA-seq 
data.  The first of these tools is VirDetect, which specifically detects viruses from RNA-




the human genome are then aligned to the masked viral genomes. The novelty of 
VirDetect is the masking of the viral genome for areas of human homology and areas of 
low complexity. The masking allows for higher specificity and limits the need for manual 
curation.  
The commands can be found here: 
https://github.com/dmarron/virdetect/blob/master/VirdetectManual.pdf 
The second tool is hervQuant, which allows for quantification of nearly 4,000 full-length, 
intact hERVs from short read RNA-seq data200.  hervQuant has currently been 
optimized and validated for 2x50bp fresh-frozen RNA-seq data, making it relevant for 




4.1.    For RNA extraction from FFPE, we prefer the use of blocks rather than slides, 
as the greater surface area exposure to the outside environment on slides is 
associated with more degradation.  We have greatest success from using freshly 
cut blocks, discarding the first scroll and collecting toward the center of the 
block.  Typically, we take 4-6 slides of 10 µm for RNA extraction. 
4.2.     We and others have contributed to the NCI’s Biorepositories and Biospecimen 
Research Branch best practices for assessing nucleic acid quality from FFPE 
tissues255.  In many degraded RNA samples, the average fragment size of the 
RNA is around 130-150 bp. However, we have still been able to generate 




library strategies, it is best to start with RINs >7 for best quality, though RINs 5-6 
are occasionally successful but not as consistent.  RIN cutoffs of 7 have been 
used in projects like TCGA. For more degraded RNAs, it is better to use total 
RNA or capture based protocols that do not have a strong requirement on intact 
RNA and can be used with samples of low RIN or DV200.  We typically are 
successful with 80-90% of FFPE libraries, particularly with doubling the max 
starting amount of RNA (ex 200ng for RNA exome, or 500-1000ng for Total 
RNA). When a protocol calls for fragmentation, this is based on the suspected 
quality of the RNA and the desired length of sequencing.  In general, we typically 
do not fragments samples with RINs less than 5. 
4.3.    For kits that require the starting RNA to be concentrated into a small volume, 
there are a number of concentration methods including column methods, like 
Qiagen’s Rneasy MinElute Cleanup kit, bead purifications, like KAPA’s Pure 
Beads or Beckman Coulter’s RNAClean XP, or ethanol precipitation. 
4.4.    Some samples, including RNA from blood, might produce more desirable 
results following the depletion of unwanted transcripts, such as ribosomal RNA 
or Globin RNA. Using a depletion kit, like one from Nugen’s AnyDeplete line, will 
selectively deplete unwanted transcripts, enriching for sequencing reads of 
choice. Total RNA input may need to be increased if using a depletion kit. 
4.5.     If multiple kits from Figure A1.1 would work for a given quality and quantity of 
starting RNA, other factors such as price, kit availability, and laboratory 




analysis – coding vs noncoding transcriptome, alternative transcripts, or 
structural alterations. 
4.6.    It is not recommended to compare sequencing analysis across different library 
preparation kits for the same project, as each kit will have its own biases.  
Comparing data across multiple library preparation methods may result in 
preferential up-/down-regulation of certain genes between different kits. 
4.7.    The use of dual indexes is preferred, as it reduces the prevalence of index 
hopping/library switching. 
4.8.    FASTQ format is a text-based format for storing read data, and is comprised of 
four lines per sequenced read: 
 Sequence identifier, preceded by a “@” character.  Often lists the coordinates 
on the sequencing chip. (E.g.: @UNC20:291:000000000-
AKVVA:1:1101:16893:1549 2:N:0:AGGCANACTCTCTA) 
 Nucleotide sequence letters (E.g.: AGCGTTGGG) 
 A “+” character, followed optionally by the same sequence identifier in line 1.  
Often left blank.  (E.g.: +) 
 Quality scores for each base value from line 2.  For current Illumina derived 
FASTQ files, a PHRED score between 0 and 40 are given, which provides the 
error probability for each respective base. (E.g. >>3>>ADFB) 
4.9.    Of QC metrics provided by FastQC, we focus most closely on the per-base 
sequencing quality (typically given as a PHRED score), overrepresented 
sequences, and adapter content.  Sequencing quality should ideally remain high 




sequencing methods frequently demonstrate a dramatic drop in quality in the 
last 25-50% of the read length, without significant issues with downstream 
processing.  Particularly in peripheral blood, ribosomal RNA and globin-related 
genes can often appear as overrepresented genes.  Overrepresented 
sequences can be input into NCBI nucleotide BLAST to identify the source, 
correcting for future preparations if necessary.  Lastly, high adapter content can 
result from non-ideal PCR conditions or RNA fragments shorter than the 
sequencing length.  If high adapter content is present, a trimming software to 
remove adaptor contamination should be considered (we most frequently use 
bbduk from the BBMap suite256). 
4.10. Depending on the library and the quality of the RNA, different amounts of 
reads will map to mRNA257.  In mRNA or exon capture based methods, typically 
60-80% of reads will map to mRNA.  However, in total RNA–seq, this number is 
much lower and varies by RNA quality.  Total RNA-seq can range from ~10-30% 
of reads mapping to mRNA in FFPE and ~30-50% in fresh frozen, with 
corresponding increases in intron and intergenic regions compared to mRNA-
seq.  At minimum, to reach an equivalent amount RNA expression data as in 
microarrays, it is important to aim for at least 15-30 million reads mapping to 
mRNA and to aim even higher for all the additional benefits one gets from a 
sequencing vs array based approach.                
4.11. It is important to note that certain analysis packages (such as DESeq2) 
require an unfiltered, untransformed input matrix for analysis, so it is imperative 




4.12. V’DJer can be run in normal and sensitive modes.  We typically rely on 
normal mode unless greater sensitivity in necessary – in limited testing, sensitive 
mode had a 50-1200% increase in runtimes and 0-1000% increase in 
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Figure A1.1. RNA-seq Library Preparation Kit Decision Tree. All 
quantities listed are the total RNA inputs, as recommended by 
manufacturer protocols. Several kits also have an mRNA input option 









 NextSeq HiSeq 4000 NovaSeq 
6000 
Output range 20–120 Gb 125–1500 Gb 134–6000 Gb 
Run time 11–29 hr < 1–3.5 days 13–44 hr 
Reads per run 130–400 
million 
2.5–5 billion Up to 20 billion 
Maximum read length 2 × 150 bp 2 × 150 bp 2 × 150 bp 
Samples per run 2–8 50–100 26–400 
Relative price per 
sample 
Higher Cost Mid cost Lower cost 
Relative instrument 
price 
Lower Cost Mid cost Higher cost 
 
Table A1.2: Illumina sequencing platforms recommended for whole 
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